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Hematopoiesis 
 
There are more than ten different functional cell types in the blood, all of which 
derive from one type of cell: the hematopoietic stem cell. Stem cells are defined 
by their capacity to undergo both constant self-renewal and differentiation into 
lineage-specific progenitor cells that ultimately give rise to the different mature 
blood cells (figure 1). The life span of fully differentiated blood cells is limited, 
requiring a constant replenishment of the different blood lineages. Self-renewal is 
the process whereby, upon cell division, at least one daughter cell retains the 
characteristics of the parent cell, whereas the other daughter cell can be of a 
more differentiated phenotype. This mechanism ensures a constant supply of 
terminally differentiated cells to the blood, while maintaining the capacity to 
sustain hematopoiesis throughout life. Stem cells are relatively quiescent, 
whereas progenitor cells are destined to proliferate and differentiate along a 
committed lineage, accompanied by progressive loss of self-renewal capacity 
1. 
Stem cell quiescence is thought to be of critical importance in protecting the stem 
cell compartment 
2. Upon challenge of the hematopoietic system through trauma, 
radiation-related or cytotoxic stress, tumour-induced granulocytosis, etc, stem 
cells will start cycling in order to reconstitute the full range of blood cells 
3;4.  
As billions of cells per day need to be produced in the hematopoietic 
system, careful regulation of hematopoiesis is essential. Among the first 
regulators to have been defined are the colony-stimulating factors (CSF), which 
drive the differentiation of granulocytic (G-CSF), macrophage (M-CSF) or both 
(GM-CSF) cell lines (reviewed in 
5). Around this time, Interleukin-3 (IL-3; multi-
CSF) was found to stimulate erythropoiesis, megakaryopoiesis and myelopoiesis 
6. Other cytokines have later been identified, which augment colony formation of 
erythroid cells (erythropoietin; EPO) and megakaryopoiesis (thrombopoietin, 
TPO) (figure1).  
  Dysregulation of hematopoiesis might result in severe defects in one or 
more of the cell compartments. For instance, a differentiation-block in any of the 
precursor cell compartments, leading to an accumulation of blast cells, may give 
rise to a variety of leukaemias. In addition, differentiation defects without 
increased blast formation may occur. Profound deficits of hematopoietic stem 
and progenitor cells resulting in bone marrow hypocellularity and peripheral blood 
pancytopenia has been observed in patients with aplastic anemia (AA), 
paroxysmal nocturnal heamoglobinuria (PNH) and myelodysplasia (MDS). 
Patients with severe congenital neutropenia (SCN) present with an isolated block 
in granulocytic differentiation. The heterogeneity of the different differentiation-Chapter 1 
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related diseases of the blood is indicative of the complicated nature of 
hematopoiesis.  
 
Myelopoiesis  
 
The first lineage choice a hematopoietic stem cell can make is to produce either 
a lymphoid progenitor, capable of producing only lymphoid cells (B- or T-cell) or a 
myeloid progenitor (granulocyte-erythrocyte-macrophage-megakaryocyte colony 
forming units; CFU-GEMM), capable of producing all the cells of the erythroid, 
megakaryocytic and myeloid lineages (figure 1). Although the dogma states that 
once a lineage is chosen, the progenitors are committed to this lineage, recent 
evidence suggest that there might be some plasticity within differentiation 
programmes 
7;8. For instance, 'committed' common lymphoid progenitors were 
capable of differentiation towards granulocytes and monocytes upon GM-CSF 
over-expression 
9.  
Culture of the CFU-GEMM with a mixture of cytokines and growth factors, 
including IL-3 and stem cell factor (SCF), induces further differentiation and 
lineage restriction. General myelopoiesis is driven by GM-CSF and IL-3, which 
induce the formation of neutrophil-macrophage and eosinophil progenitors (CFU-
GM and CFU-eo, respectively) 
10;11. 
Exposure of CFU-EOs to IL-5 is needed for terminal differentiation of cells into 
eosinophilic granulocytes. Incubation of CFU-GMs with GM-CSF, IL-3 and M-
CSF results in macrophage production, whereas G-CSF drives terminal 
differentiation of neutrophilic granulocytes 
12.  
Neutrophil maturation from the CFU-GM stage in the bone marrow takes about 2 
weeks. Based on morphology of the cells and the appearance of granules, 
neutrophil differentiation can be divided in a number of steps 
13. Myeloblasts are 
round cells with a large nucleus, relative to the surrounding cytoplasm. 
Promyelocytes are larger than myeloblasts and have more cytoplasm, whereas 
myelocytes are approximately the same size as a myeloblast but have a dent in 
their nucleus. Metamyelocytes are even smaller than their predecessors and 
have a kidneys-shaped nucleus. Banded neutrophils have a band-shaped 
nucleus and are the last maturation stage to be mostly retained in the bone 
marrow. Segmented neutrophils are fully mature granulocytes with a segmented 
nucleus, which will egress from the bone marrow to the peripheral blood. 
  Granulocytes form four distinct types of cytoplasmatic granules, which 
contain proteolytic enzymes and provide a storage space for membrane-bound 
proteins 
14.  Introduction 
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Figure 1. Hematopoiesis  
In the presence of growth factors, hematopoietic progenitor cells, capable of self-renewal, undergo 
differentiation towards one of the blood cell lineages. The arising lineage-restricted progenitor cells 
can be distinguished by their capacity to form colony forming units (CFUs) of the erythroid (CFU-E), 
megakaryocytic (CFU-mega), neutrophil-macrophage (CFU-GM, CFU-M and CFU-G), eosinophilic 
(CFU-eo) or basophilic (CFU-baso) lineages. General myelopoiesis is driven by a number of 
cytokines including GM-CSF and G-CSF. G-CSF is required for terminal neutrophil differentiation. 
See text for details. 
 
  
At the stage of the pro-myelocyte, formation of azurophil (primary) granules 
occurs, which contain myeloperoxidase (MPO), the proteases elastase and 
cathepsin G, small antibiotic peptides (defensins) and serine proteases such as 
proteinase 3 
15;16. This is followed at the myeloid stage by the formation of 
specific (secondary) granules, containing lactoferrin, the membrane protein 
CD66, and flavocytochrome b558, a component of the NADPH oxidase complex 
14;17. At this time, fMLP receptors (fMLP-R) and CD11b (a β2-integrin subunit) are Chapter 1 
13 
formed and stored in these granules. Exocytosis of these granules, resulting in 
fusion of the granule membrane with the plasma membrane thus increases 
fMLP-R and CD11b expression at the plasma membrane 
18. Around the band-
stage, tertiary gelatinase-containing granules arise. Lastly, secretory vesicles 
containing several membrane proteins and receptors (e.g. fMLP-R, 
flavocytochrome b558 and CD35) are produced at the segmented stage, when 
cells are fully mature.  
 
Signalling in neutrophils 
 
G-protein coupled receptors 
Neutrophils become activated upon stimulation of their membrane receptors 
(figure 2). There are two major classes of receptors; G-protein coupled receptors 
(GPCRs), and growth factor receptors. GPCRs are seven-transmembrane 
spanning receptors that bind a wide variety of ligands, including formyl-Met-Leu-
Phe (fMLP), leukotriene B4 and CXC ligands such as IL-8 and growth related 
oncogene-α (GROα) 
19;20. The intracellular domain of the GPCR is associated 
with heterotrimeric G proteins, composed of an α-,  β- and γ-subunit. Upon 
stimulation of the cell, these subunits undergo conformational changes, leading 
to the exchange of GDP for GTP bound to the α-subunit, and dissociation of the 
Gα- and Gβγ-subunits 
21. Both Gα and Gβγ can subsequently activate 
downstream effector molecules 
22, leading to a number of cellular functions in 
neutrophils. 
 
Growth factor receptors 
Growth factor receptors transduce signals to the interior of the cell by formation 
of homo-or heterodimers or-trimers (figure 2A). Most heterodimers of these 
receptors share a common receptor subunit. For example, the GM-CSF, IL-3 and 
IL-5 receptors are comprised of a ligand-specific α-subunit, and share a common 
β-chain 
23;24. In a similar manner, IL-2, IL-4 and IL-7 receptors share a common γ-
chain 
25;26. Other cytokine receptors consist of two identical receptor chains, such 
as the receptors for EPO, G-CSF and growth hormone 
27;28. 
Some growth factor receptors possess intrinsic tyrosine kinase activity, 
such as the M-CSF receptor and the receptor for SCF, the so called receptor 
tyrosine kinases 
29;30. Upon dimerisation of these receptors, autophosphorylation 
occurs, resulting in activation of the receptor and subsequent initiation of 
downstream signalling events.  Introduction 
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Figure 2. Cytokine receptor and G protein-coupled receptor (GPCR) mediated signalling (A) 
Upon stimulation of cytokine receptors with their growth-factor ligands, dimerisation of the receptor 
occurs, leading to its phosphorylation, and the creation of docking sites for SH2-domain containing 
proteins such as Src, Jaks and the PI3K regulatory subunit p85. Subsequently, the Ras and PI3K 
pathways are activated, resulting in phosphorylation of, amongst others, protein kinase B (PKB) and 
extracellular signal-regulated kinase (ERK1/2). (B) GPCRs are heptahelical receptors that span the 
plasma membrane. Stimulation of GPCRs leads to dissociation of the Gα and the Gβγ subunits, 
which results in subsequent activation of Ras and PI3K, possibly through the recruitment of Src, Grb2 
and Sos to the receptor.  
 
However, the cytoplasmatic domains of most cytokine receptors lack any 
intrinsic catalytic activity, and need to be phosphorylated by cytosolic factors in 
order to become active. One of these factors is the Janus family tyrosine kinase 
(Jak). Four Jaks have been identified to date; Jak1, Jak2, Jak3 and TYK2 
(reviewed in 
31).  Jaks bind with their N-terminal regions to a conserved box I Chapter 1 
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domain of the cytokine receptor chains, critical for signal transduction 
32-34. Upon 
ligand binding, dimerisation of receptor chains brings the Jaks into close 
proximity of each other, resulting in cross-phosphorylation and activation. 
Subsequent phosphorylation of receptor β-chains occurs, leading to downstream 
signalling. Tyrosine phosphorylation of the receptor creates binding sites for Src 
homology 2 (SH2) domain containing proteins, such as the family of Src kinases 
35, which includes Fgr, Fyn, Hck, Lyn, Yes and Src in hematopoietic cells 
36, and 
the signal transducer and activator of transcription (STAT) molecules 
37. The 
ensuing phosphorylation, dimerisation and nuclear translocation of STATs are 
important for linking many cytokines to gene regulation 
37.  
It is as yet unclear if STAT activation is directly involved in regulating 
granulocyte effector functions. However, GM-CSF stimulation of mature 
neutrophils results in the specific activation of Jak2, but not Jak1, 3 or Tyk2, and 
the subsequent phosphorylation of STAT5B and STAT3, but not the isoforms 
STAT1, 2, 4, 5A and 6 
38. This specificity of Jak/STAT activation indicates that 
this pathway might indeed be involved in modulating functions of mature 
granulocytes. Another SH2-domain containing protein that is recruited to the 
receptor upon stimulation is the adapter molecule Grb2. Being bound to the 
guanine nucleotide exchange factor Sos, translocation of Grb2 results in the 
recruitment of Sos to the membrane, where it is in close proximity to its 
substrate, the membrane-anchored small GTPase Ras 
39-41.  
It was once thought that only cytokine receptors signalled through 
activation of non-receptor tyrosine kinases, but recent evidence has shown that 
GPCRs can also activate Src kinases, through association with either the Gα or 
the Gβγ subunits 
42;43. Furthermore, Src kinase activity is involved in GPCR-
stimulated functional cellular behaviour in neutrophils 
44;45. Activation of GPCRs 
such as the fMLP-R also results in activation of Ras 
46;47. Although some studies 
have suggested that GPCR-triggered Ras activation might occur in a different 
manner than cytokine receptor-stimulated Ras activation 
48, others have shown 
that similar pathways are involved in both receptor types, i.e. Grb2-Sos signalling 
(figure 2B) 
49;50 .  
 
GTPases 
Ras is a member of a family of small GTPases, which can be divided into a 
number of subgroups; the Ras-GTPases, the Rho-GTPases, the Rab-GTPases, 
the Ran-GTPases, and the Sar/Arf family of GTPases (for extensive review see 
51). The most well described of these are the Ras subgroup of GTPases, which 
contain Ras, Rap1 and Ral 
52, and the Rho-GTPases, including Rac, Rho and Introduction 
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Figure 3. Activation of GTPases.  
All Ras and Rho GTPases are activated in a
similar manner. In resting cells, GTPases [Ra(x)]
are bound to GDP, and inactive. Upon receptor
stimulation of the cell, guanine nucleotide
exchange factors (GEFs) become activated
through PI3K-dependent or -independent
pathways. GEF activation results in activation of
the GTPase by the exchange of the GDP for a
GTP, enabling the GTPase to activate
downstream targets in an as yet unidentified
manner. Intrinsic GTPase activity, enhanced by
GTPase activating proteins, results in
hydrolysation of the GTP, returning the GTPase
to its inactive state.   
Cdc42 
53. GTPases act as molecular switches within a cell, cycling between an 
'on', GTP-bound state, and 'off', GDP-bound state (figure 3). Upon stimulation of 
a cell, guanine nucleotide exchange factors (GEFs) activate the GTPase by 
exchanging the GDP for a GTP, thereby enabling transduction of the activation 
signal within the cell. Intrinsic GTPase activity, enhanced by GTPase activating 
proteins (GAPs) subsequently results in hydrolisation of the GTP, returning the 
GTPase to the 'off'-state 
54.  
    There is a great redundancy when it comes to GEFs. Aside the 
GEF Sos, RasGRF and RasGRP are known to activate Ras, although these are 
predominantly expressed in brain 
55. Sos is a well known activator of Ras, when 
associated to Grb2, but can also activate Rac, when engaged in a tricomplex 
with Eps8 and E3b1-Abi 
56. Other activators of Rac are the GEFs Vav, Tiam, 
SWAP-70, αPIX and P-Rex1 
57-59. Furthermore, it appears that Rac is not only 
activated by conventional GEFs, but also by the RhoG/Dock180/ELMO complex 
60.  
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
The cellular functions of the different small GTPases are diverse. Ras mediates 
differentiation, proliferation and apoptosis, whereas Ral is involved in cell-
migration, vesicle sorting and cell morphology 
55;61;62. The Rho-GTPases are 
generally known for their role in regulating the actin cytoskeleton. Rho activation 
results in assembly of contractile actin-myosin filaments (stress fibres), Rac 
activation leads to the assembly of actin filaments at the cell periphery 
(lamellipodia and membrane ruffles) and Cdc42 activity induces actin-rich 
surface protrusions (filopodia) 
63.  Chapter 1 
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  There is a lot of cross talk within the cell between the different GTPases. 
Activated Cdc42 leads to activation of Rac, which in turn can activate Rho. The 
balance between the activation of these GTPases determines the morphology of 
cells and their migratory behaviour 
64-66. Furthermore, cross talk between the 
Ras-GTPases and the Rho-GTPases has also been described. Upon activation 
of Ras, three major downstream signalling targets are activated 
67 (figure 4).  
One of these, the RalGDS, leads to activation of Ral, which in turn might exert a 
negative regulatory function on Rac activity 
68. Another pathway activated by Ras 
is the phosphatidylinositol 3-kinase (PI3K) pathway. PI3K can activate Rac by 
entering in a complex with Eps8/Abi1/Sos 
69 and can activate some, but not all of 
the Rac GEFs 
58;70;71. However, Rac might also be activated by Ras in a PI3K-
independent manner 
72. The third, best-known, pathway activated by Ras is the 
Raf-mitogen activated kinase (MEK)-extracellular signal-regulated kinase (ERK) 
pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cross talk between signal-transduction pathways.  
Ras can activate three signal transduction pathways, the best described of these is the Raf-MEK-
ERK1/2 pathway. In addition, Ras can activate PI3K, which activates PKB, and has been implicated in
ERK1/2 signaling. Furthermore, PI3K activates the GTPase Rac by interacting with some of its GEFs.
Rac activation results in PAK activity. PAK can also be activated by PKB directly, and has been
described to activate ERK1/2, athough this effect might be mediated through activation of Raf-MEK. In
addition to Raf and PI3K, Ras can also activate the GTPase Ral, which might exerts a negative
regulatory role on Rac ativation. Furthermore, active Ras might result in Rac activation through PI3K-
dependent and -independent mechanisms. Rac has also been shown to be activated by Cdc42, and in
itself activates the GTPase Rho. Introduction 
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The PI3K pathway 
PI3Ks are lipid kinases that phosphorylate phosphoinositides on the 3-position of 
the inositol ring (figure 5). The intracellular levels of phosphoinositides are
 tightly 
regulated
  through the action of PI3Ks and phosphatases such as SHIP (SH2 
domain-containing inositol 5-phosphatase) and PTEN (phosphatase and tensin 
homologue deleted on chromosome ten) 
73. Phosphatidylinositol (PtdIns) lipids 
are anchored to the plasma membrane, therefore translocation of PI3K from the 
cytoplasm to the membrane is required 
74. The first PI3Ks to be identified were 
the Class IA of PI3Ks. These PI3Ks share a common regulatory subunit, p85, but 
have different catalytic subunits, p110αβδ for PI3Kα, PI3Kβ and PI3Kδ, 
respectively. The regulatory p85 subunit contains a SH domain through which it 
can recruit the catalytic domain to growth factor receptors upon activation of 
these receptors 
75. Tyrosine phosphorylation of the p85 occurs, and increases 
PI3K activity 
76.  
A second class of PI3K, Class IB, was identified a few years after the 
'classical' PI3Ks 
77, and only contains one isoform. This PI3K consists of the 
regulatory subunit p101 and the catalytic subunit p110γ, and is hence referred to 
as PI3Kγ. It was initially thought that this PI3K was the predominant form 
activated by GPCRs 
78-81. However, it is becoming increasingly clear that 
stimulation of GPCRs also results in activation of Class 1A PI3Ks, and 
subsequent cellular functions, which is either mediated by the Gβγ subunit 
directly or through GPCR-triggered tyrosine kinase activity 
82-84. Furthermore, a 
recent study shows that PI3Kγ can also be activated by cytokine receptor 
signalling 
85. 
In addition to being stimulated by direct coupling to either cytokine 
receptors or GPCRs, both Class 1A and 1B PI3Ks bind to Ras in a GTP-
dependent manner, resulting in PI3K activation 
86-88.  
  Activation of PI3Ks results in the production of phosphorylated lipid 
products, of which PtdIns(3,4)P2 and PtdIns(3,4,5)P3 act as second messengers 
in transducing signals. They do this by attracting molecules with a specific 
phospholipid-binding site (PH domain).  One of these proteins is the protein 
kinase B (PKB; otherwise known as Akt). PKB binds to both PtdIns(3,4)P2 and 
PtdIns(3,4,5)P3, though it has a higher affinity for the latter 
89. However, 
PtdIns(3,4,5)P3 binding alone does not result in PKB activation. PKB contains 
two phosphorylation sites, Ser473 and Thr308, both of which need to be 
phosphorylated for full PKB activity 
90. The kinase responsible for 
phosphorylating the Thr308 residue on PKB is PtdIns(3,4,5)3-dependent protein 
kinase-1 (PDK-1) 
91. This kinase also contains a PH domain through which it Chapter 1 
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binds to PtdIns(3,4,5)P3. Prior phosphorylation of the Ser473 residue of PKB is 
required for PDK1 to perform its kinase activity on the Thr308 residue 
92.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recent evidence suggests that PtdIns(3,4,5)P3 recruits both PKB and PDK-1, 
resulting in Thr308 phosphorylation, whereas PtdIns(3,4)P2 results in 
phosphorylation of PKB at Ser473 
93, possibly by recruiting an unidentified 
Ser473 kinase that has been termed PDK2. Being a kinase, PKB activation 
results in phosphorylation of a host of substrates, amongst which are the kinases 
mTOR and GSK3, and the Forkhead transcription factors 
94-98. 
Another class of molecules that contain a PH domain is the GEFs for Rac, as 
described above. Although PI3K dependence of the GEFs αPIX and Tiam are 
somewhat controversial 
70;99, PI3K involvement in Sos, SWAP-70 and Vav is well 
established 
58. Of interest, P-Rex1 is the only known GEF to be directly activated 
by Gβγ subunits of GPCR 
100, making it tempting to speculate that its activation 
might be PI3Kγ dependent. This remains a bit of a mystery however, as at least 
in neutrophils, chemokines activating GPCR, are better activators of Rac than 
are growth factors 
101.  
 
 
Figure 5. Regulation of intracellular phosphoinositide levels by phosphatidyl inositol kinases 
and phosphatases (PTEN and SHIP1/2). 
Inositol lipids, anchored at the plasma membrane, are phosphorylated by the lipid kinases PI4K and
PI3K, of which PI3K is the best described kinase. The resulting phospholipids, especially
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are capable of tranducing signals within the cells by recruitement
of proteins with a specific lipid-binding domain; a plecstrin-homology (PH) domain. Amongst these
proteins are PKB, PDK and some Rac GEFs, such as Vav and SWAP-70. Phosphoinositides are
dephosphorylated by the phosphatases PTEN and SHIP, of which there are two isoforms. The levels
of phosphoiniositides are tightly regulated by the action of these kinases and phosphatases. Introduction 
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ERK signalling 
A third signalling pathway activated by Ras, and the best described of the three, 
is the RasÆRafÆMEKÆERK pathway 
102. Upon activation of Ras, the 
serine/threonine kinase Raf is recruited to the membrane, where it will bind to 
GTP-loaded Ras 
103. Three Raf kinases have been identified; Raf-1, B-Raf and 
A-Raf, which confer isozyme-specific functions 
104. Association of all Raf kinases 
with Ras has been shown, although the manner of activation differs 
105;106. 
Recruitment of B-Raf to the membrane results in its phosphorylation at residues 
Thr598 and Ser601, which is a direct result of Ras binding and sufficient for full 
Raf-B activation 
107. In contrast, activation of Raf-1 requires both binding to active 
Ras and phosphorylation at Tyr431 by independent tyrosine kinases such as Src 
108;109. Once active, Raf binds to and phosphorylates the MEK1 and MEK2 
protein kinases on two serine/threonine residues 
110-112. This activates the MEKs, 
enabling them to transduce the signal further within the cell. MEK1 and 2 are 
dual specificity kinases that can phosphorylate threonine and tyrosine residues 
on two ERK MAP kinases; the 44kDa protein ERK1 and the 42kDa protein ERK2 
113;114. Phosphorylation of both Thr202 and Tyr204 is required for full ERK1/2 
activity 
115;116. Upon phosphorylation of ERK1/2 in the cytoplasm, the activated 
MAPK translocates to the nucleus 
117;118 where it can initiate activation of 
transcription factors such as Elk. Alternatively, activated ERK1/2 can activate a 
number of cytosolic or membrane-bound substrates, resulting in a host of cellular 
functions (reviewed in 
119).  
Interplay between different signal transduction pathways has been 
described (figure 4). Although the Ras pathway leading to ERK1/2 activation is 
well established, recent studies suggests that ERK activity can be increased by 
Rac in a Ras dependent-or independent manner 
120-122, and that 
chemoattractant-induced ERK1/2 activation is decreased in Rac2-/- cells 
123. This 
effect appears to be mediated through the Rac target PAK 
121;124;125. In addition, 
ERK1/2 activation has been described to be dependent on PI3K activity and PDK 
signalling in some 
126;127, but not all systems 
128;129, although whether or not this 
PI3K activity is activated by Ras is unclear. Furthermore, it has been shown that 
Ras-Raf induced cellular effects are not always dependent on ERK activation 
130;131. Conflicting data are obtained when using different stimuli or different cell 
types, indicating the complicated nature of signal transduction. This goes to show 
that validating signalling routes identified in other cell systems than the cell type 
of choice is of critical importance. 
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Granulocyte effector functions 
 
Development of neutrophils is critical for the body's defence against invading 
bacteria. The importance of this first line of defence is underscored by the fact 
that patients with decreased numbers of circulating neutrophils have a high 
mortality rate due to recurrent life-threatening bacterial infections 
132;133. In order 
to perform their bactericidal activity, neutrophils have to perform a number of 
steps (figure 6): (1) adhesion to and rolling along endothelial lining of blood 
vessels, (2), diapedesis through the endothelial layer, (3) migration towards the 
site of inflammation (4) degranulation, and finally (5) phagocytosis of bacteria in 
conjunction with production of bactericidal reactive oxygen species (ROS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Neutrophil functions 
Neutrophils are drawn to a site of bacterial infection by cytokines released by the surrounding
tissues. Rolling along the endothelial lining results in recognition of adhesion molecules on
endothelial cells, upregulated in response to the infection. Neutrophils become activated and start
making their way towards the invading bacteria. When in close proximity to the intruders, neutrophils
are even further stimulated by peptides derived from the bacteria. Migration towards the bacteria,
phagocytosis, degranulation and production of reactive oxygen species (ROS) subsequently take
place. After the neutrophils have performed their functions, they undergo programmed cell-death
(apoptosis) possibly as a result of the ROS production, which is not only toxic to bacteria, but also to
neutrophils and other surrounding cells.  Introduction 
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Adhesion and diapedesis 
Neutrophils in the bloodstream occasionally contact the capillary wall. During 
inflammation and infection, endothelial cells exposed to proinflammatory 
mediators such as tumour necrosis factor-α and the bacterial cell membrane 
component lipopolysaccharide (LPS) will become activated, and start expressing 
chemokines and cytokines such as Interleukin-8 (IL-8) and RANTES, that attract 
neutrophils 
134. Furthermore, activated endothelial cells express an increased 
amount of adhesion molecules such as E-selectin, P-selectin, ICAM-1 and 
135, 
which bind to the selectin family of adhesion molecules expressed on 
neutrophils, resulting in 'rolling' of neutrophils along the endothelial cells 
(reviewed in 
136). Rolling along E-selectin and P-selectin results in activation, and 
subsequent binding of neutrophil β2-integrin CD11b/CD18 to ICAM-1 on 
endothelial cells, leading to firm adhesion 
137;138. Further activation of neutrophils 
by the upregulated IL-8 expression on the endothelial cell surface increases 
neutrophil CD11b/CD18 expression. At this point, diapedesis occurs, which is 
also regulated by CD11b/CD18. It is generally assumed that neutrophils 
transmigrate between individual endothelial cells, although more and more 
evidence suggests that neutrophils might pass through the endothelial cell proper 
139. 
 
Migration towards end target  
Initial migration of neutrophils is directed at drawing the neutrophil towards the 
general vicinity of inflammation, and is induced by chemotactic agents such as 
IL-8 and GROα 
140;141. Once at the site of infection, the granulocytes show a 
more directed migration towards 'end-target' attractants such as fMLP that are 
released by the invading bacteria 
142. The difference in 'function' between these 
chemoattractants is reflected in the differences in signal transduction pathways 
that are employed by these factors to induce migration. For instance, IL-8, but 
not fMLP, was shown to activate CD18-independent endothelial transmigration of 
neutrophils 
143. IL-8 and fMLP both activate GPCRs. Nevertheless, migration 
induced by fMLP was independent of Src kinases 
44, whereas IL-8-stimulated 
migration did require Src kinase activity in neutrophils and other cell types 
144;145.  
However, much is still unclear concerning the signal transduction 
pathways involved in chemotaxis towards fMLP or IL-8 gradients. Upon 
stimulation of neutrophils with chemotactic agents, rapid polymerisation of 
monomeric actin (G-actin) into filamentous actin (F-actin) occurs 
146;147. 
Neutrophils become polarised, with actin structures forming within pseudopodia Chapter 1 
23 
at the leading edge 
148. The role of Rac in actin polymerisation has been well 
described 
63;149;150. Direct evidence for the involvement of Rac in neutrophil 
migration comes from studies showing impaired fMLP-stimulated migration in 
Rac1-or Rac-2 deficient neutrophils 
151-154. Furthermore, more and more 
evidence suggests there is a role for PI3K signalling in neutrophil migration. 
PtdIns(3,4,5)P3 is formed specifically at the leading edge of the migrating 
cell.
155;156. It has been suggested that fMLP stimulated activity of either Class IA 
82 
or Class IB 
157 PI3Ks leads to Rac activation and subsequent actin 
polymerisation. Furthermore, studies in mice lacking PI3Kγ shows that GPCR-
stimulated migration is abolished in PI3Kγ deficient neutrophils 
158;159. In 
accordance with these data, inhibition of PI3K activity resulted in attenuation of 
IL-8-stimulated migration of human neutrophils in a Boyden chamber assay 
128. In 
contrast, other studies showed that a pharmacological inhibitor of PI3K could not 
inhibit migration of neutrophils towards either fMLP or IL-8 
160;161. Furthermore, it 
has been implied that PI3K was responsible for fMLP-, but not IL8-induced 
pseudopod formation in neutrophils 
162. And to complicate matters even further, 
yet another study suggested that it was IL-8-induced migration that was PI3K-
directed, and not fMLP-stimulated chemotaxis 
163. 
With regards to the role of ERK1/2 activation in neutrophil chemotaxis 
there is an equal amount of controversy. Whereas some studies suggest that 
fMLP- and IL-8-induced ERK1/2 activation is involved in migration 
120;164;165, 
equally convincing studies suggest there is no role for ERK in chemoattractant 
mediated chemotaxis 
128;160;166;167. Clearly, a lot of research will need to be 
performed to generate conclusive answers as to the role of the signal 
transduction pathways in neutrophil migration.  
 
Bactericidal activity 
Once at the site of infection, granulocytes will kill bacteria by a number of 
different mechanisms. Bacteria or infectious particles will be taken up in the cell 
through phagocytosis. Subsequently, bactericidal enzymes are delivered to the 
phagosome through fusion of phagosomes with cytoplasmic granules. 
Furthermore, degranulation at the plasma membrane will take place, which is 
important for inflammation, receptor expression on neighbouring cells, tissue 
damage, and bactericidal activity. In addition, reactive oxygen species are 
produced and released at the plasma membrane and delivered to phagosomes.   
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Phagocytosis 
Uptake of foreign particles is mediated by binding of surface components of 
these particles to receptors on the neutrophil membrane (reviewed in 
168). These 
receptors include the β2-integrin family of receptors, of which CD11b/CD18 is a 
major player. In addition, bacteria may become 'opsonized', meaning that they 
are coated with immunoglobulin antibodies and complement fragments. While 
the antigen-recognising domain of the immunoglobulins are bound to their target, 
the Fc domain remains unoccupied, and can be recognised by Fcγ receptors 
(FcγRs) present on neutrophils. Association of integrins or FcγRs results in the 
activation of signal transduction pathways that result in actin cytoskeletal 
changes, leading to the formation of phagocytic cups that embrace the foreign 
particles, and their ingestion 
169;170. Disruption of actin polymerisation leads to a 
reduction in phagocytosis potential, underscoring the importance of the actin 
cytoskeleton 
171. The signal transduction pathways activated by integrins and 
FcγRs in phagocytosis are not yet fully elucidated, but include activation of the 
Src family of tyrosine kinases 
172;173. Furthermore, the importance of the 
cytoskeleton indicates involvement of the Rho-GTPases 
174;175. In addition, PI3K 
activity and ERK activation have also been shown to play a role in phagocytosis 
172;176-178.  
 
Degranulation 
Degranulation of granulocytes occurs in response to adhesion and integrin 
activation, but can also be a result of chemokine stimulation. During the process 
of degranulation, granules translocate from the cytoplasm to the phagosomes or 
the plasma membrane. Whereas migration and phagocytosis are dependent on 
the formation of actin cytoskeleton, the degranulation process is facilitated by the 
breakdown of actin fibres 
179;180, possibly because an actin meshwork might act 
as a net, blocking the movement of the relatively large organelles. Granule 
release into the phagosomes and extracellular space is a sequential process; 
contents from tertiary granules are released before the specific granules 
degranulate, which again exocytose more readily then azurophilic granule 
14;181;182. This implies that different signal transduction pathways are involved in 
the degranulation of the different vesicles. Indeed, Rac2 was found to be 
involved in fMLP-stimulated primary, but not secondary or tertiary granule 
release 
183. However, exocytosis of both primary and secondary granules in 
response to adhesion or fMLP stimulation were dependent on the activity or the 
MAP kinase p38 
45. Rac and ERK activity were required for movement of lytic Chapter 1 
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granules towards ingested microbes 
120, and our own research has shown that 
exocytosis of secretory vesicles in response to fMLP stimulation can be 
attenuated by pharmacological inhibition of the MEK-ERK pathway (unpublished 
data). In contrast, chemoattractant-induced degranulation of primary and 
secondary granules was not inhibited with a pharmacological ERK1/2 inhibitor 
167. 
 
ROS production. 
The last and possibly most important action a neutrophil performs before 
undergoing programmed cell death (apoptosis), is the production of reactive 
oxygen species (ROS), otherwise known as the neutrophil respiratory burst.  
ROS production is mediated by the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (figure 7).  This enzyme consists of a membrane 
bound component, flavocytochrome b558, and the cytosolic factors p47
phox, 
p40
phox, p67
phox, which exist in the cytosol as a complex, and Rac2 
184. In resting 
cells approximately 10-20% of the flavocytochrome, which consists of the 
subunits gp91
phox and p22
phox, is anchored in the plasma membrane, whereas the 
remaining 10-20% resides in the membranes of secretory vesicles, secondary 
granules and tertiary granules 
14;185. Upon stimulation of the cell with a variety of 
factors, degranulation occurs, thereby increasing the amount of flavocytochrome 
b558 at the plasma membrane 
17;186. In addition, p47
phox becomes phosphorylated 
on multiple serine residues and is responsible for transportation of the cytosolic 
complex the plasma membrane, where assembly with flavocytochrome b558 
occurs 
187-192. Studies with cell-free systems have shown that p47
phox in itself is 
not required for ROS production, but serves as a carrier for p67
phox, which is 
essential for NADPH oxidase activity 
193. P67
phox itself is also phosphorylated 
upon stimulation of neutrophils, is required for translocation of p40
phox to the 
plasma membrane, and contains a catalytically essential binding site for NADPH 
194-197. The role of p40
phox is unclear; it has been reported to have a negative 
regulatory function, but can also increase ROS production by increasing the 
affinity of p47
phox for the NADPH oxidase 
198. The involvement of the small 
GTPase Rac2 in neutrophil ROS production is apparent from the lack of 
respiratory burst in Rac2-/- neutrophils in response to various stimuli 
122. It 
associates with the oxidase complex and might function as a carrier of p67
phox, 
independently of p47
phox 
199;200. In addition to being a direct participant in NADPH 
oxidase, Rac might also regulate ROS production by activating signal 
transduction pathways leading to oxidase assembly 
201. The GTPase Cdc42 acts Introduction 
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as negative regulator of ROS production by competing for Rac binding to the 
NADPH oxidase 
202. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formation of the NADPH oxidase complex results in the reduction of molecular 
oxygen at the expense of NADPH in the following reaction:  
2 O2 + NADPH Æ 2 O2
- + NADP
+ + H
+ 
The O2
- produced in this reaction serves as the starting material for the 
production of a plethora of reactive oxidants, including hydrogen peroxide (H2O2), 
hydroxyl radicals (
.OH), singlet oxygen (O
.
2
-), peroxinitrate anions (ONOO
-) and 
hypochlorous acid (HOCl), which have anti-bactericidal activity 
203;204 (figure 8).  
  Like degranulation, ROS production takes place at the plasma 
membrane and at the membranes of phagosomes. Different methods are 
available for measuring intra- en extracellular ROS production and the different 
radicals that are formed (reviewed in 
205). Intracellular ROS production 
measurements can be performed by using the uptake by neutrophils of non-
fluorescent probes such as H2DCFDA and dihydrorhodamine (DHR), that are 
Figure 7. The NADPH
oxidase complex. 
The NADPH oxidase consists
of a membrane bound
component, flavocytochrome
b558, and cytosolic
components. Flavocyto-
chrome b558 is composed of
two subunits; gp91
phox (gp91)
and p22
phox (p22). The
cytosolic components are
comprised of p67
phox, p40
phox
and p47
phox, which form a
complex, and the GTPase
Rac. Upon stimulation of
neutrophils, exocytosis of
specific granules and
secretory vesivles results in
enhances expression of
flavocytochrome b558 at the  
plasma membrane. In addition, p67
phox, p40
phox and p47
phox become phosphorylated, Rac becomes
activated, and the cytosolic complex translocated to the plasma membrane, where it associates with
flavocytochrome b558 to form an active NADPH oxidase complex.  Active NADPH is formed not only
at the plasma membrane, but also at phagosomes, containing internalised bacteria. 
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converted to fluorescent derivatives by H2O2, ONOO
- and HOCl, produced upon 
stimulation of the cell 
206. Extracellular O
.
2
- production can be measured by 
reduction of ferricytochrome c. Furthermore, both intra- and extracellular ROS 
production can be measured by chemiluminescence, depending on the 
chemiluminescence amplifiers used 
207. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Priming 
ROS production can be triggered by a number of stimuli, amongst which are 
phorbol esters (PMA) that elicit their effects independent of receptor activation, 
and receptor agonists such as fMLP. Stimulation of neutrophils with fMLP results 
in limited amounts of ROS being produced 
208;209. However, pre-stimulation of 
granulocytes with pro-inflammatory cytokines such as G-CSF, GM-CSF, TNFα, 
IL-8 or the bacterial peptide LPS dramatically increases the respiratory burst in 
response to fMLP, although they do not produce ROS by themselves 
210-214. This 
process is known as 'priming'.  
The molecular mechanisms underlying the process of priming in 
neutrophils remain elusive, although several suggestions have been made. 
Perhaps the most obvious explanation of cytokine priming would be through an 
increase of fMLP receptors at the plasma membrane caused by exocytosis of 
fMLP-R containing granules. However, whereas some studies indicate an 
increased fMLP-R expression upon stimulation of neutrophils with priming agents 
Figure 8.  Reactive oxigen species
produced by activated neutrophils. 
ROS production occurs both intra-and
extracellularly, and can be studied by
different techniques, which also specify
between individual ROS (see tekst for
details). Introduction 
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215, others do not find this effect 
214. Another mechanism of priming might be by 
increasing the assembly of the NADPH oxidase complex, resulting in more 
efficient fMLP-stimulated respiratory burst. Indeed, several groups suggest that 
stimulation of neutrophils with priming agents results in priming of the respiratory 
burst by increasing flavocytochrome b558 plasma membrane expression 
17;216;217.  
Several signal transduction pathways have been implicated in ROS 
production. Evidence for PI3K involvement fMLP-stimulated and cytokine-primed 
neutrophil respiratory burst comes from studies with specific inhibitors 
160;218;219. 
Lipid products of PI3K have been shown to associate with the cytosolic oxidase 
proteins p40
phox and p47
phox 
220, regulating ROS production 
221;222. Furthermore, 
priming of neutrophils enhances fMLP-stimulated PtdIns(3,4,5)P3 accumulation 
223, which in turn results in increased phosphorylation of p47
phox 224;225. It is 
unclear whether Class 1A or Class 1B PI3Ks are involved in this priming 
phenomenon. In p85 knockout mice, fMLP-triggered ROS production was 
normal, but GM-CSF priming of the neutrophil respiratory burst was impaired, 
indicating Class 1A PI3K in neutrophil priming 
226. Corroborating these findings, 
studies in p110γ-/- neutrophils suggest that fMLP induced PtdIns(3,4,5)P3 
accumulation is impaired, whereas GM-CSF functions normally 
227. However, 
others have shown that PI3Kγ is responsible for TNFα priming of PtdIns(3,4,5)P3 
accumulation 
228.  
In addition to PI3K, ERK1/2 is involved in ROS production by 
phosphorylating p47
phox 
229. Chemical inhibition of ERK1/2 resulted in reduced 
fMLP-stimulated and cytokine-primed ROS production in several studies 
219;230. In 
addition, ERK1/2 activation in response to fMLP stimulation could be enhanced 
by pre-treatment of cells with pro-inflammatory agents 
224. In contrast, others 
have found no effect of ERK inhibition on neutrophil respiratory burst 
160;231. 
Together, these conflicting data demonstrate that further study is required to 
elucidate the mechanisms involved in cytokine priming of ROS production. 
 
 
MDS 
 
The myelodysplasic syndromes are a heterogeneous group of clonal 
hematological disorders that are characterised by a disturbed hematopoiesis of 
the multipotent stem cell compartment. The ineffective and dysplastic 
differentiation affects the erythroid, megakaryocytic and myeloid lineages, 
resulting in peripheral pancytopenias in MDS patients. There is no clear cause 
for the majority of MDS cases, which are known as primary or de novo MDS. Chapter 1 
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Secondary MDS is described as the development of MDS after cancer 
treatments that cause bone marrow damage, such as radiation or chemotherapy. 
Some risk factors for the development for MDS have been established. For 
instance, exposure to chemicals such as benzene has been described to result in 
greater incidence of MDS. However, the highest risk factor is age, MDS being a 
disease of the elderly. Most patients presenting with MDS are >60 years old, 
although especially secondary MDS can also occur in younger people. The 
myelodysplastic syndromes can be classified into high-risk or low-risk groups 
according to the French American British (FAB) 
232 or the more recently 
established World Health Organisation (WHO) classification systems 
233 (table 1 
and 2). These classifications are based on the number of blasts in the bone 
marrow and peripheral blood, and the morphology of cells. Progression from low-
risk to high-risk groups can occur, and progression towards acute myeloid 
leukaemia (AML) is not uncommon. The low-risk groups consist of refractory 
anaemia (RA) and refractory anaemia with ringed sideroblasts (RARS). These 
patients make up a large group of MDS; approximately 30-40% of MDS patients 
suffers from RA or RARS. Progression towards leukaemia is rare in these groups 
(about 1-16 % of patients), and life expectancy is relatively high (2 –4 years) 
234. 
The high-risk groups show a mean survival time of 5-20 months, and progression 
rates towards AML have been reported to be as high as 60%.  
 
Table 1. French American British classification of MDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Classification     Criteria 
 
Low-grade  MDS*      
Refractory anaemia (RA)    <5% blasts 
Refractory anaemia with ring 
 sideroblasts (RARS)      >15% ring sideroblasts 
    
High-grade MDS 
Chronic myelomonocytic leukaemia 
 (CMML)        > 1 x 10
9 monocytes/l 
Refractory anemia with excess  
of blasts (RAEB)      5%-20% blasts 
Refractory anemia with excess  
of blasts in transformation (RAEB-t)  21%-30% blasts 
 
* Based on survival and blast count Introduction 
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Table 2. World Health Organisation classification of MDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytogenetic abnormalities have been reported in 50% of de novo MDS, 
and 90% of therapy-related MDS. The most frequently observed abnormalities 
are del(5q), which is associated with relatively good clinical outcome, and trisomy 
8, monosomy 7 or del(7q) which are considered unfavourable (reviewed in 
235). 
Activating Ras mutations have been found in 10-15% of mostly high risk MDS 
cases, and are thought to be associated with progression towards leukaemia 
236-
238.  
  Several transcription factors are involved in normal hematopoiesis, and 
might be affected in MDS patients. For instance, the AML1/RUNX1 transcription 
factor is critical for generation of hematopoietic stem cell generation during 
embryogenesis and for normal megakaryopoiesis. Recently, loss-of-function 
point mutations have been described in some MDS cases, and might predispose 
for leukemic transformation 
239-241. A transcription factor that has been shown to 
block granulocytic differentiation of myeloid progenitors is Evi-1. Abnormal 
expression of Evi-1 has been shown in some patients, but did not correlate to 
percentage of blasts or erythroblasts 
242. A longer form of Evi-1, MDS/Evi-1, also 
exists, and in contrast to Evi-1 is an activator of hematopoietic gene promoters 
243, although repressing transcriptional activity has also been shown 
244. In MDS 
patients, RNA expression of MDS/Evi-1 is also increased, and results in reduced 
colony formation of hematopoietic progenitor cells 
245. A third transcription factor, 
Refractory  anaemia  (RA)      
Refractory anaemia with ring sideroblasts (RARS)   
Refractory anemia with multilineage dysplasia 
Refractory anemia with excess of blasts I   
Refractory anemia with excess of blasts II     
Myelodysplastic syndrome, unclassifiable 
Myelodysplastic syndrome associated with isolated del(5q) 
chromosome abnormality (5q-syndrome) 
 
1CMML was reclassified as a disorder with both myelodysplastic and 
myeloproliferative features. RAEB-t is now reclassified as AML. 
REAB I: 5%-20% blasts 
REAB II: 11%-20% blasts Chapter 1 
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essential for granulopoiesis, is the CCAAT enhancer binding protein-α (C/EBPα). 
However, although alterations in the C/EBPα gene have been found in AML 
cases, they are rare in MDS patients 
246;247.  
 
Peripheral blood hypocellularity in MDS 
Despite the reported peripheral cytopenias, MDS bone marrows are usually 
normo-or even hypercellular. Ineffective hematopoiesis in MDS might be the 
result of a decreased proliferative potential of hematopoietic progenitors. The 
proliferative capacity of precursor cells can be measured by studying the in vitro 
CFU formation by bone marrow CD34+ cells. Indeed, impaired colony formation 
by erythroid (CFU-E and burst-forming unit (BFU)-E), granulocyte-macrophage 
(CFU-GM) and megakaryocyte (CFU-meg) progenitors has been shown in MDS 
248;249. CFU-E/BFU-E defects are most common, but can be accompanied by 
defects in colony formation of the other lineages 
250. Besides a decreased 
proliferation, an impaired differentiation pattern might also explain the reduced 
number of circulating blood cells in MDS patients. Morphological differentiation 
defects have been observed in multiple blood lineages 
249;251;252. However, 
CD34+ cells from MDS bone marrow might retain the capacity to differentiate in 
vitro upon growth factor stimulation 
253.  
In addition to impaired proliferation/differentiation, excessive 
programmed cell death or apoptosis of hematopoietic progenitor cells in MDS 
might explain the apparent discrepancy between high bone marrow and low 
peripheral blood cellularity. Increased apoptosis of CD34+ progenitor cells from 
MDS patients compared to healthy donors has been shown by Annexin V 
staining 
254;255, in situ end-labelling (ISEL) which identifies DNA strand brakes 
generated during apoptosis 
256, electrophoretic analysis of DNA degradation and  
TUNEL staining 
257. Interestingly however, this increased apoptosis is mostly 
apparent in the low-risk MDS groups. Aside an increased cell-death in MDS 
progenitors, increased proliferation of the same population of cells has 
simultaneously been observed 
255;256. In fact, it would seem that the apoptosis to 
proliferation ratio is important in the progression of the disease. Increased 
apoptosis in low-risk MDS reverses the increased proliferation of the CD34+ 
cells, whereas in more advanced subtypes or AML, increased proliferation rates 
are no longer kept in check by excessive apoptosis. Recently, several studies 
have focussed on the investigation of gene profiles in MDS progenitor 
populations using DNA microarrays. These studies show that genes involved in 
hematopoiesis regulation are differentially expressed in MDS compared to 
normal bone marrow cells 
258;259, and that differential gene expression patterns Introduction 
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exist between high risk and low risk MDS groups 
260. Among the genes that are 
down-regulated in low risk MDS are those involved in DNA defence against 
mutagenesis 
260. Furthermore, genes involved in differentiation, proliferation and 
apoptosis have been found to be differentially expressed in MDS bone marrow 
cells 
259, with evidence for increased expression of proliferation genes, and 
reduced expression of apoptotic genes in high risk compared to low risk MDS 
261;262. 
These results are supported by reports stating that the ratios of pro-and 
anti-apoptotic proteins are shifted in the progression of the disease. For example, 
expression of the pro-apoptotic proteins Bax, Bad, Bak and Bcl-xS was detected 
in a higher percentage of bone marrow mononuclear cells (BMMNC) in RA and 
RARS than in the high-risk MDS groups. Conversely, the percentage of BMMNC 
expressing the anti-apoptotic proteins Bcl-2 and Bcl-xL were lower in low-risk 
MDS compared to either high-risk MDS or healthy volunteers 
255;263;264. The Bcl-2 
family of proteins either stimulates (pro-apoptotic) or inhibits (anti-apoptotic) 
cytochrome  c release from mitochondria. Cytochrome c associates with the 
procaspase-9/Apaf complex whereupon procaspase-9 is activated by self-
cleavage. Active caspase-9 further activates other caspases, such as caspase-3 
and caspase-7, thereby activating a caspase cascade, which leads to apoptosis. 
Evidence of increased expression and activity of caspase-3 has been observed 
in RA patients, compared to RAEB patients and healthy controls 
265.  Activation of 
caspases can also be achieved by activating death receptors, the most well 
described of which is the Fas receptor (CD95). Activation of this receptor by its 
ligand, FasL, results in massive induction of apoptosis. In MDS CD34+ cells, 
expression of Fas and FasL are increased, most noticeably in RA and RARS 
patients 
266. FasL expression is regulated by the NF-κB transcription factor, and 
NF-κB activity was shown to be increased in MDS cases in some 
267, but not all 
studies 
268.   
Despite the large amount of evidence indicating increased apoptosis in 
MDS precursor cells, a recent study suggests that necrosis-like programmed cell 
death rather than 'classical' apoptosis is responsible for increased cell death in 
MDS bone marrow 
269. Furthermore, the observed apoptosis observed in in vitro 
studies might not be a reflection of the situation in the bone marrow, but rather a 
result from increased susceptibility to apoptosis upon detachment from the bone 
marrow microenvironment 
270.  
Cells can be protected from apoptosis by cytokines such as GM-CSF and 
G-CSF. Recent evidence suggests that G-CSF inhibits translocation of the pro-
apoptotic protein Bax to the mitochondria and subsequent caspase 3 activation, Chapter 1 
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thus preventing apoptosis 
271. Similarly, GM-CSF performs its anti-apoptotic 
function through PI3K-dependent phosphorylation and cytosolic translocation of 
Bad 
272. Expression of the G-CSF receptor indeed seems to be decreased on 
MDS CD34+ cells 
273, although the expression did not seem to correlate to G-
CSF-induced signal transduction in these patients 
274. Expression of the GM-CSF 
receptor has been reported to be normal on peripheral blood neutrophils from 
MDS patients 
275. 
Although erythroid differentiation is most often affected in MDS patients, 
recurrent bacterial infections suggest an important role for the myeloid lineage in 
the pathology of this disease. In fact, next to progression towards leukaemia, 
bacterial infections are the most common cause of death in MDS patients 
276. A 
defect in the myelopoiesis can lead to neutropenia in some patients as a result of 
the increased apoptosis in the bone marrow compartment. A recent study 
suggests that apoptosis was abundant in peripheral blood neutrophils from MDS 
patients, contributing to the cytopenia 
277. Nevertheless, the residual mature 
granulocytes consist of pathological clones, as intracellular signalling and 
subsequent cellular functions are disturbed in these cells. 
 
Disturbed neutrophil functions in MDS  
Decreased presence of mature neutrophils is not the sole cause of the increased 
susceptibility to bacterial infections in MDS patients, as neutropenia does not 
correlate with infective episodes 
278. In fact, several reports have shown evidence 
of impaired functioning of MDS neutrophils, affecting all anti-bactericidal 
responses of neutrophils 
279. For instance, fMLP-induced migration of MDS 
neutrophils has been reported to be decreased 
280;281. In accordance with this, 
the fMLP-induced expression of the CD11b/CD18 integrin was also decreased in 
neutrophils from MDS patients 
282. CD11b/CD18 plays an important role in 
granulocyte adherence, locomotion, diapedesis and migration into inflammatory 
sites 
283-285. Another factor necessary for migration and locomotion of neutrophils 
is the reorganisation of the actin cytoskeleton (reviewed in 
155). In MDS 
neutrophils, fMLP mediated actin polymerisation has been reported to be 
impaired 
286. These studies indicate that the attraction of MDS neutrophils 
towards the site of bacterial infection is affected. It is apparent that this alone 
would result in decreased efficiency of bactericidal activity in MDS patients. Upon 
arrival at the vicinity of the inflammation, neutrophils will be stimulated by 
bacterial peptides to attack the residing bacteria. Again, cytoskeletal 
reorganisations are required to perform such functions, e.g. granule trafficking, 
phagocytosis of pathogens and the neutrophil respiratory burst. In MDS patients, Introduction 
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deficiencies in the contents of primary and specific granules have been reported 
287-289. Expression of MPO, elastase and lactoferrin were decreased 
287;289 and 
enzyme activity of elastase, but not cathepsin G, were impaired 
288. Furthermore, 
phagocytosis and killing of C. guilliermondii or S. aureus were described to be 
affected in MDS neutrophils 
290. Another important defence mechanism against 
bacterial infections is the production of ROS. The effect of fMLP stimulation on 
ROS production in neutrophils from MDS patients is somewhat controversial. 
Nakaseko et al reported a defective fMLP-induced luminol-dependent 
chemiluminescence in MDS neutrophils 
291. In contrast, using a ferricytochrome c 
reduction assay, Ohsaka et al showed that ROS production in response to fMLP 
is increased in several patients 
292, whereas no significant differences were 
observed by Zabernigg et al, who employed a DHR FACS assay 
293. It has been 
suggested that patients who have a decreased fMLP-induced ROS production 
have a decreased basal expression levels of the NADPH component 
flavocytochrome b558 
294. On the other hand, it is clear that priming of respiratory 
burst with cytokines such as GM-CSF, G-CSF or TNFα is significantly decreased 
in MDS patients 
292;293. The total amount of ROS that could be produced in MDS 
neutrophils was not affected however, as the strong stimulus PMA induced a 
high respiratory burst in granulocytes from healthy donors and MDS patients 
293.  
Taken together, these data clearly show that neutrophil effector functions are 
impaired at all possible levels in MDS patients, thus resulting in a poor innate 
immune system. In contrast to the myeloid system, the lymphoid compartment of 
the peripheral blood appears to be hardly affected.   
 
Signal transduction in MDS 
Although a number of defects of MDS progenitor cells and their myeloid progeny 
have been described, the signal transduction pathways involved in these defects 
have scarcely been investigated. As described above, activating Ras mutations 
have been found in a subset of MDS cases. However, no studies have been 
performed on the activity of the Ras protein in MDS cells, nor have the 
downstream signalling molecules been investigated. Phase I and II trials with 
farnesyl transferase inhibitors, commonly known as 'Ras inhibitors', have only 
been marginally successful 
295. The observation that the beneficial effects were 
obtained in MDS patients who do not have the activating Ras mutation suggests 
that another mechanism might be involved 
296.  
  The activation of signal transduction pathways in response to stimuli has 
mostly been studied with regard to the disturbed erythropoiesis in MDS patients. 
Erythropoiesis can be stimulated by EPO, which upon receptor binding leads to Chapter 1 
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activation of, amongst others, STAT5, PKB and ERK1/2. Recent studies have 
shown that EPO-stimulated, but not GM-CSF-or IL-3-induced STAT5 DNA 
binding and ERK1/2 activation were decreased in unfractionated mononuclear 
cells from MDS bone marrow 
297;298. However, in another study, STAT5, PKB, 
forkhead (FKHRL1) and ERK1/2 were normally activated by EPO in erythroid 
progenitor cells obtained in vitro from isolated CD34+ cells from MDS patients 
299. Furthermore, an additional study showed that impaired STAT5 DNA binding 
upon EPO stimulation did not correlate with impaired erythroid colony formation 
in MDS BMMNC 
300. The role of STAT5 in the disturbed erythroid differentiation 
of MDS progenitor cells therefor remains elusive.  
  Recently, it has been shown that inhibition of the MAPK p38 in CD34+ 
cells from MDS patients resulted in an increased erythroid and myeloid colony 
formation 
301. This was caused by inhibitory cytokine signalling in MDS patients, 
as MDS serum inhibited CFU-E and CFU-GM colony formation of normal 
hematopoietic progenitor cell, a feature that could be reversed by co-culture with 
p38-inhibitors. Furthermore, p38 activation was activated under basal culture 
conditions in a MDS cell line, possibly resulting in increased generation of the 
pro-apoptotic TNFα 
302. These results indicate a role for p38 in the impaired 
erythropoiesis and myelopoiesis in MDS.  
  With regards to signal transduction in megakaryopoiesis, it has been 
shown that STAT3, STAT5 and ERK1/2 were normally activated in CD34+ cells 
from a low-risk MDS patient in response to stimulation with Thrombopoietin, but 
increased in a high-risk patient 
303. Increased STAT3 activation has also been 
found as a result of G-CSF stimulation of cell lines transfected with a mutated G-
CSF receptor that has been found in high-risk MDS 
304. Patients with this 
receptor defect also showed an augmented colony growth. Further studies will 
need to illuminate whether increased STAT/MAPK activation is involved in the 
progression of the disease. 
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Scope of the thesis  
 
So far, no further studies have been performed with regards to the disturbed 
myelopoiesis in MDS patients, nor has activation of signal transduction pathways 
been studied in differentiated cells. As neutrophils appear to play such an 
important role in the pathology of the disease, it is of importance not only to 
describe the defects in these cells, but also to elucidate the molecular 
mechanisms underlying these defects. Identification of signal transduction 
pathways that are impaired in differentiated myeloid cells might give insight into 
the mechanisms of the occurance of defects in the molecular biology of their 
progenitors. Therefore, the dual aim of this thesis is to (1) investigate the 
disturbed neutrophil functions in MDS patients, with special emphasis on the 
impaired priming responses observed in these patients, and (2) identify the 
signalling pathways that might be involved in the affected neutrophil responses in 
these patients. In chapter 2 we show that priming of ROS production is impaired 
in MDS patients, and that disturbed PKB and ERK1/2 phosphorylation might play 
a role in this defect. In chapter 3, we further investigated the impaired GM-CSF 
priming response in MDS neutrophils, and observed a defective priming of 
PtdIns(3,4,5)P3 accumulation, leading to impaired priming of Rac activation in  
neutrophils from MDS patients. In chapter 3 we studied the NADPH oxidase in 
MDS neutrophils, and demonstrate an impaired protein- and plasma membrane-
expression of flavocytochrome b558 in these patients, which might contribute to 
the defective priming of ROS production. Finally, in chapter 4, we show that 
besides ROS production, chemotaxis in response IL-8 and GROα are also 
impaired in MDS neutrophils, and that this might be a consequence of decreased 
IL-8/GROα-induced PI3K and ERK-signaling in neutrophils from these patients.  
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Abstract 
 
Neutrophils from patients with myelodysplastic syndrome (MDS) show a 
disturbed differentiation pattern and are generally dysfunctional. To study these 
defects in more detail we investigated the reactive oxygen species (ROS) 
production and F-actin polymerisation in neutrophils from MDS patients and 
healthy controls, and the involvement of N-formyl-L-metionyl-L-lucyl-L-
phenylalanine (fMLP) and granulocyte macrophage-colony-stimulating factor 
(GM-CSF)-stimulated signal transduction pathways. Following fMLP stimulation, 
similar levels of respiratory burst, F-actin polymerisation and activation of the 
small GTPase Rac2 were demonstrated in MDS and normal neutrophils. 
However, GM-CSF and G-CSF priming of ROS production were significantly 
decreased in MDS patients. We subsequently investigated the signal 
transduction pathways involved in ROS generation, and demonstrated that fMLP-
stimulated ROS production was inhibited by the phosphatidylinositol 3 kinase 
(PI3K) inhibitor LY294002, but not by the MAP/ERK kinase (MEK) inhibitor 
U0126. In contrast, ROS production induced by fMLP stimulation of GM-CSF-
primed cells was inhibited by both LY294002 and U0126. This coincides with an 
enhanced protein kinase B (PKB/Akt) phosphorylation that was PI3K dependent 
and enhanced extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) 
phosphorylation that was PI3K independent. We demonstrated higher protein 
levels of the PI3K subunit p110 in neutrophils from MDS patients and found that 
though the fMLP-induced phosphorylation of PKB/Akt and ERK1/2 could also be 
enhanced by pre-treatment with GM-CSF in these patients, the degree and 
kinetics of PKB/Akt and ERK1/2 phosphorylation were significantly disturbed. 
These defects were observed despite a normal GM-CSF-induced signal 
transducer and activator of transcription 5 (STAT5) phosphorylation. Our results 
indicate that the reduced priming of neutrophil ROS production in MDS patients 
might be caused by a disturbed convergence of the fMLP and GM-CSF signalling 
routes. Chapter 2 
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Introduction 
 
The Myelodysplastic syndromes (MDS) are characterised by a differentiation 
defect in the multipotent stem cell compartment, resulting in a disturbed 
proliferation and differentiation of the erythroid, myeloid or megakaryocytic 
lineage 
1. With regard to the myeloid lineage it has been shown that the intrinsic 
defect leads to granulocytopenia and to aberrant functioning of neutrophils. For 
instance, there have been reports indicating that reorganisation of the actin 
cytoskeleton 
2 and the production of reactive oxygen species (ROS) 
3;4 are 
affected in neutrophils from MDS patients.  
Bacterial infections are the most common cause of death in MDS 
patients 
5. The capacity of neutrophils to produce ROS such as O2
- and H2O2 
during the respiratory burst is essential for their bactericidal activity 
6. ROS 
production can be stimulated by chemotactic factors, such as the bacterial 
peptide analogue N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) 
7. 
Proinflammatory agents like granulocyte-macrophage-colony stimulating factor 
(GM-CSF) or granulocyte-colony-stimulating factor (G-CSF) prime the fMLP-
mediated respiratory burst, but do not elicit ROS production on their own 
8;9. This 
priming effect is not specific for ROS production but has also been described for 
other cellular events, such as degranulation, migration and adherence 
10;11.  
The respiratory burst and additional neutrophil effector functions such as 
granule trafficking and phagocytosis are dependent on the organisation of the 
actin cytoskeleton 
12-15. There are 2 forms of actin, a monomeric form (G-actin) 
and a filamentous form (F-actin), that exist in an equilibrium in the cell. Upon 
stimulation of neutrophils with chemotactic factors, rapid conversion of G-actin to 
F-actin occurs 
16;17. In contrast to ROS production, F-actin polymerisation cannot 
be primed by proinflammatory factors. 
  Different signal transduction pathways have been identified that are 
critical for the cellular functions of neutrophils. Rac2, a member of the Rho family 
of small GTPases, acts as a molecular switch by cycling between an inactive 
guanosine diphosphate (GDP)-bound state and an active guanosine triphosphate 
(GTP)-bound state. Rac2 is involved in the reorganisation of the actin 
cytoskeleton 
18-20 and the fMLP mediated respiratory burst, as demonstrated by 
experiments in Rac
-/- mice and in patients with an inhibitory Rac2 mutation 
21-24. 
In addition, phosphatidylinositol 3 kinase (PI3K) plays an important role in 
neutrophil ROS production. Several class I isoforms of PI3K have been identified; 
class IA catalytic subunits p110α, β and δ associate with the regulatory subunit 
p85, whereas the class IB catalytic subunit p110γ associates with p101. Evidence Reduced PKB/Akt and ERK phosphorylation in MDS 
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for PI3K involvement in neutrophil respiratory burst comes from studies with 
specific PI3K inhibitors 
25-27. Furthermore, lipid products of PI3K associate with 
the phagocyte oxidase proteins p47
phox  and p40
phox, two components of the 
neutrophil oxidase complex. The association of one of these lipids with p40
phox 
has a regulatory effect on ROS production 
28;29. Additional studies have revealed 
that the extracellular signal-regulated protein kinase 1 and 2 (ERK1/2), a key 
member of the mitogen-activated protein kinase (MAPK) cascade, might be 
involved in the neutrophil respiratory burst. Inhibition of ERK activation by 
chemical inhibitors resulted in a reduction of fMLP-induced and GM-CSF-primed 
ROS production in human neutrophils in several studies 
27;30.   
In this study, we further characterised the disturbed neutrophil responses 
in MDS and questioned which signal transduction pathways might be involved in 
aberrant neutrophil functioning. We demonstrated normal fMLP-mediated 
respiratory burst, F-actin polymerisation and Rac2 activation in neutrophils from 
MDS patients but found a strongly decreased priming effect of GM-CSF and G-
CSF on ROS production. Analysis of signal transduction pathways revealed 
higher protein expression levels of the PI3K subunit p110 in neutrophils from 
MDS patients. Further examination also indicated altered phosphorylation levels 
of protein kinase B (PKB/Akt) and ERK1/2 in MDS patients. 
 
 
Materials and methods 
 
Reagents 
N-formyl-L-methionyl-L-leucyl-L-Phenylalanine (fMLP), phorbol 12-myristate 13-
acetate (PMA), ferricytochrome c and superoxide dismutase (SOD) were 
obtained from Sigma (St. Louis, MO). Recombinant human GM-CSF was from 
Sandoz (Uden, The Netherlands) and r-metHuG-CSF was from Roche (Almere, 
The Netherlands). The PI3K inhibitor LY294002 was purchased from Alexis 
(Läufelfingen, Switzerland) and the MEK inhibitor U0126 was obtained from New 
England Biolabs (Beverly, MA). The GST-PAK-CD construct was a generous gift 
from Dr. P. J. Coffer. Oregon Green 514-phalloidin and Dihydro-rhodamine 123 
(DHR123) were purchased from Molecular Probes (Eugene, OR). Polyclonal 
antibody against ERK1/2 (K23), and monoclonal antibody against PI3-kinase 
p110 (D-4) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Monoclonal antibody against phosphorylated STAT5A/B (Y694/Y699) was from 
Upstate Biotechnology (Lake Placid, NY), antibodies against phosphorylated 
ERK1/2 (Thr202/Tyr204) and phosphorylated PKB/Akt (Ser473) were obtained Chapter 2 
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from Cell Signaling technology (Beverly, MA). Anti-Rac antibody was from 
Transduction Laboratories (Lexington, KY). 
  
Patients 
Fourteen patients with MDS were studied. MDS was classified as refractory 
anemia (RA) or RA with ringed sideroblasts (RARS) according to FAB 
cooperative group criteria 
31. Informed consent was obtained from all patients. 
The protocol was approved by the Human Subject Review Board of the 
University Hospital Groningen. 
 
Isolation of neutrophils 
Peripheral blood, anti-coagulated with 0.32% sodium citrate, was obtained from 
healthy volunteers and MDS patients. Neutrophils were isolated as described by 
Koenderman et al 
32. In short, mononuclear cells were removed by centrifugation 
over Fycoll-Paque (Amersham, Upsala, Sweden) and erythrocytes were lysed 
with ice-cold NH4Cl solution. Neutrophils were allowed to recover for 30 min at 37 
°C in RPMI 1640 (Bio Whittaker, Verviers, Belgium) supplemented with 0.5% 
human serum albumin (HSA; CLB, Amsterdam, The Netherlands). Before 
stimulation, cells were resuspended in incubation buffer (20 mM HEPES, 132 
mM NaCl, 6 mM KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM 
CaCl2, 0.5% HSA). In all cases, the cell population isolated consisted of >95% 
neutrophils as determined by May-Grünwald Giemsa staining. 
 
F-actin polymerisation assay 
F-actin polymerisation was measured as described by Nijhuis et al 
33. In short, 
neutrophils (2.5 x 10
6 cells/mL) were stimulated with 1 µM fMLP. At indicated 
time points, cells were fixed and permeabilised for 10 min at room temperature 
with ice-cold 3% formaldehyde in PBS, containing 100 µg/mL 
lysophosphatidylcholine (Sigma, St.Louis, MO). Polymerised F-actin was stained 
with 2.5 U/mL Oregon Green 514-phalloidin for 30 minutes at room temperature. 
The intracellular fluorescence was determined by flow cytometry (FACScalibur, 
Becton Dickinson Medical Systems, Sharon, MA). 
 
Respiratory burst measurement 
Production of H2O2 was measured as described by Mardiney III et al 
34, with 
some alterations. Briefly, neutrophils (2.5x10
6  cells/mL) were incubated with 
DHR123 for 15 minutes and stimulated with 1 µM fMLP for 30 minutes. For 
priming experiments, cells were pretreated with 5 ng/mL GM-CSF and/or 2.5 Reduced PKB/Akt and ERK phosphorylation in MDS 
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ng/mL G-CSF for 15 minutes prior to fMLP stimulation. When indicated, 
neutrophils were pretreated with signal transduction inhibitors. Stimulation of the 
neutrophils with fMLP was terminated by washing the cells with ice-cold PBS 
containing 1% HSA and placing them on ice. Oxidation of DHR123 to the 
fluorescent Rhodamine 123 was measured by FACS-analysis within 30 minutes.  
Alternatively, O2
- generation was measured by the superoxide 
dismutase-inhibitable reduction of ferricytochrome c as described by Franssen et 
al 
35. In short, GM-CSF-primed or unprimed neutrophils (1x10
6 cells/mL) were 
incubated in 96-well microtiter plates with ferricytochrome c at a final 
concentration of 0.856 mg/mL, either with SOD at a final concentration of 13.16 
units/mL or with an equal volume incubation buffer. Cells were stimulated with 1 
µM fMLP or 100 ng/mL PMA, and plates were scanned repetitively at 550 nm 
using an automated microplate reader (Thermomax, Molecular Devices, USA). 
Between readings, plates were kept at 37°C. The superoxide production was 
expressed as the difference in OD550 nm (∆OD 550) between the ferricytochrome 
c reduction test in the absence and in the presence of SOD. Each test was 
performed in quadruplicate.    
  
Rac activation assay 
Activated Rac was precipitated using the Cdc42 and Rac interactive binding 
(CRIB) domain of PAK (aa 56-272) as described previously 
36. Briefly, neutrophils 
(1 x 10
6 cells/ml) were stimulated with 0.1 µM fMLP for the indicated time and 
lysed for 10 minutes in Lysis Buffer (50 mMTris pH 7.4, 10% glycerol, 200 mM 
NaCl, 1% NP-40, 2 mM MgCl2, 2 mM Sodiumorthovanadate and protease 
inhibitors [1 tablet Complete (Roche, Mannheim, Germany) per 50 mL buffer]). 
Lysates were cleared by centrifugation, and GST-PAKcrib protein precoupled to 
glutathione-Sepharose beads (Pharmacia, Upsala, Sweden) was added for 30-
45 minutes at 4 °C. Beads were washed 3 times with 1 X Lysis Buffer and boiled 
in Laemmli sample buffer. The bound proteins were separated by 15% SDS-
PAGE and transferred to polyvinylidene difluoride membrane (Immobilon-P; 
Millipore, Bedford, MA). Activated Rac was detected by probing the membrane 
with anti-Rac antibodies and rabbit-anti-mouse peroxidase-conjugated antibodies 
(DAKO, Denmark) followed by enhanced chemiluminescence.  
 
Western blotting 
The amount of ERK, PI3-kinase p110 protein, and the phosphorylation of STAT5, 
ERK and PKB/Akt were determined by Western blotting. Neutrophils (2 x 10
6 
cells/mL) were preincubated with inhibitors and stimulated with 1 µM fMLP or 5 Chapter 2 
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ng/mL GM-CSF as indicated in the figures. Stimulation was terminated by placing 
the cells on ice, immediate centrifugation and resuspending the cell pellets in 1X 
Laemmli sample buffer. After boiling for 10 minutes, the proteins were separated 
on 10% SDS-PAGE and electrophoretically transferred to nitrocellulose 
membranes (Protran; Schleicher &Schuel, Dassel, Germany). Membranes were 
probed with antibodies against ERK1/2 (K23), PI3-kinase p110, phosphorylated 
STAT5A/B (Y694/Y699), phosphorylated ERK1/2 and phosphorylated PKB/Akt 
(Ser473) according to the manufacturers protocols. Proteins were detected by 
enhanced chemiluminescence.  The total amount of PKB/Akt present in the 
samples could not be quantified on membranes that were previously probed with 
antibodies against phosphorylated PKB/Akt due to high chemiluminescence of 
the phosphorylated protein. However, Western blot analysis of cell lysates from 3 
MDS patients and 3 healthy volunteers run on one gel and probed with PKB/Akt 
antibody (Cell Signaling technology, Beverly, MA), did not show differences in the 
amount of total PKB/Akt protein (data not shown). Quantification of 
phosphorylation levels was performed by densitometry of the films, using 
ImageMaster1D Elite (Pharmacia, Woerden, the Netherlands). 
 
Statistical analysis 
For respiratory burst measurements, differences in experimental values between 
healthy controls and MDS patients were calculated using the Mann-Whitney U 
test. Differences between paired samples were calculated using the Wilcoxon 
nonparametric test or the Student t test for samples treated with signal 
transduction inhibitors. For comparison of PI3K p110 levels in MDS patients and 
healthy donors, densitometry values of p110 protein were corrected for the 
amount of ERK protein present in the samples, and differences between the 
normalised values were calculated using the Student t test for unpaired samples. 
For quantification of phospho-PKB/Akt and phospho-ERK1/2 blots, differences in 
densitometry values of healthy controls as a percentage of that of MDS patients 
were calculated using the Student t test for paired samples. Data were expressed 
as mean ± SEM. P values <0.05 were considered significant. 
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Results 
 
FMLP stimulated F-actin polymerisation and Rac2 activation are not 
disturbed in neutrophils from MDS patients  
The fMLP-induced F-actin polymerisation was examined in neutrophils and 
compared in neutrophils from MDS patients and healthy controls (n = 8 for each 
group). On stimulation of neutrophils with 1 µM fMLP, a transient increase in the 
relative amount of F-actin was observed, that was maximal within 30 seconds 
and declined after 2 to 5 minutes. The maximum relative increase of F-actin 
content in neutrophils from healthy subjects was 507 ± 22%. This was 
comparable to the maximum relative increase of F-actin in neutrophils from MDS 
patients (507 ± 52%; p=0.963), though in MDS patients there was a wider 
variation in relative F-actin increase. The kinetics of F-actin polymerisation in 
MDS neutrophils was similar to that of healthy volunteers (data not shown). 
Although patients and healthy controls showed no significant difference in the 
kinetics and relative amount of F-actin formed in response to fMLP, 3 MDS 
patients did have a subpopulation of neutrophils (21, 48 and 49% of the total 
population) that had virtually no detectable F-actin polymerisation (Figure 1). 
These subpopulations could not be distinguished from the responsive neutrophil 
populations in dot-plot profiles, because their scattering profiles were identical. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A subpopulation of
neutrophils that does not
polymerise F-actin in response to
fMLP stimulation is present in some
MDS patients. 
Human neutrophils were stimulated
with 1 µM fMLP for the indicated time.
Cells were fixed and permeabilised,
and F-actin was stained with 2.5 U/ml
Oregon Green 514-phalloidin.
Fluorescence histograms are shown
for a representative healthy control (A)
and one of the MDS patients with a
nonresponsive neutrophil
subpopulation (B).  Chapter 2 
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To confirm the normal fMLP response of MDS neutrophils at the molecular level, 
the fMLP-stimulated Rac2 activation was studied by using a GST-beads pull-
down technique.  Figure 2A demonstrates that maximal Rac2 activation in 
neutrophils from healthy subjects was achieved after 15 seconds of fMLP 
stimulation and declined to near baseline levels within 15 minutes. Similar results 
were obtained in neutrophils from MDS patients (n = 8) though there was some 
variation in the extent and time course of Rac2 activation among donors (Figure 
2B). The mean increase in Rac2 activation after 15 seconds of fMLP stimulation 
was 729 ± 202% in neutrophils from healthy donors (n = 8), versus 658 ± 179% 
in neutrophils from MDS patients, as determined by densitometry of the films 
(p=0.795, data not shown). Western blot analysis of whole cell lysates of 
neutrophils from 5 MDS patients and 3 healthy controls, run on one gel, 
demonstrated equal amounts of total Rac protein present in all individuals (data 
not shown). 
 
Priming of the respiratory burst leads to an enhancement of superoxide 
radical production that is higher in healthy controls than in MDS patients  
Given that the production of ROS is an essential antibacterial defence 
mechanism of neutrophils, we studied the amount of superoxide produced in 
neutrophils in response to fMLP and the enhancement of this response by 
priming with GM-CSF, G-CSF, or both. H2O2 production was calculated by 
expressing the fluorescence of rhodamine 123 in stimulated cells as a 
percentage of the fluorescence of unstimulated cells.  
Figure 2. Rac2 is activated in response to
fMLP in neutrophils from healthy volunteers
and MDS patients. Neutrophils were stimulated
with 0.1 µM fMLP for the indicated time.
Stimulation was stopped by the addition of 3 X
Lysis Buffer. Activated Rac2 was precipitated
using GST-PAKcrib protein precoupled to
glutathione-Sepharose beads. Proteins were
separated by 15% SDS-PAGE and membranes
were probed with Rac antibodies, followed by
enhanced chemiluminescence. Rac activation
was investigated in neutrophils from 8 MDS
patients and 8 healthy controls. (A) Two
representative blots from healthy subjects. 
 (B) Three representative blots from MDS patients. Equal amounts of glutathione-Sepharose beads
were loaded in all samples, as determined by Ponceau S staining of the membranes (not shown).    Reduced PKB/Akt and ERK phosphorylation in MDS 
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As shown in Figure 3A, fMLP stimulation induced the production of ROS to a 
similar level in neutrophils from healthy controls and MDS patients (196 ± 18% 
and 257 ± 48%, respectively; p=0.753). In neutrophils from healthy donors, 
stimulation with GM-CSF or G-CSF alone did not lead to H2O2 production (data 
not shown). However, priming of the neutrophils with GM-CSF or G-CSF or both 
followed by fMLP stimulation lead to a significantly higher respiratory burst (656 ± 
65%, 329 ± 44% and 646 ± 60%, respectively) than when cells were stimulated 
with fMLP alone (p=0.012 for all 3 groups). In neutrophils from MDS patients, the 
mean percentage increase in fluorescence intensity stimulated by 1 µM fMLP 
following GM-CSF or G-CSF priming were 323 ± 39% and 276 ± 50%, 
respectively, which was significantly higher than fMLP stimulation alone (p=0.017 
and 0.018, respectively). However, as shown in Figure 3B, the percentage 
increase in H2O2 production because of priming of neutrophils with GM-CSF, G-
CSF or both was significantly decreased in neutrophils from MDS patients 
Figure 3. Priming of fMLP-stimulated H2O2
production by GM-CSF and G-CSF is
significantly decreased in neutrophils from
MDS patients compared with healthy
subjects.  Neutrophils were stimulated for 30
minutes with 1 µM fMLP with or without
preincubation for 15 minutes with 5 ng/mL GM-
CSF, 2.5 ng/mL G-CSF or both. The production
of H2O2 after stimulation was measured by FACS
analysis and expressed as a percentage of the
fluorescence in unstimulated cells. (A) Mean
ROS  production was calculated for 8 healthy
subject and 8 MDS patients. Asterisks represent
significant differences in percentage H2O2
production in the primed groups versus the
groups that were stimulated with fMLP alone (P <
0.05). (B) The respiratory burst enhancing
capabilities of GM-CSF, G-CSF, or both were
calculated for each individual donor as follows;
(GM-CSF + fMLP)/fMLP, (G-CSF + fMLP)/fMLP
and (GM-CSF + G-CSF + fMLP)/fMLP. The
mean priming capacity of GM-CSF, G-CSF or 
both on neutrophil respiratory burst are shown for 8 healthy subjects and 8 MDS patients.
Differences between MDS patients and healthy controls were calculated using the Wilcoxon
nonparametric tests. (* P < 0.05).  Chapter 2 
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compared to healthy controls (p=0.002, p=0.012 and p=0.003 respectively). 
These results indicate that whereas the fMLP triggered H2O2 production is 
normal in MDS patients, GM-CSF and G-CSF priming of the respiratory burst are 
considerably disturbed. These results were confirmed for O2
-  production by 
measuring ferricytochrome c reduction in the presence and absence of 
superoxide dismutase. Figure 4A shows that there was no significant difference 
in O2
- production in response to fMLP stimulation in neutrophils from healthy 
donors (n=3) and MDS patients (n=4). When neutrophils were primed with GM-
CSF, subsequent fMLP stimulation triggered significantly higher O2
- generation in 
neutrophils from healthy donors then in MDS patients (Figure 4B). In contrast, 
stimulation of O2
- production by PMA, which is much slower in onset, was equal 
in neutrophils from MDS patients and healthy donors (Figure 4C). These results 
indicate that priming of the generation of multiple ROS is greatly disturbed in 
neutrophils from MDS patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
expressed as the difference in OD550 nm (∆OD 550) between the ferricitochrome c reduction test in
the absence and in the presence of 13.16 U/mL SOD. Each test was performed in quadruplicate.
The mean O2- production for 3 healthy volunteers and 4 MDS patients are shown. Differences
between MDS patients and healthy controls were calculated using the Wilcoxon nonparametric test.
(* P < 0.05).  
Figure 4. Priming of fMLP-stimulated O2
-
production by GM-CSF is significantly
decreased in neutrophils from MDS
patients compared with healthy subjects.
Freshly isolated neutrophils were (A)
stimulated with 1 µM fMLP, (B) primed with 5
ng/mL GM-CSF for 15 min before fMLP
stimulation or (C) stimulated with 100 ng/mL
PMA, and plates were scanned repetitively at
550 nm using an automated microplate
reader. Superoxide production was  Reduced PKB/Akt and ERK phosphorylation in MDS 
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PI3K is involved in fMLP-and GM-CSF-stimulated respiratory burst and 
PKB/Akt phosphorylation in neutrophils from healthy donors 
Our studies indicate that the priming effect of GM-CSF and G-CSF on the fMLP-
induced respiratory burst is disturbed in MDS. To elucidate the signal 
transduction routes involved in the ROS production in healthy neutrophils, 
several chemical inhibitors of signal transduction pathways were used. First, we 
tested the effect of the specific PI3K inhibitor, LY294002, on the fMLP-stimulated 
respiratory burst in neutrophils, with or without GM-CSF pretreatment. Figure 5A 
demonstrates that the fMLP-induced respiratory burst could be significantly 
inhibited at a concentration of 1 µM LY294002 (32 ± 8%; p=0.021). Higher 
concentrations of LY294002 lead to an even more pronounced reduction in 
fMLP-stimulated ROS production (66 ± 5% and 85 ± 8% for 10 and 100 µM 
LY294002, respectively; p<0.05). The GM-CSF-primed respiratory burst was also 
significantly attenuated by preincubation of neutrophils with all concentrations 
LY294002 tested. At concentrations of 1 and 10 µM LY294002, the reduction in 
fMLP-stimulated ROS production was significantly higher in the GM-CSF-primed 
group (70±4% and 89±4%, respectively) than in the unprimed group (p<0.05). 
Incubation of neutrophils with 100 µM LY294002 lead to an inhibition of the GM-
CSF-primed ROS production of 93 ± 3%, which was statistically similar to the 
unprimed group. 
    An important downstream target of PI3K is PKB/Akt.
37;38 As shown in 
Figure 5B (upper panel), fMLP induced PKB/Akt serine phosphorylation in a time 
dependent manner. Phosphorylation was maximal within 2 minutes and declined 
to near basal levels after 10 minutes of stimulation. GM-CSF alone stimulated 
PKB/Akt phosphorylation to a much lower extent (Figure 5B). Longer exposure 
demonstrated that GM-CSF-stimulated phosphorylation occurred with a 
maximum at 2 minutes (Figure 5C). Interestingly, PKB/Akt phosphorylation by 
fMLP could be enhanced by pretreatment of the neutrophils with GM-CSF. 
Figure 5D demonstrates that the phosphorylation of PKB/Akt by 
stimulation of unprimed or GM-CSF-primed neutrophils with fMLP, or GM-CSF 
alone, could be partially inhibited by preincubation of the neutrophils with 1 µM 
LY294002 and completely with 10 µM. This indicates that the concentrations 
LY294002 used effectively inhibited PI3K activation. Our results demonstrate that 
fMLP stimulation of neutrophils leads to the production of reactive oxygen 
species at least partially by activating PI3K, and they imply that the priming effect 
of GM-CSF on the fMLP-induced neutrophil burst is completely dependent on 
activation of PI3K. 
 Chapter 2 
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Figure 5. Effect of LY294002 on ROS production and PKB/Akt phosphorylation in neutrophils
from healthy volunteers. (A) Isolated neutrophils were preincubated with 1, 10 or 100 µM
LY294002 for 30 minutes and stimulated for 20 minutes with 1 µM fMLP with or without priming with
5 ng/mL GM-CSF. ROS production was measured by FACS analysis. Results represent the mean
increase in ROS produced after stimulation, compared with unstimulated cells, of 4 individual
experiments. Significant reductions in the respiratory burst by pretreatment of the neutrophils with
LY294002 are indicated by single asterisks (P < 0.05). Significant differences between the unprimed
and GM-CSF-primed groups in inhibition of ROS production by LY294002 are indicated with two
asterisks (P < 0.05) (B) Neutrophils were stimulated with 1 µM fMLP, with or without priming with 5
ng/mL GM-CSF, or with GM-CSF alone. Serine-phosphorylated PKB/Akt was detected by Western
blot analysis and immunodetection. ERK1/2 antibodies were used to determine equal loading (lower
panel). (C) To better visualise the GM-CSF-stimulated PKB/Akt phosphorylation, a longer exposure
of another Western blot is shown. (D) Isolated human neutrophils were preincubated with increasing
amounts of LY294002 for 30 minutes and stimulated for 2 minutes with either 1 µM fMLP, with or
without GM-CSF priming,  or 5 ng/mL GM-CSF alone. Unstimulated cells were run as negative
control (c). Cell lysates were analysed by Western blotting, using an antibody against serine-
phosphorylated PKB/Akt (upper panel). Equal protein loading in the samples was confirmed by
immunodetection of ERK1/2 (lower panel). A representative blot of 3 independent experiments is
shown. Reduced PKB/Akt and ERK phosphorylation in MDS 
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GM-CSF-mediated enhancement of fMLP-stimulated respiratory burst is 
inhibited by preincubation of healthy neutrophils with the ERK inhibitor, 
U0126  
Next, we studied the role of the MEK/ERK-pathway in the fMLP-induced 
respiratory burst in neutrophils by using the extremely potent, selective inhibitor 
of MEK1/2, U0126. Figure 6A shows that the unprimed fMLP-stimulated ROS 
production was not significantly reduced by preincubation of the neutrophils with 
U0126 (39 ± 20%; p=0.554). However, GM-CSF priming of the respiratory burst 
could be significantly inhibited by 10 µM U0126 by 65 ± 1% (p=0.021). Similar 
results were obtained when neutrophils were preincubated with 50 µM PD98059, 
another chemical MEK1/2 inhibitor (data not shown). 
We subsequently examined the activation of the MEK/ERK pathway at 
the protein level. Phosphorylation of Thr202/Tyr204 of ERK1/2 was observed 
within 30 seconds of fMLP stimulation (Figure 6B). GM-CSF stimulation alone 
lead to ERK1/2 phosphorylation with a maximum at 2 minutes, although at a 
much lower level than the fMLP-stimulated ERK1/2 phosphorylation. Priming of 
neutrophils with GM-CSF, followed by fMLP stimulation resulted in an enhanced 
ERK1/2 phosphorylation compared to the effects of either fMLP or GM-CSF 
alone. The MEK1/2 inhibitor U0126, when added at a concentration of 10 µM, 
was capable of completely inhibiting ERK1/2 phosphorylation in unprimed and 
GM-CSF-primed neutrophils stimulated with 1 µM fMLP, and in neutrophils 
stimulated with 5 ng/ml GM-CSF alone (Figure 6C). Together these data suggest 
that the MEK-ERK route is not involved in the unprimed ROS production, but that 
it does play a role in the GM-CSF-priming effect of the respiratory burst. 
To establish the place of ERK in the signal transduction cascade, 
neutrophils were preincubated with LY294002 before fMLP or GM-CSF 
stimulation. As shown in Figure 7, ERK1/2 activation by fMLP with or without 
GM-CSF priming was not inhibited by preincubation of the cells with increasing 
concentrations LY294002. In contrast, the ERK1/2 activation induced by GM-
CSF stimulation alone was completely inhibited at 10 µM LY294002. These 
results indicate that whereas GM-CSF-mediated ERK1/2 phosphorylation is a 
downstream event of PI3K activation, the fMLP stimulated ERK1/2 
phosphorylation in GM-CSF-primed cells is PI3K independent. 
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Figure 6. Effect of U0126 on ROS production and ERK1/2 phosphorylation in neutrophils from
healthy volunteers. (A) Isolated neutrophils were preincubated with 10 µM U0126 for 30 minutes
and stimulated for 20 minutes with 1 µM fMLP with or without priming with 5 ng/mL GM-CSF. ROS
production was measured by FACS analysis. Results represent the mean increase in ROS produced
after stimulation, compared with unstimulated cells, of 4 individual experiments. Significant reduction
of the respiratory burst by U0126 is indicated by an asterisk (P < 0.05). (B) Neutrophils were
stimulated with 1 µM fMLP with or without priming with 5 ng/mL GM-CSF, or GM-CSF alone.
Phosphorylation of ERK1/2 was detected by Western blot analysis and immunodetection. To confirm
equal loading the total amount of ERK1/2 was detected using the ERK1/2 K23 antibody (lower panel).
A representative blot is shown of 3 independent experiments. (C) Neutrophils were preincubated with
10 µM U0126 for 30 minutes when indicated and were stimulated for the indicated amount of time
with 1 µM fMLP, with or without priming with 5 ng/mL GM-CSF, or GM-CSF alone. Cell lysates were
analysed by Western blotting, using an antibody against phosphorylated ERK1/2 (upper panel). Equal
protein loading in the samples was confirmed by immunodetection of ERK1/2 (lower panel). 
 
Figure 7. Effect of LY294002 on the
fMLP-and GM-CSF-induced phospho-
rylation of ERK1/2 in human
neutrophils. 
Neutrophils from a healthy volunteer
were preincubated with the indicated
concentrations LY294002 for 30
minutes. Neutrophils were subsequently 
 stimulated for two minutes with 1 µM fMLP alone, fMLP following priming of the neutrophils with 5
ng/mL GM-CSF, or 5 ng/mL GM-CSF alone. Stimulation was stopped by the addition of 1 X Laemmli
buffer to the pelleted neutrophils and boiling the samples. Proteins were separated by SDS-PAGE,
and Western blotting was performed using an antibody against phosphorylated ERK1/2 (upper
panel). Lysates of unstimulated cells were run as negative controls (C). Equal loading was
demonstrated by reprobing the blots with an antibody against ERK1/2 (lower panels). Reduced PKB/Akt and ERK phosphorylation in MDS 
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Altered PI3K p110 protein levels and decreased PKB/Akt phosphorylation 
in neutrophils from MDS patients 
Because our results indicate an involvement of PI3K in the priming of the 
respiratory burst and a disturbed priming of this burst in neutrophils from MDS 
patients, we investigated the protein levels of the PI3K subunit p110 in 
neutrophils from healthy donors (n=5) and MDS patients (n=7). Figure 8 shows 
that though the p110 levels differed between individual donors (Figure 8A), the 
amount of p110 present in the neutrophil lysates of MDS patients was 
significantly higher then in healthy volunteers after correction for ERK levels 
(Figure 8B, p<0.05). These results indicate increased protein expression of the 
catalytically active p110 subunit in MDS neutrophils, possibly resulting in a 
disturbed regulation of the PI3K signalling pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We subsequently examined the activation of PKB/Akt in neutrophils from 
MDS patients (n = 5). Isolated neutrophils were stimulated with fMLP with or 
without GM-CSF pretreatment or GM-CSF alone, and proteins were separated 
by SDS-PAGE. In each experiment, lysates of neutrophils from healthy controls, 
stimulated under the same experimental conditions, were run as controls. Time 
curve experiments in neutrophils from MDS patients demonstrated maximal 
PKB/Akt phosphorylation after 30 seconds of fMLP stimulation and after 2 min of 
Figure 8. Increased PI3-kinase subunit p110 protein levels in neutrophils from MDS patients.
(A) Neutrophils from healthy donors (n=5) and MDS patients (n=7) were resuspended in 1 X Laemmli
buffer, and samples were boiled. Proteins were separated by SDS-PAGE, and Western blotting was
performed using an antibody against PI3-kinase p110 (upper panels).  Equal loading was
demonstrated by reprobing the blots with an antibody against ERK1/2 (lower panels). (B) Protein
levels were quantified by densitometry of the films. The p110 protein levels were corrected for ERK
levels, and differences between the means of the normalised values were calculated between MDS
neutrophils and healthy donors using the Student t test for unpaired samples. Significant differences
are indicated with an asterisk (P < 0.05).Chapter 2 
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GM-CSF stimulation in most patients (Figure 9A-C). As in healthy donors, GM-
CSF priming of the neutrophils from the MDS patients resulted in an enhanced 
phosphorylation of PKB/Akt compared with the effects of fMLP or GM-CSF alone. 
Interestingly, in all cases studied, the total amount of phosphorylated PKB/Akt 
present after stimulation with fMLP with or without priming appeared lower in 
MDS neutrophils than in healthy controls (compare lanes 3 and 9 and lanes 6 
and 10 in Figure 9A and lanes 3 and 11 and lanes 6 and 12 in Figure 9B-C). 
Quantification of the phosphorylation levels by densitometry indicated that the 
amount of phosphorylated PKB/Akt present in fMLP-stimulated neutrophil lysates 
was significantly higher in healthy donors than in MDS patients (p<0.05). In GM-
CSF-primed cells, fMLP stimulation also lead to a higher phosphorylation of 
PKB/Akt in healthy donors than in MDS patients, though this was not significant, 
because of the high SEM (p=0.073) (Figure 9D). Furthermore, a difference in the 
kinetics of phosphorylation was noted between MDS neutrophils and healthy 
controls. In 4 of 5 patients studied, the amount of fMLP-induced phosphorylation 
of PKB/Akt following GM-CSF priming was identical at 30 seconds and 2 minutes 
of stimulation, whereas in the majority of healthy controls the phosphorylation 
level was significantly higher at 2 minutes than at 30 seconds (Figure 5B and 
data not shown). Protein loading was equal in all samples, as assessed by 
Western blotting for ERK1/2. These data indicate that in neutrophils from MDS 
patients, the kinetics and the maximal levels of PKB/Akt phosphorylation induced 
by fMLP stimulation and GM-CSF priming are affected. 
 
Phosphorylation of ERK1/2 is decreased in neutrophils from MDS patients 
Since we demonstrated that the MEK/ERK pathway is also involved in the GM-
CSF-mediated priming of the respiratory burst, we compared the phosphorylation 
pattern of ERK1/2 after stimulation in neutrophils from healthy volunteers and 
MDS patients. FMLP-induced phosphorylation in MDS neutrophils could be 
enhanced by GM-CSF pretreatment in a manner similar to that in neutrophils 
from healthy controls (Figure 9A-C, middle panels). In all cases it was observed 
that the total amount of phosphorylated ERK1/2 present after 2 minutes of fMLP 
stimulation was slightly, but significantly, higher in GM-CSF-primed and unprimed 
neutrophils from healthy donors than in those from MDS patients (p=0.013 and 
0.010, respectively), though this was much less pronounced than for 
phosphorylated PKB/Akt (Figure 9D). 
  Finally, to exclude the possibility that the GM-CSF receptor in MDS is 
defective in general, we examined the capability of GM-CSF to induce the 
tyrosine phosphorylation of STAT5. Figure 10 shows that the GM-CSF-induced Reduced PKB/Akt and ERK phosphorylation in MDS 
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STAT5 phosphorylation, though varying slightly between persons, did not differ 
significantly between MDS patients and healthy subjects. These data suggest 
that GM-CSF receptors on neutrophils from MDS patients are functional. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Phosphorylation of PKB/AKT and ERK1/2 in response to fMLP and GM-CSF is
decreased in MDS patients.    
Neutrophils were isolated from whole blood from MDS patients and healthy controls as described.
Cells were stimulated with 1 µM fMLP with or without priming with 5 ng/mL GM-CSF, or 5 ng/mL GM-
CSF alone for the indicated time. Stimulation of the neutrophils was stopped by the boiling samples
in 1 X Laemmli buffer. The proteins were separated by SDS-PAGE, and PKB/Akt activation was
detected by Western blotting, using antibodies against phosphorylated PKB/Akt (A-C, upper panels).
The same blots were reprobed with an antibody against phosphorylated ERK1/2 (A-C, middle
panels). ERK1/2 is shown in the lower panels and represents equal protein loading. The experiment
was performed for 5 individual MDS patients and healthy controls. One patient was tested twice
independently, with identical results. results of 3 representative experiments are shown (A-C). (D)
Phosphorylation of PKB/Akt and ERK1/2 was quantified by densitometry of the films. The level of
phosphorylation of PKB/Akt and ERK1/2 in neutrophil lysates from healthy donors was expressed as
a percentage of the phosphorylation observed in cell lysates from MDS patients, run on the same
gel. Significant differences are indicated with asterisks (P < 0.05). 
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Discussion 
 
The present study demonstrates that the responses of neutrophils from MDS 
patients are significantly disturbed with regard to GM-CSF and G-CSF priming of 
the ROS production, whereas the fMLP-mediated cellular effects are not 
affected. In contrast to our findings, Carulli et al demonstrated a defect in the F-
actin polymerisation in neutrophils from MDS patients, but that applied especially 
to patients with refractory anemia (RA) with excess blasts (RAEB), REAB in 
transformation (RAEB-t) and chronic myelomonocytic leukaemia (CMML) 
2. In the 
present study, with patients with RA and RA with ring sideroblasts (RARS), no 
significant decrease in actin polymerisation was observed, though in 3 out of 8 
patients a neutrophil subpopulation was observed that did not polymerise F-actin 
in response to fMLP. However, respiratory burst measurements in these patients 
did not reveal separate neutrophil subpopulations; all neutrophils were capable of 
producing H2O2 following fMLP stimulation, indicating that the lack of F-actin 
polymerisation can not be attributed to an fMLP receptor defect. These results 
were further supported by our finding that Rac2 activation after fMLP stimulation 
was normal in neutrophils from MDS patients.  
In contrast, the priming effects of GM-CSF and G-CSF on ROS 
production were severely disturbed in neutrophils from MDS patients. Previous 
studies by Zabernigg et al 
3 and Ohsaka et al 
4 also demonstrated disturbed GM-
CSF priming of the respiratory burst in neutrophils from most, but not all, MDS 
Figure 10. GM-CSF stimulates STAT5 activation in neutrophils from MDS patients and healthy
controls to a similar extent. 
Cell lysates from unstimulated neutrophils (-) and neutrophils that were stimulated for 10 minutes
with 5 ng/mL GM-CSF (+) were analysed for 3 MDS patients and 3 healthy volunteers. Western blot
analysis was performed and proteins were detected using an antibody against phosphorylated
STAT5 (upper panel). Equal loading was confirmed by reprobing the blot with antibodies against
ERK1/2.  Reduced PKB/Akt and ERK phosphorylation in MDS 
70 
patients. In contrast to our study, Ohsaka et al found increased fMLP-induced O2
- 
production in several patients. Although we demonstrated a slightly higher O2
- 
generation in response to fMLP in neutrophils from MDS patients compared with 
healthy donors, the difference was not significant. This discrepancy might be 
explained by the greater heterogeneity of the patient population reported in the 
study by Ohsaka et al. In accordance with Zabernigg et al, we found a normal 
PMA-induced ROS production in neutrophils from MDS patients, indicating that 
the decreased respiratory burst observed after GM-CSF or G-CSF priming was 
not due to a general incapability of MDS neutrophils to generate high levels of 
ROS. 
The respiratory burst in neutrophils is produced by the reduced 
nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase complex, which 
in its inactive state consists of flavocytochrome b558, stored in the membrane of 
specific granules, and the cytosolic components p47
phox, p67
phox, p40
phox and 
Rac2. On stimulation of the neutrophils, the expression of the flavocytochrome 
on the plasma membrane is up-regulated, and the cytosolic components are 
transported to the membrane 
39;40. DeLeo et al have shown that 
lipopolysaccharide (LPS) priming of the neutrophils respiratory burst is 
accompanied by enhanced recruitment of flavocytochrome b558 and association 
of p47
phox, p67
phox and Rac2 with the plasma membrane 
41. Recently, it has been 
described that PI3K binds and activates the NADPH complex, including p40
phox 
and p47
phox, suggesting that it plays a major role in the respiratory burst 
28;29. This 
is confirmed by our finding that the PI3K inhibitor LY294002 is capable of 
inhibiting fMLP-stimulated ROS production in unprimed and GM-CSF primed 
neutrophils. To what extent the PI3K downstream target PKB/Akt is involved in 
the activation of the NADPH complex is unknown. Its involvement is often 
assumed as a result of the corresponding kinetics between PKB/Akt activation 
and respiratory burst as measured by cytochrome c reduction in response to 
chemoattractants 
42. Furthermore, as for ROS production, we show that the 
response of neutrophils to fMLP with regard to PKB/Akt phosphorylation can be 
primed by GM-CSF.  
fMLP-induced p47
phox phosphorylation has been shown to be mediated 
by ERK1/2 
43. However, the role of ERK1/2 in the chemoattractant-stimulated 
respiratory burst is disputed. Some studies indicate that MAPK is at least partially 
responsible for fMLP-induced ROS formation 
30;43-45, whereas in additional 
studies, no effect of ERK inhibitors on the neutrophil respiratory burst were 
observed 
26;46. The present study demonstrates that the fMLP-mediated ROS 
production is not significantly attenuated by the MEK inhibitor U0126. Moreover, Chapter 2 
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it appeared that LY294002 at 1 and 10 µM significantly inhibited the fMLP-
triggered respiratory burst without an effect on the fMLP-stimulated ERK1/2 
phosphorylation in unprimed or GM-CSF-primed neutrophils, indicating a PI3K-
independent activation of ERK. These data corroborate findings from Kodama et 
al who demonstrated that GM-CSF priming of ERK activity could not be inhibited 
by LY294002 
46. However, ROS formation in response to fMLP in GM-CSF-
primed neutrophils was significantly inhibited by the MEK inhibitor U0126. These 
findings underscore the role of ERK in ROS production of primed granulocytes 
independent of the PI3K cascade and are in line with the recent findings of Hedin 
et al. They demonstrated that ERK activation by Gi protein is regulated in part by 
a Ras- and PI3K-independent pathway which might be modulated by a tyrosine 
kinase 
47. One of signalling cascades that might be involved in this process is the 
GTPase Rap that can activate ERK independently of Ras 
48. 
Limited studies have been directed on the signalling events in 
hematopoietic cells of MDS patients. STAT5 DNA binding in response to 
erythropoietin (EPO) was shown to be impaired in cells of the erythroid lineage 
49;50. EPO exerts its STAT5-activating effect through phosphorylation of the Janus 
kinase 2 (JAK2) 
51;52, suggesting a central role for JAK2 in the disturbed 
signalling in MDS. However, GM-CSF stimulation of neutrophils from MDS 
patients led to STAT5 tyrosine phosphorylation that was comparable to healthy 
controls, implying that GM-CSF receptor and JAK2 activation is normal in MDS. 
In contrast, a significant defect was observed with regard to PKB/Akt and ERK1/2 
phosphorylation. FMLP-stimulated PKB/Akt phosphorylation in unprimed and 
GM-CSF-primed neutrophils was drastically lowered in MDS patients. Moreover, 
the kinetics of PKB/Akt phosphorylation were different than they were in healthy 
controls. These findings might be related to the altered p110 protein levels found 
in MDS neutrophils. The abundance of the catalytically active PI3K subunit, p110 
might result in a disturbed activation of the PI3K pathway. A recent study 
suggests that overexpression of myr-p110 in murine fibroblasts, resulting in 
constitutive PI3K activation, does not lead to constitutive PKB/Akt activation but 
rather to a reduced ability of stimuli to induce phosphorylation of PKB 
53.  
Differences similar to those for PKB/Akt activation were observed for 
ERK1/2 phosphorylation, albeit to a lesser extent. Because the fMLP-mediated 
cellular responses were normal in MDS patients and GM-CSF could properly 
stimulate STAT5 activation, it is tempting to speculate that the convergence of 
fMLP and GM-CSF signalling is disturbed in MDS patients. It is conceivable that 
altered PI3K-PKB/Akt and ERK1/2 activation patterns found in MDS patients Reduced PKB/Akt and ERK phosphorylation in MDS 
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might lead to decreased priming of the respiratory burst by preventing proper 
assembly of the NADPH enzyme complex. 
 In conclusion, our studies indicate that PI3-kinase p110 protein levels 
are increased in neutrophils from MDS patients and that the phosphorylation of 
PKB/Akt and, to a lesser extent, ERK1/2 is disturbed in neutrophils from these 
patients. Further research will have to elucidate to what extent these alterations 
in signalling events are responsible for the disturbed neutrophil effector functions 
in MDS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
 
We thank all patients and healthy volunteers who participated in the study. We 
also thank Drs Paul J. Coffer and Evert Nijhuis for their assistance regarding 
technical procedures and for their helpful suggestions.  Chapter 2 
73 
Reference List 
 
1.      Kouides PA, Bennett JM. Morphology and classification of the Myelodysplastic 
Syndromes and their pathologic variants. Seminars in Hematology. 1996;33:95-100.  
2.     Carulli G, Sbrana S, Minnucci S, et al. Actin polymerization in neutrophils from patients 
affected by myelodysplastic syndromes- a flow cytometric study. Leukemia Research. 
1997;21:513-518.  
3.     Zabernigg A, Hilbe W, Eisterer W, Greil R, Ludescher C, Thaler J. Cytokine priming of 
the granulocyte respiratory burst in myelodysplastic syndromes. Leuk Lymphoma. 
1997;27:137-143.  
4.     Ohsaka A, Kitagawa S, Yuo A, et al. Effects of granulocyte colony-stimulating factor and 
granulocyte- macrophage colony-stimulating factor on respiratory burst activity of 
neutrophils in patients with myelodysplastic syndromes. Clin Exp Immunol. 1993;91:308-
313.  
5.     Kouides PA, Bennett JM. Understanding the Myelodysplastic Syndromes. Oncologist. 
1997;2:389-401.  
6.      Babior BM. Oxidants from phagocytes: agents of defense and destruction. Blood. 
1984;64:959-966.  
7.     McPhail LC, Henson PM, Johnston RB, Jr. Respiratory burst enzyme in human 
neutrophils. Evidence for multiple mechanisms of activation. J Clin Invest. 1981;67:710-
716.  
8.     Weisbart RH, Kwan L, Golde DW, Gasson JC. Human GM-CSF primes neutrophils for 
enhanced oxidative metabolism in response to the major physiological chemoattractants. 
Blood. 1987;69:18-21.  
9.      Kitagawa S, Yuo A, Souza LM, Saito M, Miura Y, Takaku F. Recombinant human 
granulocyte colony-stimulating factor enhances superoxide release in human 
granulocytes stimulated by the chemotactic peptide. Biochem Biophys Res Commun. 
1987;144:1143-1146.  
10.      Gomez-Cambronero J, Veatch C. Emerging paradigms in granulocyte-macrophage 
colony-stimulating factor signaling. Life Sci. 1996;59:2099-2111.  
11.      Clark SC. Biological activities of human granulocyte-macrophage colony- stimulating 
factor. Int J Cell Cloning. 1988;6:365-377.  
12.     Grogan A, Reeves E, Keep N, et al. Cytosolic phox proteins interact with and regulate 
the assembly of coronin in neutrophils. J Cell Sci. 1997;110 ( Pt 24):3071-3081.  
13.     Mukherjee G, Quinn MT, Linner JG, Jesaitis AJ. Remodeling of the plasma membrane 
after stimulation of neutrophils with f-Met-Leu-Phe and dihydrocytochalasin B: 
identification of membrane subdomains containing NADPH oxidase activity. J Leukoc 
Biol. 1994;55:685-694.  
14.      Serrander L, Skarman P, Rasmussen B, et al. Selective inhibition of IgG-mediated 
phagocytosis in gelsolin-deficient murine neutrophils. J Immunol. 2000;165:2451-2457.  
15.      Rizoli SB, Rotstein OD, Parodo J, Phillips MJ, Kapus A. Hypertonic inhibition of 
exocytosis in neutrophils: central role for osmotic actin skeleton remodeling. Am J 
Physiol Cell Physiol. 2000;279:C619-C633.  
16.      Howard TH, Meyer WH. Chemotactic peptide modulation of actin assembly and 
locomotion in neutrophils. The Journal of Cell Biology. 1984;98:1265-1271.  
17.      Watts RG, Howard TH. Mechanisms for actin reorganization in chemotactic factor-
activated polymorphonuclear leukocytes. Blood. 1993;81:2750-2757.  
18.     Hall A. Rho-GTPases and the actin Cytoskeleton. Science. 1998;279:509-514.  
19.     Ma AD, Metjian A, Bagrodia S, Taylor S, Abrams CS. Cytoskeletal reorganization by G 
protein-coupled receptors is dependent on phosphoinositide 3-kinase gamma, a Rac 
guanosine exchange factor, and Rac. Mol Cell Biol. 1998;18:4744-4751.  
20.     Chung CY, Lee S, Briscoe C, Ellsworth C, Firtel RA. Role of Rac in controlling the actin 
cytoskeleton and chemotaxis in motile cells. Proc Natl Acad Sci U S A. 2000;97:5225-
5230.  
21.     Kim C, Dinauer MC. Rac2 is an essential regulator of neutrophil nicotinamide adenine 
dinucleotide phosphate oxidase activation in response to specific signaling pathways. J 
Immunol. 2001;166:1223-1232.  Reduced PKB/Akt and ERK phosphorylation in MDS 
74 
22.     Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency syndrome is 
associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci U S A. 2000;97:4654-
4659.  
23.     Williams DA, Tao W, Yang F, et al. Dominant negative mutation of the hematopoietic-
specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. 
Blood. 2000;96:1646-1654.  
24.     Dorseuil O, Reibel L, Bokoch GM, Camonis J, Gacon G. The Rac target NADPH oxidase 
p67phox interacts preferentially with Rac2 rather than Rac1. J Biol Chem. 1996;271:83-
88.  
25.     Ding J, Vlahos CJ, Liu R, Brown RF, Badwey JA. Antagonists of phosphatidylinositol 3-
kinase block activation of several novel protein kinases in neutrophils. J Biol Chem. 
1995;270:11684-11691.  
26.      Coffer PJ, Geijsen N, M'rabet L, et al. Comparison of the roles of mitogen-activated 
protein kinase kinase and phosphatidylinositol 3-kinase signal transduction in neutrophil 
effector function. Biochem J. 1998;329 ( Pt 1):121-130.  
27.      McLeish KR, Knall C, Ward RA, et al. Activation of mitogen-activated protein kinase 
cascades during priming of human neutrophils by TNF-alpha and GM-CSF. J Leukoc 
Biol. 1998;64:537-545.  
28.     Kanai F, Liu H, Field SJ, et al. The PX domains of p47phox and p40phox bind to lipid 
products of PI(3)K. Nat Cell Biol. 2001;3:675-678.  
29.      Ellson CD, Gobert-Gosse S, Anderson KE, et al. PtdIns(3)P regulates the neutrophil 
oxidase complex by binding to the PX domain of p40phox. Nat Cell Biol. 2001;3:679-682.  
30.     Djerdjouri B, Lenoir M, Giroud JP, Perianin A. Contribution of mitogen-activated protein 
kinase to stimulation of phospholipase D by the chemotactic peptide fMet-Leu-Phe in 
human neutrophils. Biochem Biophys Res Commun. 1999;264:371-375.  
31.      Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the 
myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.  
32.      Koenderman L, Kok PT, Hamelink ML, Verhoeven AJ, Bruijnzeel PL. An improved 
method for the isolation of eosinophilic granulocytes from peripheral blood of normal 
individuals. J Leukoc Biol. 1988;44:79-86.  
33.     Nijhuis E, Lammers JW, Koenderman L, Coffer PJ. Src kinases regulate PKB activation 
and modulate cytokine and chemoattractant-controlled neutrophil functioning. J Leukoc 
Biol. 2002;71:115-124.  
34.     Mardiney M, III, Jackson SH, Spratt SK, Li F, Holland SM, Malech HL. Enhanced host 
defense after gene transfer in the murine p47phox- deficient model of chronic 
granulomatous disease. Blood. 1997;89:2268-2275.  
35.     Franssen CF, Huitema MG, Muller Kobold AC, et al. In vitro neutrophil activation by 
antibodies to proteinase 3 and myeloperoxidase from patients with crescentic 
glomerulonephritis. J Am Soc Nephrol. 1999;10:1506-1515.  
36.     Sander EE, van Delft S, ten Klooster JP, et al. Matrix-dependent Tiam1/Rac signaling in 
epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by 
phosphatidylinositol 3-kinase. J Cell Biol. 1998;143:1385-1398.  
37.     Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of 
phosphatidylinositol 3-kinase activation. Biochem J. 1998;335 ( Pt 1):1-13.  
38.     Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to 
PKB. Biochem J. 2000;346 Pt 3:561-576.  
39.     Ward RA, Nakamura M, McLeish KR. Priming of the neutrophil respiratory burst involves 
p38 mitogen- activated protein kinase-dependent exocytosis of flavocytochrome b558- 
containing granules. J Biol Chem. 2000;275:36713-36719.  
40.     Babior BM. NADPH oxidase: an update. Blood. 1999;93:1464-1476.  
41.      DeLeo FR, Renee J, McCormick S, et al. Neutrophils exposed to bacterial 
lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Invest. 1998;101:455-
463.  
42.     Tilton B, Andjelkovic M, Didichenko SA, Hemmings BA, Thelen M. G-Protein-coupled 
receptors and Fcgamma-receptors mediate activation of Akt/protein kinase B in human 
phagocytes. J Biol Chem. 1997;272:28096-28101.  
43.    Dewas C, Fay M, Gougerot-Pocidalo MA, El Benna J. The mitogen-activated protein 
kinase extracellular signal-regulated kinase 1/2 pathway is involved in formyl-methionyl-
leucyl-phenylalanine- induced p47phox phosphorylation in human neutrophils. J 
Immunol. 2000;165:5238-5244.  Chapter 2 
75 
44.     Downey GP, Butler JR, Tapper H, et al. Importance of MEK in neutrophil microbicidal 
responsiveness. J Immunol. 1998;160:434-443.  
45.     Rane MJ, Carrithers SL, Arthur JM, Klein JB, McLeish KR. Formyl peptide receptors are 
coupled to multiple mitogen-activated protein kinase cascades by distinct signal 
transduction pathways: role in activation of reduced nicotinamide adenine dinucleotide 
oxidase. J Immunol. 1997;159:5070-5078.  
46.     Kodama T, Hazeki K, Hazeki O, Okada T, Ui M. Enhancement of chemotactic peptide-
induced activation of phosphoinositide 3-kinase by granulocyte-macrophage colony-
stimulating factor and its relation to the cytokine-mediated priming of neutrophil 
superoxide-anion production. Biochem J. 1999;337 ( Pt 2):201-209.  
47.     Hedin KE, Bell MP, Huntoon CJ, Karnitz LM, McKean DJ. Gi proteins use a novel beta 
gamma-and Ras-independent pathway to activate extracellular signal-related kinase and 
mobilize AP-1 transcription factors in Jurkat T lymphocytes. J Biol Chem. 
1999;274:19992-20001.  
48.      Garcia J, de Gunzburg J, Eychene A, Gisselbrecht S, Porteu F. Thrombopoietin-
mediated sustained activation of extracellular signal- regulated kinase in UT7-Mpl cells 
requires both Ras-Raf-1- and Rap1-B- Raf-dependent pathways. Mol Cell Biol. 
2001;21:2659-2670.  
49.     Hoefsloot LH, Amelsfoort vMP, Broeders LCAM, et al. Erythropoietin-induced activation 
of STAT5 is impared in the Myelodysplastic syndrome. Blood. 1997;89:1690-1700.  
50.    Fontenay-Roupie M, Bouscary D, Guesnu M, et al. Ineffective erythropoiesis in 
Myelodysplastic syndromes: correlation with Fas expression but not with lack of 
erythropoietin receptor signal transduction. Britisch Journal of Haematology. 
1999;106:464-473.  
51.      Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A. Interleukin 2 and erythropoietin 
activate STAT5/MGF via distinct pathways. EMBO J. 1995;14:2527-2535.  
52.        Pallard C, Gouilleux F, Charon M, Groner B, Gisselbrecht S, Dusanter-Fourt I. 
Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells. 
J Biol Chem. 1995;270:15942-15945.  
53.      Auger KR, Wang J, Narsimhan RP, Holcombe T, Roberts TM. Constitutive cellular 
expression of PI 3-kinase is distinct from transient expression. Biochem Biophys Res 
Commun. 2000;272:822-829.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Reduced PKB/Akt and ERK phosphorylation in MDS 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Disturbed granulocyte macrophage-colony 
stimulating factor priming of phosphatidylinositol 
3,4,5-trisphosphate accumulation and Rac activation 
in fMLP-stimulated neutrophils from patients with 
myelodysplasia 
 
 
 
 
Gwenny M. Fuhler, Karen A. Cadwallader, Gerlinde J. Knol,  
Edwin R. Chilvers, A. Lyndsay Drayer and Edo Vellenga 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal of Leukocyte Biology 76 (2004), 254-262 Disturbed priming in MDS 
78 
 
Abstract 
The production of reactive oxygen species (ROS) by human neutrophils is 
imperative for their bactericidal activity. Proinflammatory agents such as 
granulocyte macrophage-colony stimulating factor (GM-CSF) can prime ROS 
production in response to chemoattractants such as N-formyl-L-methionyl-leucyl-
L-phenylalanine (fMLP). In neutrophils from patients suffering from 
Myelodysplasic syndromes (MDS), a clonal, hematological disorder 
characterised by recurrent bacterial infections, this GM-CSF priming is severely 
impaired. In this study, we set out to further delineate the defects in neutrophils 
from MDS patients. We examined the effect of GM-CSF priming on fMLP-
triggered activation of Rac, a small GTPase implicated in neutrophil ROS 
production. In contrast to healthy neutrophils, activation of Rac in response to 
fMLP was not enhanced by GM-CSF pretreatment in MDS neutrophils. 
Furthermore, activation of Rac was attenuated by pretreatment of neutrophils 
with the phosphatidylinositol 3-kinase (PI-3K) inhibitor LY294002. Unlike healthy 
neutrophils, fMLP-induced accumulation of the PI-3K lipid product 
PI(3,4,5)trisphosphate was not increased by GM-CSF pretreatment in MDS 
neutrophils. The disturbed Rac and PI-3K activation observed in MDS neutrophils 
did not appear to reflect a general GM-CSF or fMLP receptor-signalling defect, 
as fMLP-triggered Ras activation could be primed by GM-CSF in both MDS and 
healthy neutrophils. Moreover, fMLP-induced activation of the GTPase Ral was 
also normal in neutrophils from MDS patients. Taken together, our data suggest 
that in neutrophils from MDS patients, a defect in priming of the PI-3K-Rac 
signalling pathway, located at the level of PI-3K, results in a decreased GM-CSF 
priming of ROS production. Chapter 3 
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Introduction 
 
The production of reactive oxygen species (ROS) by neutrophils is one of the 
most important defence mechanisms against infectious disease, and can be 
stimulated by chemoattractants such as the bacterial peptide analogue N-formyl-
L-methionyl-L-leucyl-L-phenylalanine (fMLP) 
1;2. Circulating neutrophils usually 
generate only limited amounts of oxygen radicals in response to such stimuli. 
However, proinflammatory agents released during infection, e.g., granulocyte 
macrophage-colony stimulating factor (GM-CSF), although not triggering ROS 
production directly, are capable of enhancing the neutrophil respiratory burst in 
response to other stimuli 
3. This process is known as 'priming', and greatly 
augments the innate immune system. Incapacity of neutrophils to produce 
superoxide anions efficiently results in syndromes that are characterised by an 
increased occurrence of life-threatening bacterial and fungal infections, such as 
glycogen storage disease type b or chronic granulomatous disease 
4;5.  
The Myelodysplastic syndromes (MDS) are distinguished by a 
differentiation defect in the multipotent stem-cell compartment, resulting in 
disturbed proliferation and differentiation of the erythroid, myeloid or 
megakaryocytic lineages 
6. The ensuing granulocytopenia and aberrant 
functioning of neutrophils make bacterial infections the most common cause of 
death in MDS patients 
7. We have recently shown that GM-CSF priming of the 
fMLP-triggered respiratory burst is severely impaired in neutrophils from MDS 
patients 
8. 
The molecular mechanisms underlying priming of ROS production are 
still unclear 
9-12. Generation of ROS is mediated by the granulocyte nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase. This enzyme consists of a 
membrane-bound component, flavocytochrome b558, and the cytosolic factors 
p47
phox, p40
phox, p67
phox and Rac 
13. Several reports have suggested that priming 
of the neutrophil respiratory burst results from enhanced translocation of 
flavocytochrome b558, which is stored in the membranes of specific granules and 
secundary vesicles, to the plasma membrane 
14;15.  However, we have previously 
shown that whereas GM-CSF priming of ROS production is decreased in 
neutrophils from MDS patients, GM-CSF-induced increases in flavocytochrome 
b558 expression at the plasma membrane are normal in these cells 
16. This 
suggests that an additional mechanism involved in GM-CSF priming is affected in 
MDS patients.  
Several signal-transduction molecules have been implicated in the 
priming of NADPH oxidase activity 
17-19. For example, the involvement of the lipid Disturbed priming in MDS 
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kinase phosphatidylinositol 3-kinase (PI-3K) in GM-CSF priming of fMLP 
stimulated ROS production has been established by using specific inhibitors 
8;17;20;21. A number of class I isoforms of PI-3K have been identified; class IA 
catalytic subunits p110α, -β and -δ associate with the regulatory subunit p85, 
whereas the class IB catalytic subunit p110γ associates with p101 
22. Upon 
stimulation of neutrophils, these PI-3Ks produce the phosphoinositide 
PI(3,4,5)trisphosphate (PIP3), which acts as an important second messenger for 
superoxide anion generation 
23. Its immediate metabolic products, PI(3,4)P2 and 
PI(3)P1, have also been implicated in regulating ROS production through an 
interaction with p47
phox and p40
phox  24;25.  
Evidence of priming at a molecular level comes from studies showing 
increased fMLP-stimulated PI-3K activation in GM-CSF-primed neutrophils 
compared to unprimed cells 
26;27. Furthermore, phosphorylation of the PI-3K 
downstream target protein kinase B (PKB/Akt) can be enhanced by GM-CSF 
pretreatment of neutrophils. Previously, we have shown that PKB/Akt activation 
in neutrophils from MDS patients is defective, suggesting disturbed PI-3K 
signalling in these cells 
8. 
Rac, a member of the Rho family of small GTPases, plays an important role in 
ROS production by regulating the assembly of the NADPH oxidase complex 
28. In 
resting cells, Rac is bound to guanosine 5'-diphosphate (GDP), and hence is 
inactive. Guanine nucleotide exchange factors (GEFs), stimulated upon 
neutrophil stimulation, activate Rac by allowing the exchange of GDP for 
guanosine 5'-triphosphate (GTP) (reviewed in ref 
29). Inactivation occurs as a 
result of intrinsic GTPase activity, which can be enhanced by GTPase-activating 
proteins (GAPs). Different GEFs for Rac have been described to possess a PI-
3K-binding domain, resulting in PI-3K-dependent activation of Rac (reviewed by 
Welch et al 
30). In return, Rac can activate PI-3K itself, although the mechanism 
for this is still unclear. Another GTPase capable of triggering PI-3K activity is 
Ras, a member of the well-studied Ras-Raf-mitogen-activated protein kinase 
kinase-extracellular signal-regulated kinase (ERK) signalling pathway 
31. Ras can 
also activate the GTPase Ral, through PI-3K-dependent or independent 
pathways 
32. However, Ras-independent mechanisms of Ral activation have also 
been identified 
33. The cellular function of Ral is still unclear, although recent 
evidence suggests that a downstream target of Ral, RLIP1, may play a regulatory 
role in Rac activation 
34.  Chapter 3 
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In this study, we addressed whether the disturbed GM-CSF priming of 
fMLP-induced ROS production in MDS neutrophils might reflect a defect in the 
activation of the GTPases Rac, Ras and Ral, and the production of PIP3. Our 
results demonstrate that in contrast to healthy donor neutrophils, Rac activation 
and PIP3 mass accumulation in response to fMLP stimulation could not be 
enhanced by GM-CSF in neutrophils from MDS patients. These impaired 
responses did not appear to be due to a general GM-CSF or fMLP receptor-
signalling defect, as the fMLP-triggered activation of Ral and GM-CSF priming of 
Ras activity were normal in MDS neutrophils. Taken together, our data suggest 
that in neutrophils from MDS patients, an impaired priming of the PI-3K-Rac 
signalling pathway results in a decreased GM-CSF priming of ROS production, 
and that this defect is located at the level of PI-3K.  
 
 
Materials and methods 
 
Reagents 
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) was obtained from Sigma 
(St. Louis, MO). Recombinant human GM-CSF supplied by Sandoz (Uden, The 
Netherlands). The PI-3K inhibitor LY294002 was purchased from Alexis 
(Läufelfingen, Switzerland). The GST-PAK-CRIB, GST-Raf-RBD and GST-RLIP-
RBD constructs were a generous gift from Dr. P. J. Coffer (Dept of Pulmonary 
Diseases, University Medical Center, Utrecht, The Netherlands). Anti-Rac, anti-
Ras and anti-Ral antibodies were supplied by Transduction Laboratories 
(Lexington, KY). [Inositol-1-[
3H](N)]-1,3,4,5-tetrakisphosphate was obtained from 
NEN Life Sciences (Boston, MA) and inositol 1,3,4,5-tetrakisphosphate 
(Ins(1,3,4,5)P4) was purchased from Cell Signals (Lexington, KY). 
  
Patients 
Eleven patients with MDS were studied. MDS was classified as refractory anemia 
(RA) or RA with ringed sideroblasts (RARS) according to French-American-
British Cooperative Group criteria 
35. Informed consent was obtained from all 
patients. The Human Subject Review Board of the University Hospital Groningen 
(The Netherlands) approved the protocol. 
 
Isolation of neutrophils 
Peripheral blood, anti-coagulated with 0.32% sodium citrate, was obtained from 
healthy volunteers and MDS patients. Neutrophils were isolated as described 
8;36. Disturbed priming in MDS 
82 
In short, mononuclear cells were removed by centrifugation over Fycoll-Paque 
(Amersham, Upsala, Sweden) and erythrocytes were lysed with ice-cold NH4Cl 
solution. Neutrophils were allowed to recover for 30 min at 37°°C in RPMI 1640 
(Bio Whittaker, Verviers, Belgium) supplemented with 0.5% human serum 
albumin (HSA; CLB, Amsterdam, The Netherlands). Before stimulation, cells 
were resuspended in incubation buffer (20 mM HEPES, 132 mM NaCl, 6 mM 
KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM CaCl2, 0.5% HSA). In 
all cases, the cell population isolated consisted of >95% neutrophils as 
determined by May-Grünwald Giemsa staining. 
 
Rac, Ras and Ral activation assays  
Activated Rac was precipitated using bacterial lysate containing GST-cdc42-and-
Rac-interactive-binding (CRIB) domain of PAK (GST-PAK-CRIB), activated Ras 
was pulled down using bacterial lysate containing GST-Ras-binding domain of 
Raf (GST-Raf-RBD), and activated Ral was precipitated using bacterial lysate 
containing GST-Ral-binding domain of RLIP76 (GST-RLIP-RBD) as described 
previously 
8;33. Briefly, neutrophils (1 x 10
6 cells/mL for Rac activation assay and 
10 x 10
6 cells/mL for Ral and Ras activation assays) were stimulated with 1 µM 
fMLP for the indicated time and lysed for 10 minutes in lysis buffer (50 mM Tris 
pH 7.4, 10% glycerol, 200 mM NaCl, 1% NP-40, 2 mM MgCl2, 2 mM 
sodiumorthovanadate and protease inhibitors [1 tablet Complete (Roche, 
Mannheim, Germany) per 50 ml buffer]). Lysates were cleared by centrifugation, 
and GST-PAK-CRIB, GST-Raf-RBD or GST-RLIP-RBD protein, pre-coupled to 
glutathione-sepharose beads (Pharmacia, Upsala, Sweden), was added for 30-
45 minutes at 4 °C. Beads were washed 3 times with 1 X lysis buffer and boiled 
in Laemmli sample buffer. The bound proteins were separated by 15% SDS-
PAGE and transferred to polyvinylidene difluoride membrane (Immobilon-P; 
Millipore, Bedford, MA). Activated Rac, Ras or Ral was detected by probing the 
membrane with anti-Rac, anti-Ras or anti-Ral antibodies, respectively, and 
rabbit-anti-mouse peroxidase-conjugated antibodies (DAKO, Denmark) followed 
by enhanced chemiluminescence. Equal amounts of glutathione sepharose 
beads were loaded in all samples as determined by Ponceau S staining of the 
membranes. Quantification of the amount of precipitated active GTPase was 
performed by densitometry of the films, using ImageMaster1D Elite (Pharmacia, 
Woerden, the Netherlands). Results are presented as normalised densitometry 
values (arbitrary units [AU]). 
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PIP3 mass assay 
Recombinant Ins(1,3,4,5)P4 binding protein (GAP
IP4BP) was purified as described 
previously 
37 and sample purity was analysed by SDS-PAGE. Total and non-
specific binding of [
3H]Ins(1,3,4,5)P4 in each preparation of GAP
IP4BP was 
assessed by serial dilution and inclusion of 0.1 nM InsP6, respectively. Thereafter 
the GAP
IP4BP was used at a concentration to achieve a maximum binding of 20% 
of the total [
3H]Ins(1,3,4,5)P4 input. Purified neutrophils (8 x 10
6) were stimulated 
with 1 µM fMLP or vehicle for the indicated times, with or without prior priming 
with GM-CSF (5 ng/mL) for 15 minutes. The reactions were stopped by the 
addition of methanol/chloroform (2:1, v/v) and lipid extractions were performed as 
described previously
27;38. After drying, the samples were processed as previously 
detailed and stored at -20°C until analysed. Immediately before the assay, 
samples were resuspended in dilute acetic acid to a final pH of 5. The 
Ins(1,3,4,5)P4 radioreceptor assay was performed as described using 0.005 µCi 
of [
3H]ins(1,3,4,5)P4 per sample 
23.                                                                                                                     
 
Statistical analysis 
Differences between unstimulated and stimulated samples from the same donor, 
and differences between samples treated with or without signal transduction 
inhibitors were calculated using the Wilcoxon non-parametric test for paired 
samples. Differences between healthy volunteers and MDS patients were 
calculated using the Mann-Whitney non-parametric test for unpaired samples. 
Data were expressed as mean ± SEM. P  values <0.05 were considered 
statistically significant. 
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Results 
 
Rac activation in response to fMLP can be primed by GM-CSF in 
neutrophils from healthy donors  
As GM-CSF is capable of priming the fMLP-mediated respiratory burst in 
neutrophils from healthy volunteers, we investigated the effect of neutrophil 
priming on fMLP-triggered Rac activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. GM-CSF priming of Rac activation is disturbed in neutrophils from MDS patients  
Unprimed neutrophils, and neutrophils that were primed with 5 ng/mL GM-CSF for 15 minutes, were
stimulated with 1 µM fMLP for the indicated times (s). Stimulation was stopped by adding 3X lysis
buffer. Activated Rac was precipitated using GST-PAKcrib protein precoupled to glutathione-
sepharose beads. Proteins were separated by 15% SDS-PAGE and membranes were probed with
Rac antibodies, followed by enhanced chemiluminescence. Rac activation was investigated in
neutrophils from seven healthy controls and seven MDS patients. Two representative blots from
healthy subjects (a) and three representative blots from MDS patients (c) are shown. Equal amounts
of glutathione sepharose beads were loaded in all samples, as determined by Ponceau S staining of
the membranes (not shown). Protein levels of activated Rac were quantified by densitometry of the
films. The means of the normalised values were calculated for the healthy donors (b) and the MDS
patients (d). Significant differences between unprimed and GM-CSF-primed groups were calculated
using the Wilcoxon-nonparametric test for paired samples, and are indicated (*, P < 0.05). Chapter 3 
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When neutrophils from healthy donors were stimulated with 1 µM fMLP, Rac was 
rapidly activated (Figure 1, a and b). Pretreatment of neutrophils with GM-CSF, 
which in itself did not activate Rac, resulted in a significantly increased response 
to fMLP stimulation (t=10 secs: 23±2 vs 14±3 (AU), p=0.018, t=30 secs: 25±2 vs 
14±2 (AU), p=0.03, n=7). These results indicate that the fMLP-triggered Rac 
activation can indeed be primed by GM-CSF in neutrophils from healthy donors.  
 
Decreased priming of Rac activation in neutrophils from MDS patients  
We subsequently analysed Rac activation in neutrophils from seven MDS 
patients. In accordance with our previous results 
8, fMLP induced Rac activation 
in neutrophils from MDS patients in a similar manner to that in healthy 
neutrophils; a rapid and transient activation was observed in response to 
stimulation with 1 µM fMLP (Figure 1, c and d). Rac activation in response to 10 
seconds fMLP stimulation appeared to be higher in unprimed MDS neutrophils 
compared with neutrophils from healthy donors, although this dissimilarity was 
not statistically different. In contrast to the results obtained with healthy 
neutrophils, priming of MDS neutrophils with GM-CSF did not increase the 
amount of Rac activated in response to fMLP stimulation (Figure 1, c and d) 
(t=10 secs: 19±3 vs 22±3 (AU), p=0.3). Stimulation of unprimed neutrophils for 
30 seconds with fMLP resulted in an activation of Rac that was equal in 
neutrophils from MDS patients and healthy donors. Again, GM-CSF priming did 
not enhance this response in MDS neutrophils (t=30 secs: 17±4 vs 15±2 (AU), 
p=0.8), in contrast to neutrophils from healthy donors. 
These results imply that in agreement with the decreased GM-CSF priming of 
fMLP-induced ROS production, priming of Rac activity by GM-CSF is also 
disturbed in neutrophils from MDS patients.  
 
Rac activation is sensitive to the PI-3K-inhibitor LY294002 
To elucidate the sequence of activation of Rac and PI-3K upon fMLP stimulation, 
healthy neutrophils were preincubated for 15 minutes with the specific PI-3K 
inhibitor LY294002, prior to priming with GM-CSF for 15 minutes and/or 
stimulation with fMLP for 30 seconds. Figure 2a demonstrates that LY294002 
treatment resulted in a significant attenuation of Rac activation in response to 
fMLP stimulation, in either unprimed or GM-CSF-primed cells. Densitometry of 
the blots revealed that inhibition of PI-3K activity reduced the fMLP-triggered Rac 
activation from 14±2 to 8±2 (AU, n=5, p=0.04) in unprimed cells. In GM-CSF 
primed neutrophils, the fMLP-triggered Rac activation was reduced from 21±1 to 
7±1 (AU, n=5, p=0.04) as a result of LY294002 treatment (Figure 2b). These Disturbed priming in MDS 
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results demonstrate that activation of the small GTPase Rac by fMLP could be a 
downstream event from PI-3K activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disturbed GM-CSF priming of fMLP-triggered PIP3 mass accumulation in 
neutrophils from MDS patients 
To establish whether a disturbed activity of PI-3K might be responsible for the 
decreased priming of Rac activity observed in MDS neutrophils, we investigated 
the accumulation of the PI-3K product PIP3 in neutrophils from five healthy 
donors and five MDS patients. As shown in Figure 3a, in neutrophils from healthy 
donors and MDS patients, PIP3 levels increased after 10 seconds of stimulation 
with 1 µM fMLP. After 45 seconds, a rapid decline in PIP3 levels to near baseline 
values was observed in healthy neutrophils. While in neutrophils from MDS 
patients, the accumulation of PIP3 mass appeared to be prolonged slightly, this 
was not statistically different from the values in healthy neutrophils. Pretreatment 
of neutrophils from healthy donors with 5 ng/mL GM-CSF for 15 minutes resulted 
in a slight but significant increase in PIP3 accumulation (3.1±1 pmol/8x10
6 cells) 
compared with unstimulated neutrophils (1.4±1 pmol/8x10
6  cells, p=0.04). 
Figure 2. Effect of LY294002 on Rac activation in unprimed and GM-CSF-primed, healthy
neutrophils 
Unprimed neutrophils, and neutrophils that were primed with 5 ng/mL GM-CSF for 15 minutes, were
stimulated with 1 µM fMLP for 30 seconds. Where indicated, cells were pretreated with 10 µM
LY294002 for 15 minutes. Activated Rac was precipitated as described in Figure 1. Three
representative blots are shown (a). Protein levels of activated Rac were quantified by densitometry of
the films, and the means of the normalised values for five individual experiments are shown (b).
Differences between LY294002 treated and untreated groups were calculated using the Wilcoxon-
nonparametric test for paired samples, and significant reductions in Rac activation are indicated (*, P
< 0.05). Chapter 3 
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However, in accordance with previous results 
27, subsequent stimulation of 
neutrophils with 1 µM fMLP lead to a significantly increased and prolonged PIP3 
signal, compared with that with fMLP alone (t=45 secs: 11.6±2 vs 1.6 pmol/8x10
6 
cells, p=0.04). In contrast, GM-CSF priming of neutrophils from MDS patients did 
not result in any enhancement of the fMLP-induced PIP3 accumulation (t=45 
secs: 4.4±2 vs 5.4±2 pmol/8x10
6 cells, p=0.5).  
The involvement of a class I PI-3K in the accumulation of PIP3 in human 
neutrophils was confirmed by the inhibition of the fMLP induced PIP3 signal after 
pretreatment of GM-CSF primed healthy neutrophils with the PI-3K inhibitor 
LY294002 (Figure 3b).     
In conclusion, these results indicate that, as for ROS production and Rac 
activation, priming of PI-3K activity by GM-CSF is severely disturbed in 
neutrophils from MDS patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Impaired GM-CSF priming of PIP3 mass accumulation in neutrophils from MDS
patients. 
(a) Neutrophils were stimulated with 1 µM fMLP for the indicated amount of time, with or without prior
treatment with 5ng/mL GM-CSF for 15 minutes. Reactions were stopped by the addition of
MeOH/CHCl3 (2:1 v/v), lipids were extracted, and the Ins(1,3,4,5)P4 isotope dilution assay was
performed as described in Material and Methods. Results represent the mean PIP3 mass
accumulation in samples from five healthy volunteers and five MDS patients. Statistical differences
between unstimulated and fMLP-stimulated groups were calculated using the Wilcoxon-
nonparametric test for paired samples, and significant differences are indicated (*, P < 0.05).
Significant differences between unprimed and GM-CSF-primed groups are indicated (**, P < 0.05).
(b) Neutrophils from healthy donors were primed with 5 ng/mL GM-CSF for 15 minutes, prior to
stimulation with 1 µM fMLP for 45 seconds. Where indicated, cells were preincubated with LY294002
(10  µM for 30 minutes). PIP3 measurement was performed in 3 independent experiments as
described. PIP3 mass accumulation of a representative experiment is shown. Disturbed priming in MDS 
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Priming of Ras activation in neutrophils from healthy donors and MDS 
patients 
Activation of the Ras GTPase has been placed upstream of PI-3K activity. To 
establish whether the observed disturbance in PIP3 accumulation in MDS 
neutrophils could be attributed to disturbed Ras signalling, we investigated the 
activation of this small GTPase in neutrophils from healthy donors compared with 
MDS patients. Stimulation of healthy neutrophils with 1 µM fMLP resulted in a 
transient activation of Ras, with a maximum activation after 30 seconds (Figure 
Figure 4. fMLP-induced Ras activation can be primed by GM-CSF in neutrophils from healthy
donors and MDS patients.  
Unprimed neutrophils, and neutrophils that were primed with 5 ng/mL GM-CSF for 15 minutes, were
stimulated with 1 µM fMLP for the indicated time (s). Activated Ras was precipitated using GST-Raf-
RBD protein precoupled to glutathione-sepharose beads as described. Ras activation was
investigated in neutrophils from five healthy controls and seven MDS patients. Two representative
blots from healthy subjects (a) and three representative blots from MDS patients (c) are shown.
Protein levels of activated Ras were quantified by densitometry of the films. The means of the
normalised values were calculated for the healthy donors (b) and the MDS patients (d). Significant
differences between unprimed and GM-CSF-primed groups were calculated using the Wilcoxon-
nonparametric test for paired samples, and are indicated (*, P < 0.05). Chapter 3 
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4a). After 10 minutes of fMLP stimulation, levels of active Ras were reduced to 
baseline values (not shown). Preincubation of neutrophils with 5 ng/mL GM-CSF 
prior to fMLP stimulation resulted in a significantly increased and prolonged 
activation of Ras when compared with fMLP stimulation without GM-CSF 
pretreatment. Densitometry of the blots showed that this priming effect was 
significantly higher than the accumulative activation of Ras by fMLP and GM-
CSF alone (Figure 4b). These data are consistent with the increased and 
prolonged fMLP-induced phosphorylation of the Ras downstream target ERK1/2 
that we previously found in healthy GM-CSF-primed neutrophils 
8. 
  We next tested the capacity of fMLP to activate Ras and the efficacy of 
GM-CSF in priming this activation, in neutrophils from MDS patients. As shown in 
figure 4, c and d, fMLP stimulated Ras activity in a similar manner in neutrophils 
from MDS patients (n=7) as in neutrophils from healthy volunteers (n=5), with a 
maximum after 30 seconds of stimulation. Furthermore, as in healthy neutrophils, 
GM-CSF was capable of priming the fMLP-triggered response.  
We subsequently set out to investigate the position of Ras relative to PI-
3K in signal transduction (Figure 5a). Incubation of neutrophils with 10 µM of the 
PI-3K inhibitor LY294002 prior to stimulation of the cells with fMLP did not reduce 
the amount of activated Ras present in the cells (14±4 vs 12±4 (AU), p=0.7). 
Likewise, priming of fMLP-stimulated Ras activation by GM-CSF pretreatment of 
neutrophils, was also not affected by the PI-3K inhibitor (31±3 vs 39±3 (AU), 
p=0.08) (Figure 5b). These results indicate that fMLP-induced Ras activation can 
be primed by GM-CSF in a PI-3K-independent manner, and that this priming is 
normal in MDS neutrophils. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of LY294002 on Ras 
activation in unprimed and GM-CSF- 
primed healthy neutrophils. 
Unprimed neutrophils, and neutrophils that were primed with 5 ng/mL GM-CSF for 15 minutes, were
stimulated with 1 µM fMLP for 2 minutes. Where indicated, cells were pretreated with 10 µM
LY294002 for 30 minutes. Activated Ras was precipitated as described previously. Two
representative blots are shown (a). Protein levels of activated Ras were quantified by densitometry of
the films, and the means of the normalised values for five individual experiments are shown (b).  Disturbed priming in MDS 
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Ral activation in response to fMLP is normal in neutrophils from MDS 
patients   
One of the described downstream targets of Ras is the small GTPase Ral, which 
has been shown to play a regulatory role in the activity of Rac through its effector 
molecule RLIP1. To examine whether the priming of Ras activation in response 
to GM-CSF also resulted in priming of Ral activity, neutrophils from healthy 
volunteers (n=3) were pretreated with 5 ng/mL GM-CSF for 15 minutes prior to 
stimulation with 1 µM fMLP for the indicated time-points, and active Ral was 
precipitated using GST-RLIP-RBD fusion protein. As shown in Figure 6, a and b, 
fMLP stimulation of neutrophils resulted in a transient activation of the Ral 
Figure 6. fMLP-induced Ral activation cannot be primed by GM-CSF, and is not inhibited by
LY294002 in neutrophils from healthy donors.  
(a) Unprimed healthy neutrophils, and neutrophils that were primed with 5 ng/mL GM-CSF for 15
minutes, were stimulated with 1 µM fMLP for the indicated time (s). Activated Ral was precipitated
using GST-RLIP-RBD protein precoupled to glutathione-sepharose beads as described. Two
representative blots are shown. (b) Protein levels of activated Ral were quantified by densitometry of
the films. The means of the normalised values from three individual experiments were calculated. (c)
Neutrophils were stimulated with 1 µM fMLP for 30 seconds, with or without prior incubation with 10
µM LY294002 for 30 minutes. Activated Ral was precipitated as described. Blots from two individual
experiments are shown. (d) Active Ral precipitated in c was quantified by densitometry. The means
of the normalised values from three individual experiments were calculated. Chapter 3 
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GTPase, which returned to near baseline levels after 10 minutes (not shown). In 
contrast to Rac and Ras activation, fMLP-stimulated Ral activation could not be 
primed by GM-CSF treatment. 
Neutrophils from healthy donors were subsequently pre-incubated with 
the PI-3K inhibitor LY294002 and stimulated with 1 µM fMLP for 2 minutes. No 
inhibition of Ral activation was observed as a result of LY294002 pretreatment 
(Figures 6, c and d).  
  We next compared the fMLP-stimulated activation of Ral in neutrophils 
from healthy donors (n=7) and MDS patients (n=3). Figure 7a shows that as in 
healthy donors, Ral activation in response to fMLP was rapid and transient in 
neutrophils from MDS patients. Densitometry of the blots indicated that the 
degree of Ral activation was identical in MDS patients and healthy volunteers 
(Figure 7b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
healthy subjects (a) and three representative blots from MDS patients (b) are shown. Protein levels
of activated Ral were quantified by densitometry of the films. The means of the normalised values
were calculated for seven healthy donors and three MDS patients (c).  
Figure 7. Ral activation by fMLP is normal in
neutrophils from MDS patients.  
Neutrophils were stimulated with 1 µM fMLP for
the indicated time (s), and activated Ral was
precipitated using GST-RLIP-RBD protein
precoupled to glutathione-sepharose beads as
described. Two representative blots from  Disturbed priming in MDS 
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Discussion 
 
The production of ROS by neutrophils is extremely important in the defence 
against invading bacteria. In neutrophils from MDS patients, GM-CSF priming of 
ROS production is severely disturbed, whereas fMLP-triggered ROS production 
in unprimed cells is relatively normal 
8;39;40. The molecular mechanisms 
underlying priming of ROS production are still unclear 
9-12. In the present study, 
we wanted to further elucidate the molecular effects of GM-CSF priming on 
human neutrophils. Our results demonstrate that pretreatment of neutrophils with 
GM-CSF leads to an increased activity of the small GTPase Ras in response to 
fMLP. Although the precise involvement of Ras in ROS production remains to be 
determined, the capacity of Ras to activate both extracellular signal-regulated 
kinase (ERK) 1/2 and PI-3K is well established 
21;41. Studies with specific signal 
transduction inhibitors have revealed the importance of these signal transducers 
in the GM-CSF-mediated priming of ROS production. Previously it has been 
shown that fMLP-triggered activation of ERK1/2 and the PI-3K target PKB/Akt 
could be enhanced by GM-CSF pretreatment of neutrophils, and that this 
activation was disturbed in neutrophils from MDS patients 
8. However, although 
Ras has frequently been reported to activate ERK1/2, the present study shows 
that activation of Ras by fMLP, and GM-CSF priming thereof, are not affected in 
neutrophils from MDS patients. These data suggest that the molecular defect 
leading to the disturbed ROS priming in neutrophils from MDS patients is located 
downstream of Ras activation. Furthermore, these results indicate that the 
disturbed priming of ROS production and activation of signal transduction 
molecules in MDS granulocytes are not the result of a general defect in fMLP or 
GM-CSF receptor signalling. This is also confirmed by our results showing 
normal activation of the GTPase Ral in neutrophils from MDS patients. 
Several studies have shown that PI-3K can be activated by the GTPase 
Ras 
31. However, we now show that although priming of PIP3 accumulation, a 
result of PI-3K activity, was absent in neutrophils from MDS patients, Ras 
actvation was normal. This suggests that another signal transducer capable of 
activating PI-3K might be affected in MDS neutrophils. Alternatively, the defect is 
located at the level of PI-3K itself, a suggestion corroberated by our finding that 
protein levels of PI-3K subunits are disturbed in MDS neutrophils 
8. Other studies 
have revealed that the level of PIP3 within cells is carefully balanced by different 
lipid kinases and phosphatases 
42. It can therefore not be formally excluded that 
one or more of these enzymes are responsible for the disturbed PIP3 
accumulation in neutrophils from MDS patients.  Chapter 3 
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Neutrophils from PI-3Kγ-/- mice, which do not produce PIP3 and ROS in 
response to fMLP, show normal activation of the small GTPase Rac after fMLP 
stimulation 
43. This would indicate a PI-3K-independent Rac activation, which is 
not involved in the neutrophil respiratory burst. In contrast, studies describing a 
patient with an inhibitory Rac2 mutation have clearly established the importance 
of this GTPase in ROS production 
44. Furthermore, other studies indicate that 
Rac activation in response to fMLP is PI-3K-dependent, in both unprimed and 
GM-CSF-primed neutrophils 
45. In the present study attenuation of Rac 
activation, although significant, was not complete. This suggests that Rac 
activation might occur through multiple signal-transduction routes, including a PI-
3K-independent pathway.  
Early reports suggested that the diversity in PI-3Ks (PI-3Kα, -β, -δ and -γ) 
contributes to the distinct PI-3K-dependent cellular functions activated upon 
stimulation of cells with different stimuli (reviewed in ref 
22). For example, G-
protein coupled receptors (GPCRs), e.g., the fMLP receptor, were described to 
exclusively activate p110γ, whereas p110α, -β and -δ activation was attributed to 
receptor tyrosine kinases and cytokine receptors such as the GM-CSF receptor 
46-48. Recent studies, however, have shown that GPCRs can activate class IA PI-
3Ks, in addition to PI-3Kγ
49-51. Another recent study demonstrated that in p85α-/- 
mice, GM-CSF priming of fMLP-stimulated ROS production is severely 
decreased, indicating the involvement of class IA PI-3Ks in the GM-CSF-priming 
response 
52. However, equally convincing studies have shown that p110γ is the 
primary subunit responsible for the enhanced PIP3 production seen in primed 
neutrophils 
27. It is conceivable that full activation of class IA and class IB PI-3Ks is 
necessary in GM-CSF-primed neutrophils in order to get a full fMLP-induced 
response, as was recently described for stromal cell-derived factor-1-induced 
migration of leukemic T cells 
53. To what extent activation of the different PI-3K 
classes is affected in MDS neutrophils remains to be elucidated. 
In conclusion, we show a disturbed GM-CSF priming of fMLP-induced 
PIP3 accumulation and Rac activation in neutrophils from MDS patients. 
Activation of Ras could be normally primed by GM-CSF in MDS neutrophils, and 
fMLP-triggered activity of the Ras target Ral was likewise undisturbed in these 
cells. Taken together, our data suggest that in neutrophils from MDS patients, a 
defect in priming of the PI-3K-Rac signalling pathway results in a decreased GM-
CSF priming of ROS production, and that this defect is located at the level of PI-
3K activity.  
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Abstract 
 
Objective. Patients with myelodysplasia (MDS) show a disturbed production ROS 
in response to N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) in 
granulocyte-macrophage colony-stimulating factor (GM-CSF)-primed neutrophils. 
Because generation of ROS is mediated by the NADPH oxidase complex, a 
component of which is flavocytochrome b558, we investigated whether the 
expression of flavocytochrome b558 in neutrophils from MDS patients is affected. 
Material and methods. Neutrophils were stimulated with fMLP and GM-CSF, and 
plasma membrane expression of flavocytochrome b558  and specific granule 
markers were assessed by fluorescence-activated cell sorting analysis. Protein 
levels of the flavocytochrome b558 subunits gp91
phox and p22
phox in whole 
neutrophil lysates were detected by Western blotting.  
Results. Stimulation of neutrophils with GM-CSF and fMLP increased the 
flavocytochrome b558  plasma membrane expression. The fMLP-induced 
translocation of flavocytochrome b558 was reduced in neutrophils from MDS 
patients (140±9% vs 180±13%, p<0.05). Analysis of cell surface expression of 
markers of flavocytochrome b558 containing granules (CD35 and CD66b) 
indicated that exocytosis of these granules in response to fMLP stimulation was 
not affected in MDS patients. Western blot analysis demonstrated a decreased 
protein expression level of the flavocytochrome b558 subunits gp91
phox and p22
phox 
in neutrophils from MDS patients.  
Conclusion. Our results indicate both a lower basal protein level and a disturbed 
fMLP-induced increase in plasma membrane expression of flavocytochrome b558 
in neutrophils from MDS patients, which together might play a role in decreased 
ROS production.  Chapter 4 
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Introduction 
 
The myelodysplastic syndromes (MDS) are a group of clonal stem cell disorders 
characterised by a disturbed differentiation of the myeloid, erythroid or 
megakaryocytic lineage 
1. In approximately 30% of cases, transformation to 
acute myeloid leukaemia (AML) occurs 
2. However, bacterial infections pose an 
even greater threat to MDS patients, as shown by the high incidence of bacterial 
infection-related deaths, indicating an important role for granulocytes in the 
pathology of the disease 
3. Indeed, the differentiation defect in the MDS 
multipotent stem cell compartment not only leads to neutropenia, but also results 
in aberrant neutrophil functioning. For instance, deficiencies in the contents of 
primary and specific granules have been reported in neutrophils from MDS 
patients 
4;5. Furthermore, we and others have shown that the production of 
reactive oxygen species (ROS) is affected in MDS patients 
6-8. 
 ROS production during the respiratory burst is essential for neutrophil 
bactericidal activity, and can be stimulated by chemoattractants such as the 
bacterial peptide analogue N-formyl-L-Methionyl-L-Leucyl-L-Phenylalanine 
(fMLP) 
9;10. Pro-inflammatory agents such as granulocyte-macrophage colony-
stimulating factor (GM-CSF) are capable of enhancing the fMLP-mediated 
respiratory burst, but do not elicit ROS production on their own 
11. This process is 
known as priming. 
  The generation of ROS is mediated by the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase. This enzyme consists of a membrane 
bound component, flavocytochrome b558, and the cytosolic factors p47
phox, 
p40
phox, p67
phox and Rac2, which exist in the cytosol as a complex 
12. In 
unstimulated neutrophils, 10-20% of the flavocytochrome b558, which is 
composed of the subunits gp91
phox and p22
phox, is anchored in the plasma 
membrane, whereas the remaining 80-90% resides in the membrane of secretory 
vesicles, specific granules and tertiary granules 
13;14. Upon activation of the cells 
with a variety of stimuli, exocytosis of these granules results in an increase of 
flavocytochrome b558 present at the plasma membrane 
13. Furthermore, 
stimulation of the cells results in phosphorylation of p47
phox on multiple serine 
residues, activation of the GTP-ase Rac, and subsequent translocation of the 
entire cytosolic complex to the membrane, where it associates with 
flavocytochrome b558 to form the active oxidase 
15-20. 
Several signal transduction pathways have been implicated in NADPH oxidase 
activation 
21-23. For example, the involvement of phosphatidylinositol 3-kinase 
(PI3K) in fMLP-stimulated ROS production has been established by using Flavocytochrome b558 expression in MDS neutrophils 
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specific inhibitors 
24-26. Furthermore, lipid products of PI3K associate with the 
cytosolic oxidase proteins p47
phox and p40
phox 
27.  The association of one of these 
lipids with p40
phox has been shown to have a regulatory effect on ROS production 
28;29. In addition to PI3K, extracellular signal-regulated protein kinase 1 and 2 
(ERK1/2), a key member of the mitogen-activated protein kinase (MAPK) 
signalling route, is involved in the neutrophil respiratory burst 
30. Inhibition of ERK 
activation by chemical inhibitors resulted in a reduction of fMLP-induced ROS 
production in GM-CSF-primed human neutrophils 
26;31.  
Our previous studies demonstrated that the fMLP-induced ROS 
production in GM-CSF-primed neutrophils was significantly reduced in 
neutrophils from MDS patients, which coincided with a decreased level of 
phosphorylation of ERK1/2 in response to fMLP in these cells 
6. In this study, we 
set out to further investigate the mechanisms underlying the defects in ROS 
generation observed in MDS patients. We demonstrate that in normal neutrophils 
both fMLP and GM-CSF induce an increase in flavocytochrome b558 expression 
at the plasma membrane, and that the fMLP-stimulated expression is reduced in 
MDS patients. Furthermore, we show that the decreased expression of 
flavocytochrome at the plasma membrane of MDS neutrophils is most likely due 
to reduced protein levels of the p91
phox and p22
phox subunits, rather than a 
disturbed exocytosis of the flavocytochrome b558 containing secretory vesicles 
and specific granules.    
 
Materials and methods 
 
Reagents 
N-formyl-L-Methionyl-L-Leucyl-L-Phenylalanine (fMLP), ferricytochrome c and 
superoxide dismutase (SOD) were obtained from Sigma (St. Louis, MO). 
Recombinant human GM-CSF was from Novartis (Basel, Switserland). Antibody 
7D5 was a kind gift from Prof. Dr. D. Roos (Central Laboratory of the Netherlands 
Blood Transfusion Service (CLB), Amsterdam, The Netherlands) and Dr. M. 
Nakamura (Institute of Tropical Medicine, Nagasaki, Japan). Antibodies against 
gp91
phox (Ab 48) and p22
phox (Ab 449) were also kindly provided by Prof. Dr. D. 
Roos.   
 
Patients 
Twelve patients with MDS were studied. MDS was classified as refractory 
anemia (RA), RA with ringed sideroblasts (RARS) or RA with excess of blasts 
(RAEB) according to FAB cooperative group criteria 
32 (Table 1). None of the Chapter 4 
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patients suffered from recurring infections during the course of this study. 
Informed consent was obtained from all patients. The protocol was approved by 
the Human Subject Review Board of the University Hospital Groningen. 
 
Isolation of neutrophils 
Peripheral blood was obtained from healthy volunteers and MDS patients. 
Neutrophils were isolated as described previously 
6;33. In all cases, the cell 
population isolated consisted of >95% neutrophils as determined by May-
Grünwald Giemsa staining. 
 
Respiratory burst measurement 
O2
- generation was measured by the superoxide dismutase-inhibitable reduction 
of ferricytochrome c, using an automated microplate reader (Thermomax, 
Molecular Devices, Sunnyvale, CA, USA), as described previously 
6;34. The 
superoxide production was expressed as the difference in OD550 nm between the 
ferricytochrome c reduction test in the absence and in the presence of SOD. 
Each test was performed in quadruplicate.  
 
Expression of plasma membrane proteins   
The plasma membrane expression of flavocytochrome b558, CD35 and CD66b 
were determined by flow cytometry. Isolated neutrophils were stimulated as 
indicated in the figure legends. Plasma membrane expression of 
flavocytochrome b558 was determined using a monoclonal antibody against its 
extracellular domain, 7D5 
35, as described 
36. In short, neutrophils were blocked 
by incubation with 2% goat serum for 10 min at 4°C, and subsequently incubated 
with 7D5 for 30 min at 4°C. After washing of the cells with ice-cold PBS, the 
neutrophils were incubated for an additional 30 min at 4°C with FITC-conjugated 
anti-mouse IgG. Plasma membrane expression of CD35 and CD66b were 
determined as described by Ward et al. 
37. Briefly, stimulated neutrophils were 
washed with ice-cold PBS and samples were incubated with FITC-conjugated 
monoclonal anti-CD35 or FITC-conjugated monoclonal anti-CD66b for 45 min at 
4°C. FITC-conjugated IgG1 and FITC-conjugated IgM, were used as isotype 
controls, respectively. Fluorescence intensities were measured by FACS analysis 
(FACScalibur, Becton Dickinson Medical Systems, Sharon, MA).  
 
Western blotting 
The protein expression levels of the flavocytochrome b558 subunits present in 
whole cell lysates were determined by Western blotting. Proteins were separated Flavocytochrome b558 expression in MDS neutrophils 
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on 10% SDS-PAGE and electrophoretically transferred to nitrocellulose 
membranes (Protran; Schleicher & Schuel, Dassel, Germany). Membranes were 
probed with Ab 48 and Ab 449 
38. Proteins were detected by enhanced 
chemiluminescence. To confirm equal loading, blots were subsequently reprobed 
with antibodies against ERK (K23). Quantification of protein levels was 
performed by densitometry of the films, using imagemaster1D Elite (Pharmacia, 
Woerden, the Netherlands).  
 
Statistical analysis 
For comparison of O2
- generation and expression of plasma membrane proteins, 
differences between stimulations with or without inhibitors were calculated using 
the Student t-test for paired samples. Differences in values between healthy 
donors and MDS patients were calculated using the Student t-test for unpaired 
samples. For quantification of p22
phox protein levels, p22
phox densitometry values 
were divided by the densitometry values of ERK1/2 protein present in the same 
samples and differences between the normalised values of healthy controls and 
MDS patients were calculated using the Student t-test for unpaired samples. 
Data were expressed as mean ± SEM. P values <0.05 were considered 
significant.  
 
 
Table 1. 
FAB: French-American-British Classification (RA = refractory anemia; RARS = refractory anemia with 
ringed sideroblasts; RAEB = refractory anemia with excess of blasts); Hb = hemoglobin; Transf = 
blood transfusion after collection of peripheral blood for this study; Plat = platelets; Leuko = 
leukocytes; Ganulo = granulocytes; Mono = monocytes; Chrom. abn = presence (abn.) or absence 
(norm.) of chromosomal abnormalities; ND = not done. 
No. FAB  Hb 
(mmol/L) 
Plat. 
(10
9/L) 
Leuko. 
(10
9/L) 
Granulo. 
(%) 
Mono. 
(%) 
Chrom. 
Abn. 
1 RA  78/F  117  11  63  7  Abn. 
2 RA  78/M  130  3.3  74  6  Abn. 
3 RA  83/M  63  3.3  72  10  ND 
4  RA 29/F 80 3.8  19  1 Abn. 
5 RA  68/M  30  2.0  42  16  ND 
6 RA  33/M  70  3.1  80  11  Abn. 
7 MDS  30M  30  4.0  60 4  Norm. 
8 RARS  64/M  150  2.9  40 8  Abn. 
9 RARS  71/F  225  2.5  14 6 ND 
10 REAB  65/M 32 2.2  52  10  Abn. 
11 REAB  29/F 56 6.7  40  10  Abn. 
12 RAEB  76/F 25 2.3  45  6  Norm. Chapter 4 
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Results 
 
FMLP and GM-CSF induce plasma membrane expression of 
flavocytochrome b558 on neutrophils from healthy donors 
GM-CSF priming of the fMLP-triggered neutrophil respiratory burst is significantly 
decreased in MDS patients (6). As extracellular O2
- is generated by the active 
NADPH oxidase complex at the plasma membrane of the neutrophil 
39, we 
examined the plasma membrane expression of flavocytochrome b558, the 
membrane-bound component of the NADPH oxidase complex. As demonstrated 
in Figure 1A, stimulation of neutrophils with 5 ng/mL GM-CSF resulted in a 
significant increase of flavocytochrome b558 present at the plasma membrane 
(142  ± 9%, p<0.05, n=8). Stimulation of neutrophils with 1 µM fMLP for 10 
minutes resulted in a higher membrane expression of flavocytochrome b558 (180 
± 13%, p<0.05). Pretreatment of neutrophils with GM-CSF prior to fMLP 
stimulation led to a flavocytochrome b558 membrane expression of 171 ± 11% of 
that of unstimulated cells (p<0.05), which was not significantly different from that 
of fMLP-stimulated, unprimed neutrophils (p=0.64). These results indicate that 
both GM-CSF and fMLP are capable of increasing the levels of flavocytochrome 
b558 present at the plasma membrane. However, in contrast to O2
- generation, 
GM-CSF has no priming effect on the fMLP-triggered flavocytochrome plasma 
membrane expression.   
 
Decreased fMLP-mediated flavocytochrome b558 expression on plasma 
membrane of neutrophils from MDS patients. 
Next we studied the fMLP-and GM-CSF-stimulated increase in flavocytochrome 
b558 translocation to the plasma membrane, by comparing the expression of this 
NADPH oxidase component at the plasma membrane of neutrophils from 7 MDS 
patients and 8 healthy donors. When we compared the basal expression of 
flavocytochrome on the plasma membrane of unstimulated neutrophils, no 
significant difference was observed between MDS patients (28 ± 5 [mean 
fluorescence intensity]) versus healthy volunteers (26 ± 3 [mfi]) (p=0.73). 
Stimulation of MDS neutrophils with 5 ng/mL GM-CSF or 1 µM fMLP resulted in a 
significant increase in flavocytochrome b558 membrane expression to 128 ± 8% 
and 140 ± 9% of control, respectively (Figure 1B, p<0.05). 
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However, although one patient exhibited an fMLP-induced translocation that was 
more than 2 SD higher than the mean of that group, the fMLP-induced 
flavocytochrome b558 translocation was significantly lower in neutrophils from 
MDS patients than in those from healthy volunteers (140 ± 9% vs 180 ± 13%, 
p<0.05). The GM-CSF-induced flavocytochrome b558 plasma membrane 
expression also seemed to be slightly lower compared to healthy donors, 
although this difference was not significant (128 ± 8% vs 141 ± 9%, p=0.27). Our 
data indicate that, upon stimulation with fMLP, the increase in expression levels 
of flavocytochrome b558 at the plasma membrane of neutrophils from MDS 
patients is significantly disturbed.  
 
 
 
 
Figure 1. Flavocytochrome b558 plasma membrane expression on neutrophils from healthy
donors and MDS patients. (A) Isolated neutrophils were stimulated with 1 µM fMLP for 10 minutes,
either with or without prior priming with 5 ng/mL GM-CSF for 15 minutes. Alternatively, neutrophils
were stimulated for 15 minutes with GM-CSF alone. Stimulation was stopped by washing the cells
with ice-cold PBS. Neutrophils were blocked by incubation with 2% goat serum for 10 minutes at 4°C,
and incubated with 7D5 antibody for 30 minutes. After washing of the cells with ice-cold PBS, the
neutrophils were incubated for an additional 30 minutes with FITC-conjugated anti-mouse IgG.
Fluorescence intensities were measured by FACS analysis. Results represent the mean increase in
flavocytochrome b558 plasma membrane expression after stimulation, compared to unstimulated
cells, on neutrophils from eight healthy donors. Significant differences between stimulated groups are
indicated by asterisks (P < 0.05). (B) Freshly isolated neutrophils from 7 MDS patients and 8 healthy
donors were stimulated with either 5 ng/mL GM-CSF for 15 minutes or 1 µM fMLP. Flavocytochrome
b558 plasma membrane expression was measured as described above. Significant differences
between MDS patients and healthy donors are indicated by an asterisk (P < 0.05). Chapter 4 
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Normal exocytosis of secretory vesicles and specific granules in 
neutrophils from MDS patients 
Previous studies have indicated that in the resting neutrophil, most 
flavocytochrome b558 is anchored in the membrane of specific granules and 
secretory vesicles. Upon stimulation of the cell, these granules fuse with the 
plasma membrane, leading to an increased expression of flavocytochrome at the 
plasma membrane. To determine whether the decreased flavocytochrome b558 
expression at the plasma membrane of MDS neutrophils could be attributed to a 
decreased exocytosis of flavocytochrome-containing granules, we studied the 
membrane expression of CD35 and CD66b, which are specific markers of 
secretory vesicles and specific granules, respectively 
40. Similar to 
flavocytochrome b558 expression, stimulation of healthy neutrophils with 5 ng/mL 
GM-CSF lead to an enhanced membrane expression of the secretory vesicle 
marker, CD35 (124 ± 4%, p>0.05, n=5). Similarly, 1 µM fMLP induced an 
enhancement of CD35 membrane expression of 164 ± 9% (p<0.05), which could 
not be further elevated by pretreatment of the neutrophils with GM-CSF (Figure 
2A). The expression pattern of CD66b was different from that of CD35 and 
flavocytochrome b558. GM-CSF stimulation alone was not capable of significantly 
increasing the amount of CD66b present at the plasma membrane (109 ± 6%, 
p=0.20, n=5; Figure 2B). FMLP alone increased the CD66b membrane 
expression up to 147 ± 16% (p<0.05). However, unlike either CD35 or 
flavocytochrome b558 expression, CD66b expression could be significantly 
increased by priming the neutrophils with GM-CSF prior to fMLP stimulation (202 
± 31%, p=0.05).  
We next analysed the capacity of fMLP and GM-CSF to induce 
exocytosis of secretory vesicles and specific granules in neutrophils from 5 MDS 
patients compared to 5 healthy donors. Figure 2C shows that both the GM-CSF-
and the fMLP-stimulated increase in CD35 membrane expression were not 
altered in MDS neutrophils. The basal expression of CD35 on unstimulated 
neutrophils of MDS patients and healthy donors was similar (21 ± 3 [mfi] vs 19 ± 
1 [mfi], p=0.50, data not shown). Likewise, the fMLP-stimulated increase in 
CD66b membrane expression in GM-CSF-primed and unprimed neutrophils was 
comparable between MDS patients and healthy donors (Fig 2D). Again, basal 
CD66b membrane expression on unstimulated cells was equal between 
neutrophils from MDS patients and healthy volunteers (34 ± 5 [mfi] vs 39 ± 4 
[mfi], p=0.40, not shown). Taken together, these results indicate that the 
decreased fMLP-induced plasma membrane expression of flavocytochrome b558 Flavocytochrome b558 expression in MDS neutrophils 
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on MDS neutrophils is not due to a decreased fusion of secretory vesicles or 
specific granules with the neutrophil plasma membrane. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CD35 and CD66b plasma membrane expression on neutrophils from healthy
donors and MDS patients. (A, B) Isolated neutrophils were stimulated with 1 µM fMLP for 10
minutes, either with or without prior priming with 5 ng/mL GM-CSF for 15 minutes. Alternatively,
neutrophils were stimulated for 15 minutes with GM-CSF alone. Stimulation was terminated by
washing the neutrophils with ice-cold PBS and placing them on ice. The samples were incubated
with FITC-conjugated monoclonal anti-CD35 (A) or FITC-conjugated monoclonal anti-CD66b (B) for
45 minutes at 4°C. FITC-conjugated IgG1 and FITC-conjugated IgM, were used as isotype controls,
respectively. Fluorescence intensities were measured by FACS analysis. The mean increase in
CD35 and CD66b plasma membrane expression after stimulation, compared to unstimulated cells,
is shown for 5 healthy donors. Significant differences between stimulated groups are indicated by
an asterisks (P < 0.05). (C) Isolated neutrophils from 5 MDS patients and 5 healthy volunteers were
stimulated with either 5 ng/mL GM-CSF for 15 minutes, or 1 µM fMLP. CD35 expression at the cell
surface was measured as described above. (D) Isolated neutrophils from 5 MDS patients and 5
healthy volunteers were stimulated with 1 µM fMLP for 10 minutes, either with or without prior
priming with 5 ng/mL GM-CSF for 15 minutes. CD66b plasma membrane expression was measured
as described earlier. Chapter 4 
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Decreased expression of flavocytochrome b558 subunits in neutrophils from 
MDS patients 
To further examine the possible cause of the lower flavocytochrome b558 
expression in response to fMLP stimulation on neutrophils from MDS patients, 
we next investigated the total amount of flavocytochrome b558 protein present in 
the neutrophils of MDS patients compared to healthy donors. Western blot 
analysis of whole neutrophil lysates probed with antibodies directed against the 
flavocytochrome b558 subunits gp91
phox and p22
phox indicated that these NADPH 
oxidase subunits were present in neutrophils from both MDS patients and healthy 
volunteers (Figure 3A). However, quantification of the protein levels by 
densitometry indicated that the protein levels of p22
phox present in the neutrophil 
lysates were significantly lower in MDS patients (7 ± 1, n=9) than in the healthy 
controls (17 ± 4, n=8) (Figure 3B, p<0.05). The amount of gp91
phox could not be 
Figure 3. Decreased protein levels of the flavocytochrome b558 subunits, gp91
phox and p22
phox,
in neutrophils from MDS patients. (A) Neutrophils from healthy donors and MDS patients were
resuspended in 1 X Laemmli buffer and samples were boiled. Proteins were separated by SDS-
PAGE, and Western blotting was performed using antibodies directed against gp91
phox (Ab 48)
(upper panel), p22
phox (Ab449) (lower panel). Blots were reprobed with antibodies against ERK1/2
(middle panel). Proteins were detected by enhanced chemiluminescence. Whole neutrophil lysates of
5 out of 9 MDS patients and 5 out of 8 healthy volunteers are shown. (B) Protein levels of the
flavocytochrome b558 subunit p22
phox and ERK1/2 were quantified by densitometry of the films.
ERK1/2 was used as control for equal loading, as we have previously shown that equal numbers of
neutrophils from different donors (patients or healthy donors) contains equal amounts of the ERK1/2
protein (6). The p22
phox protein levels in the samples were corrected for the ERK levels in those same
samples, and differences between the means of the normalised values were calculated between
MDS neutrophils (n=9) and healthy donors (n=8) using the Student t-test for unpaired samples.
Significant differences are indicated with an asterisk (P < 0.05). Flavocytochrome b558 expression in MDS neutrophils 
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quantified by densitometry because the monoclonal antibody detecting this 
protein results in a wide band with high background 
38.  
However, the protein levels of gp91
phox present in the MDS neutrophil lysates did 
appear to be lower than the levels of gp91
phox present in healthy neutrophils 
(Figure 3A, upper panel). Our results indicate that the total amount of 
flavocytochrome b558 present in the neutrophils from MDS patients is lower than 
that in healthy neutrophils. This might partially explain the reduced fMLP-
stimulated increase in flavocytochrome b558 plasma membrane expression 
observed in these patients.  
 
 
Discussion  
 
The generation of extracellular O2
-, as measured by cytochrome c reduction by 
neutrophils, is mediated by the NADPH oxidase enzyme complex at the plasma 
membrane of these cells 
39. The plasma membrane expression of 
flavocytochrome b558, the membrane-bound component of the oxidase complex, 
can be increased after stimulation of the neutrophil with either fMLP or GM-CSF. 
In contrast to the data reported for ROS production in neutrophils, we show here 
that the membrane expression of flavocytochrome b558 induced by fMLP cannot 
be primed by GM-CSF pretreatment. This indicates that GM-CSF priming of 
fMLP-induced O2
- generation does not occur through enhancement of the fMLP-
induced plasma membrane expression of the membrane-bound component of 
the NADPH oxidase complex. Recent studies have suggested that stimulation of 
neutrophils with priming agents (e.g. granulocyte colony-stimulating factor, 
tumour necrosis factor-α, lipopolysaccharide) results in priming of the respiratory 
burst by increasing the flavocytochrome b558 plasma membrane expression, 
irrespective of the fMLP-induced increase of flavocytochrome present at the 
membrane 
37;41. In neutrophils from MDS patients, GM-CSF priming of the fMLP-
triggered respiratory burst is significantly decreased. However, whereas in this 
study we demonstrated that the fMLP-stimulated translocation of 
flavocytochrome to the plasma membrane of MDS neutrophils was significantly 
reduced, the GM-CSF-mediated expression was not significantly affected. This 
suggests that, in neutrophils from MDS patients, the lower fMLP-induced 
increase in flavocytochrome b558 is limiting the amount of O2
- that can be 
produced in GM-CSF-primed cells. This presumption is further corroborated by 
the finding that both the GM-CSF-primed ROS production and the fMLP-triggered 
flavocytochrome b558 expression can be partially attenuated with the chemical Chapter 4 
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inhibitor U0126, indicating a role for the MEK/ERK pathway in both these 
processes (unpublished results, GM Fuhler).  
  It was previously reported that the translocation of flavocytochrome to 
the plasma membrane of neutrophils upon stimulation occurs through exocytosis 
of flavocytochrome b558 containing secretory vesicles and specific granules 
37. In 
this study we demonstrated that the degranulation of these vesicles, as 
measured by the plasma membrane expression of CD35 and CD66b, was not 
affected in neutrophils from MDS patients. Interestingly, GM-CSF alone did not 
increase the expression levels of CD66b at the plasma membrane, but was 
capable of enhancing the fMLP-induced CD66b expression. This is in distinct 
contrast to the effect of GM-CSF on membrane expression of CD35, suggesting 
that the fusion of secretory vesicles and specific granules are differentially 
regulated. The expression patterns of flavocytochrome b558  and CD35 at the 
neutrophil plasma membrane correlated with each other (compare Figure 1A to 
Figure 2A), indicating that the flavocytochrome b558 expression measured at the 
plasma membrane after fMLP stimulation might be caused by the degranulation 
of secretory vesicles. However, whereas the fMLP-induced flavocytochrome b558 
membrane expression was decreased in MDS neutrophils, the fMLP-induced 
exocytosis of secretory vesicles was not. These data indicate that degranulation 
of other types of flavocytochrome b558-containing granules, such as tertiary 
granules, might be affected in MDS patients. Indeed, flavocytochrome b558 
translocation to the plasma membrane in response to G-CSF stimulation has 
been attributed to the exocytosis of such tertiary granules 
41.  
  Another explanation for the decreased fMLP-induced flavocytochrome 
b558 membrane expression could be a reduced presence of flavocytochrome b558 
in the membrane of intracellular granules. Indeed, we demonstrated that the 
amount of p22
phox and gp91
phox were significantly reduced in neutrophils from 
MDS patients. However, this could not constitute the sole reason for the 
decreased ROS production found in MDS patients, because phorbol 12-myristate 
13-acetate (PMA) induces a high O2
- release in neutrophils from MDS patients 
6;7. 
Furthermore, GM-CSF-triggered flavocytochrome b558 membrane expression was 
not affected in MDS patients. Therefore, the defect in translocation of 
flavocytochrome to the plasma membrane is at least partially stimulant 
dependent. Indeed, it has been suggested that decreased protein levels of 
gp91
phox and p22
phox by themselves do not necessarily lead to reduced NADPH 
activity 
42;43. On the other hand, studies performed in patients suffering from X-
linked type of chronic granulomatous disease, in which neutrophils are defective 
in the gp91
phox subunit of the NADPH complex, indicate that defects in Flavocytochrome b558 expression in MDS neutrophils 
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superoxide production might be related to the absence of flavocytochrome b558 
44. 
Furthermore, Itoh et al, who spectrometrically measured the basal levels of 
flavocytochrome b558  present in neutrophils from MDS patients, found a 
correlation between the levels of flavocytochrome b558 present in resting cells and 
the amount of O2
- that could be produced by these neutrophils in response to 
fMLP 
45. 
Our data suggest that in neutrophils from MDS patients, the amount of 
O2
- produced in GM-CSF-primed cells is limited by the decreased amount of 
flavocytochrome present at the plasma membrane. However, it cannot be 
excluded that the cytosolic components of the NADPH oxidase complex, e.g. 
p47
phox, p40
phox, p67
phox and Rac, are also affected in MDS neutrophils. Although 
treatment of GM-CSF-primed neutrophils with the PI3K inhibitor LY294002 
reduces the amount of O2
- produced in response to fMLP 
6, it does not affect the 
fMLP-mediated translocation of flavocytochrome b558 to the cell surface 
(unpublished results, GM Fuhler). This indicates the involvement of PI3K-
dependent processes other than flavocytochrome translocation, in neutrophil 
ROS production.  
  In conclusion, the data presented here indicate that neutrophils from 
MDS patients demonstrate decreased flavocytochrome b558  protein levels. 
Together with the reduced fMLP-induced translocation of flavocytochrome b558 to 
the plasma membrane, this might account for the disturbed ROS production that 
is typically found in MDS patients. 
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Abstract 
 
Patients with myelodysplasia suffer from recurrent bacterial infections due to 
differentiation defects of the myeloid lineage and a disturbed functioning of 
neutrophilic granulocytes. Important physiological activators of neutrophils are 
the cytokines interleukin 8/CXC chemokine ligand 8 (IL-8/CXCL8), which 
activates both CXC chemokine receptor 1 and 2, and growth-related oncogene 
(GROα)/CXCL1, which stimulates only CXCR2. In this study, we show that 
migration towards IL-8/GROα gradients is decreased in myelodysplasic 
syndrome (MDS) neutrophils compared with healthy donors. We investigated the 
signal transduction pathways involved in IL-8/GROα-induced migration, and 
showed that specific inhibitors for extracellular signal-regulated kinase (ERK1/2) 
and phosphatidylinositol 3-kinase (PI-3K) abrogated neutrophil migration towards 
IL-8/GROα. In accordance with these results, we subsequently showed that IL-
8/GROα-stimulated activation of ERK1/2 was substantially diminished in MDS 
neutrophils. Activation of the PI-3K downstream target protein kinase B/Akt was 
disturbed in MDS neutrophils when cells were activated with IL-8 but normal 
upon GROα stimulation. IL-8 stimulation resulted in higher migratory behaviour 
and ERK1/2 activation than GROα stimulation, suggesting greater importance of 
CXCR1. We then investigated IL-8-induced activation of the small GTPase Rac 
implicated in ERK1/2-dependent migration and found that it was less efficient in 
neutrophils from MDS patients compared with healthy donors. In contrast, IL-8 
triggered a normal activation of the GTPases Ras and Ral, indicating that the 
observed defects were not due to a general disturbance in CXCR1/2 signalling. 
In conclusion, our results demonstrate a disturbed CXCR1- and CXCR2-induced 
neutrophil chemotaxis in MDS patients, which might be the consequence of 
decreased Rac-ERK1/2 and PI-3K activation within these cells.  Chapter 5 
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Introduction 
 
The Myelodysplastic syndromes are a group of clonal haematological disorders 
that are characterised by a disturbed proliferation and differentiation of the 
erythroid, myeloid and megakaryocytic cell lineages 
1. The observation that the 
high mortality rate in MDS patients is generally a direct result of recurrent 
bacterial infections underscores the importance of granulocytes in the pathology 
of the disease 
2. The responses of neutrophils leading to the eradication of 
invading bacteria can be divided into a number of steps; adhesion to and rolling 
along endothelial lining of blood vessels, migration towards the site of 
inflammation, diapedesis through the endothelial layer, degranulation, and finally 
phagocytosis of bacteria in conjunction with production of bactericidal reactive 
oxygen species (ROS). In MDS, the differentiation defect in the multipotent stem 
cell compartment not only leads to neutropenia, but also results in aberrant 
neutrophil functioning. For instance, the cell-membrane expression of the 
CD11b/CD18 complex, which regulates neutrophil adherence, migration and 
diapedesis, is decreased on neutrophils from MDS 
3. Furthermore, reduced 
activity of granule enzymes and defects in granule-membranes have been 
reported in neutrophils from MDS patients 
4-6. Other studies have shown that in 
MDS neutrophils, phagocytosis of bacteria and the production of ROS are 
defective 
7-12. Lastly, a deficit in neutrophil chemotaxis has been reported in MDS 
cases 
13;14.    
Granulocytes are attracted to sites of infection by inflammatory mediators 
that are being produced at these sites. Of particular importance in the recruitment 
of neutrophils is the 72-amino acid polypeptide Interleukin-8 or CXC chemokine 
ligand 8 (IL-8 or CXCL8) 
15;16. This chemokine is produced by monocytes and 
endothelial cells, and allows granulocytes to arrive in the general vicinity of the 
infection 
17;18. Neutrophils subsequently migrate towards a more localised 
gradient of "end-target" chemotractants such as the bacterial product N-formyl-L-
methionyl-L-leucyl-L-Phenylalanine (fMLP) 
19;20.  
Two receptors for IL-8 have been identified: CXC chemokine receptor 1 
and 2 (CXCR1 and CXCR2). CXCR1 is activated exclusively by IL-8, whereas 
CXCR2 also binds to other chemokines that are produced at the site of 
inflammation, such as growth-related oncogene (GROα or CXCL1) and 
neutrophil-activating peptide-2 (or CXCL7). 
Despite the fact that the receptors for fMLP and IL-8 both belong to the 
family of G protein-coupled seven-transmembrane-spanning domain receptors, 
the signals they transduce result in qualitatively different neutrophil effector Impaired migration and ERK activation in MDS 
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functions 
21. For instance, in contrast to fMLP, IL-8 does not directly trigger ROS 
production in human neutrophils. However, IL-8 pretreatment of cells does result 
in an enhanced production of oxygen radicals in response to fMLP stimulation 
22. 
In this capacity, IL-8 resembles priming agents such as the proinflammatory 
cytokines granulocyte macrophage-colony stimulating factor (GM-CSF) and 
tumour necrosis factor α (TNF-α) 
23;24. Although fMLP and IL-8 trigger neutrophil 
migration, the mechanisms through which chemotaxis is achieved might differ. 
Recent studies have shown that fMLP-induced transmigration is dependent on 
CD18 expression, whereas IL-8-induced chemotaxis is not 
25.  
The signal transduction pathways involved in chemotaxis towards a fMLP 
or IL-8/GROα gradient are as yet unclear. Several studies have indicated that 
although IL-8, GROα and fMLP stimulate the activation of extracellular-signal 
regulated kinase (ERK1/2), neutrophil chemotaxis induced by these agents was 
ERK1/2 independent 
26-29. In contrast, equally convincing studies did show 
involvement of ERK1/2 in IL-8- or fMLP-induced migration 
30-32. ERK1/2 is an 
important member of the Ras-Raf-mitogen-activated protein kinase (MAPK) 
kinase (MEK)-ERK1/2 signalling pathway. In addition, recent evidence suggests 
that ERK1/2 might also be activated by the small GTPase Rac, in a Ras-
independent manner 
33. Furthermore, activity of the lipid kinase 
phosphatidylinositol 3-kinase (PI-3K) has been implicated in neutrophil migration 
26;27 and has been placed upstream of ERK1/2 activation in several cell systems 
9;34.  
So far, only fMLP-induced migration has been studied in neutrophils from 
MDS patients 
13;14, and we have previously shown decreased activation of 
ERK1/2, and the PI-3K downstream product protein kinase B (PKB/Akt), in 
response to fMLP stimulation in MDS neutrophils 
9. However, differences in IL-8- 
and GROα-induced responses between MDS and healthy neutrophils have as 
yet scarcely been investigated. In this study, we show that migration towards IL-8 
and GROα are impaired in neutrophils from MDS patients, and that this migration 
is dependent on ERK1/2 and PI-3K activity. Furthermore, IL-8- and GROα-
induced phosphorylation of ERK1/2 were inefficient, as was the IL-8 stimulated 
activation of PKB/Akt and Rac. IL-8-induced activation of Ras and Ral were 
normal, demonstrating that the defects observed in MDS neutrophils were not 
due to a general CXCR1 or CXCR2 receptor defect. Our results indicate a 
disturbed IL-8/GROα-induced neutrophil chemotaxis in MDS patients, which 
might be the consequence of decreased Rac, PI-3K and ERK1/2 activation within 
these cells.    Chapter 5 
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Materials and methods 
 
Reagents 
Human recombinant Interleukin-8 and GROα were obtained from R&D Systems 
(Minneapolis, MN). The MEK inhibitor U0126 was supplied by New England 
Biolabs (Beverly, MA). The PI-3K inhibitor LY294002 was purchased from Alexis 
(Läufelfingen, Switzerland). Polyclonal antibody against ERK1/2 (K23) was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal 
antibodies against phosphorylated ERK1/2 (Thr202/Tyr204) and phosphorylated 
PKB/Akt (Ser473) were obtained from Cell Signalling technology (Beverly, MA). 
Monoclonal antibodies against Ras, Rac and Ral were purchased from 
Transduction Laboratories (Lexington, KY). 
 
Patients 
Fourteen patients with MDS were studied. MDS was classified as refractory 
anemia (RA) or RA with ringed sideroblasts (RARS) according to French-
American-British Cooperative Group criteria 
35. Informed consent was obtained 
from all patients. The Human Subject Review Board of the University Hospital 
Groningen approved the protocol. 
 
Isolation of neutrophils 
Peripheral blood, anti-coagulated with 0.32% sodium citrate, was obtained from 
healthy volunteers and MDS patients. Neutrophils were isolated as described 
previously 
36. In short, mononuclear cells were removed by centrifugation over 
Fycoll-Paque (Amersham, Upsala, Sweden) and erythrocytes were lysed with 
ice-cold NH4Cl solution. Neutrophils were allowed to recover for 30 minutes at 
37°C in RPMI 1640 (Bio Whittaker, Verviers, Belgium) supplemented with 0.5% 
human serum albumin (HSA; CLB, Amsterdam, The Netherlands). Before 
stimulation, cells were resuspended in incubation buffer (20 mM HEPES, 132 
mM NaCl, 6 mM KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM 
CaCl2, 0.5% HSA). In all cases, the cell population isolated consisted of >95% 
neutrophils as determined by May-Grünwald Giemsa staining. 
 
Migration assay  
The migration assay was performed using a microchamber transwell system with 
5  µM pores (Corning Costar Incorporated, New York, MA, USA). Neutrophils 
were resuspended in incubation buffer with or without inhibitors for 30 minutes. 
Subsequently, 1 x 10
5 neutrophils were applied to the upper compartment of the Impaired migration and ERK activation in MDS 
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chamber. Migration was induced by 5, 10 or 50 ng/mL IL-8 or GROα in 
incubation buffer present in the lower compartment of the chamber. In 
experiments with signal transduction inhibitors, the inhibitors were also present in 
the lower compartment. Cells were allowed to migrate to the lower compartment 
for 4 hours at 37°C. The upper well was removed, transmigrated neutrophils 
were harvested from the lower chamber and counted under the microscope. The 
assay was done in duplicates. Results are expressed as percentage, which 
represents the ratio between transmigrated neutrophils and the total amount of 
neutrophils added to the upper well.  
 
Ras, Rac and Ral activation assays  
Activated Rac was precipitated using bacterial lysate containing GST-cdc42/Rac-
interactive-binding (CRIB) domain of PAK (GST-PAK-CRIB), activated Ras was 
pulled down using bacterial lysate containing GST-Ras-binding domain of Raf 
(GST-Raf-RBD), and activated Ral was precipitated using bacterial lysate 
containing GST-Ral-binding domain of RLIP76 (GST-RLIP-RBD) as described 
previously 
37;38. Briefly, neutrophils (10 x 10
6 cells/mL) were stimulated with IL-8 
for the indicated time and lysed for 10 minutes in lysis buffer (50 mM Tris pH 7.4, 
10% glycerol, 200 mM NaCl, 1% NP-40, 2 mM MgCl2, 2 mM 
sodiumorthovanadate and protease inhibitors [1 tablet Complete (Roche, 
Mannheim, Germany) per 50 mL buffer]). Lysates were cleared by centrifugation, 
and GST-PAK-CRIB, GST-Raf-RBD or GST-RLIP-RBD protein, pre-coupled to 
glutathione-sepharose beads (Pharmacia, Upsala, Sweden), was added for 30-
45 minutes at 4 °C. Beads were washed 3 times with 1X lysis buffer and boiled in 
Laemmli sample buffer. The bound proteins were separated by 15% SDS-PAGE 
and transferred to polyvinylidene difluoride membrane (Immobilon-P; Millipore, 
Bedford, MA). Activated Rac, Ras or Ral was detected by probing the membrane 
with anti-Rac, anti-Ras or anti-Ral antibodies, respectively, and rabbit-anti-mouse 
peroxidase-conjugated antibodies (DAKO, Denmark) followed by enhanced 
chemiluminescence. Equal amounts of glutathione sepharose beads were loaded 
in all samples as determined by Ponceau S staining of the membranes. 
Quantification of the amount of precipitated active GTPase was performed by 
densitometry of the films, using ImageMaster1D Elite (Pharmacia, Woerden, The 
Netherlands). Results are presented as normalised densitometry values 
(arbitrary units [AU]). 
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Western blotting 
The amount of phosphorylated ERK, phosphorylated PKB/Akt and total ERK 
were determined by Western blotting. Neutrophils were stimulated with IL-8 or 
GROα as indicated in the figures. Stimulation was terminated by placing the cells 
on ice, immediate centrifugation and resuspending the cell pellets in 1X Laemmli 
sample buffer. After boiling for 10 minutes the proteins were separated on 10% 
SDS-PAGE and electrophoretically transferred to nitrocellulose membranes 
(Protran; Schleicher &Schuel, Dassel, Germany). Membranes were probed with 
antibodies against phosphorylated ERK1/2, phosphorylated PKB/Akt (Ser473) 
and ERK1/2 (K23) according to the manufacturers protocols. Proteins were 
detected by enhanced chemiluminescence. Quantification of phosphorylation 
levels was performed by densitometry of the films, using ImageMaster1D Elite 
(Pharmacia, Woerden, The Netherlands). 
 
Statistical analysis 
Differences in experimental values between MDS patients and healthy donors in 
migration assays, and the normalised densitometry values of Ral activation were 
calculated using the Mann-Whitney U nonparametric test for unpaired samples. 
Differences between migration of neutrophils and activation of Ras, Rac and Ral 
with or without inhibitors were calculated using the Student t-test for paired 
samples. For quantification of phosphorylated ERK protein, densitometry values 
were divided by the densitometry values of total ERK1/2 protein present in the 
same samples, and differences between the normalised values of MDS patients 
and healthy donors on the same blot were calculated using the Wilcoxon Signed 
Ranks test for paired samples. Likewise, differences in Ras and Rac activation 
between healthy donors and MDS patients run on the same blot were analysed 
using the Wilcoxon Signed Ranks test for paired samples. Data were expressed 
as mean ± SEM. P values ≤0.05 were considered significant. 
 
 
 
 
 
 
 
 
 Impaired migration and ERK activation in MDS 
124 
Results 
 
Decreased migration of neutrophils from MDS patients in response to IL-8 
and GROα  
Migration of neutrophils from eight MDS patients and six healthy volunteers 
towards the chemotactic cytokine IL-8 was measured in a microchamber 
chemotaxis assay. Figure 1 shows that in healthy donors, increasing 
concentrations of IL-8 resulted in increasing percentages of migrating neutrophils 
(0 ng/ml, 2±1%; 5 ng/ml, 29±7%; 10 ng, 40±7%; 50 ng/ml, 80±8%). Neutrophils 
from MDS patients also showed increasing migratory behaviour in response to 
higher IL-8 gradients (0 ng/ml; 2±1%, 5 ng/ml; 13±5%, 10ng; 21±7%, 50 ng/ml; 
40±9%). However, the IL-8-induced migration of neutrophils from MDS patients 
was significantly lower than that of their healthy counterparts (P= 0.7, 0.05, 0.07 
and 0.02, respectively). IL-8 stimulates CXCR1 and CXCR2. In order to establish 
whether one of these receptors was specifically responsible for the disturbed 
migration of MDS neutrophils, we applied the selective CXCR2 chemoattractant 
GROα. The maximal migration of healthy neutrophils toward a GROα gradient 
was reached between 10 and 50 ng/mL GROα, as the percentage of cells that 
transmigrated at 10 ng/mL GROα did not increase significantly when cells were 
allowed to migrate towards 50 ng/mL GROα (14±2 vs 19±4%, P= 0.23, n=5). Of 
note, maximal GROα-induced chemotaxis was much lower than the IL-8-induced 
migration (50 ng/mL GROα: 19±4%, 50 ng/mL IL-8: 80±8%). When comparing 
the GROα-stimulated chemotaxis between healthy donors (n=5) and MDS 
patients (n=4), it was apparent that chemotaxis was consistently lower in MDS 
neutrophils (10 ng/mL, 4±2 vs 14±2%, P= 0.05; 50 ng/mL, 9±3 vs 19±4%, P= 
0.142).  
Taken together, these results show that in terms of cellular function, MDS 
neutrophils respond less adequately to IL-8 and GROα stimulation than 
neutrophils from healthy donors. Furthermore, the disturbed GROα-induced 
response in MDS neutrophils implies a CXCR2 signalling defect. However, the 
percentage reduction of migration of MDS neutrophils in response to IL-8 is 
greater then maximal GROα-induced chemotaxis. Therefore, it cannot be 
explained solely by the disturbed CXCR2 signalling, and indicates that impaired 
CXCR1 signalling is also involved.  
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Migration of healthy neutrophils towards IL-8 or GROα is dependent on 
ERK1/2 and PI-3K activation  
To establish whether ERK1/2 and PI-3K are involved in IL-8- and GROα-induced 
neutrophil migration in our system, we applied their specific inhibitors, U0126 and 
LY294002 respectively, in the transwell assay. As is shown in Figure 2a, 
pretreatment of healthy neutrophils with 10 µM U0126 for 30 minutes resulted in 
approximately 50% attenuation of migration towards 50 ng/mL IL-8 (92±2 vs 
40±8%,  P=0.06, n=3). Furthermore, the PI-3K inhibitor LY294002 also 
significantly inhibited IL-8 induced migration (92±12 vs 64±12%, P=0.014, n=3). 
Likewise, Figure 2b demonstrates that pretreatment of healthy neutrophils with 
the ERK1/2 inhibitor or the PI-3K inhibitor also attenuated migration towards 
GROα (U0126: 22±3 vs 11±5%,  P=0.03; LY294002: 22±3 vs 9±4%,  P=0.06, 
n=3).  
The concentration U0126 used completely abolished IL-8- and GROα-
stimulated activation of ERK1/2 in healthy neutrophils (n=3; Figure 2c). Toxicity 
of the inhibitor was ruled out, as phosphorylation of PKB/Akt was not inhibited by 
pretreatment of cells with U0126. The concentration LY294002 used inhibited IL-
8- and GROα-triggered activation of PKB/Akt, whereas ERK phosphorylation was 
hardly affected. (Out of 4 independent experiments, no inhibition was shown in 2 
experiments and slight inhibition was observed in 2 others).  
Figure 1. Decreased IL-8- and GROα-
induced migration of neutrophils
from MDS patients 
Neutrophils from healthy donors and
MDS patients were applied to the upper
compartment of a microchamber
transwell system with 5 µM pores.
Migration was induced by 5, 10 or 50
ng/mL IL-8 and 10 or 50 ng/mL GROα
in incubation buffer present in the lower
compartment of the chamber. Cells
were allowed to migrate for 4 hours at
37°C after which the transmigrated
neutrophils were harvested from 
 the lower chamber and counted under the microscope. The assay was done in duplicates. Results
are expressed as the ratio between transmigrated neutrophils and the total amount of neutrophils
added to the upper well. The means of eight MDS patients and six healthy donors for IL-8-induced
migration, and four MDS patients and four healthy volunteers for GROα-induced migration are
shown. Impaired migration and ERK activation in MDS 
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Together, these data indicate that IL-8- and GROα-induced migration is 
at least partially dependent on the activation of ERK1/2 and PI-3K.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of the ERK1/2 inhibitor U0126 and the PI-3K inhibitor LY294002 on IL-8- and
GROα-induced migration of healthy neutrophils  
Neutrophils from 3 healthy donors were resuspended in incubation buffer with or without U0126 (10
µM for 30 minutes) or LY294002 (10 µM for 30 minutes). Subsequently, 1 x 10
5 neutrophils were
applied to the upper compartment of a microchamber transwell system with 5 µM pores and
migration was induced by 50 ng/mL IL-8 (a) or 50 ng/mL GROα (c) in incubation buffer containing
U0126 or LY294002 present in the lower compartment of the chamber. Cells were allowed to migrate
for 4 hours at 37°C after which the transmigrated neutrophils were harvested from the lower chamber
and counted under the microscope. The assay was done in duplicates. Results are expressed as the
ratio between transmigrated neutrophils and the total amount of neutrophils added to the upper well.
Significant differences between the groups with and without are indicated with an asterisk (P < 0.05)
(b and d) Neutrophils were pretreated with 10 µM U0126 or 10 µM LY294002 for 30 minutes where
indicated and subsequently stimulated with IL-8 (b) or GROα (d) for the indicated times.  Stimulation
of the neutrophils was stopped by boiling the samples in 1X Laemmli buffer. ERK1/2 activation was
detected by Western blotting, using antibodies against phosphorylated ERK1/2 (p-ERK; top panels).
PKB activation was detected using against phosphorylated PKB (p-PKB; middle panels) The blots
were reprobed with total ERK1/2 antibody, to control for equal loading (bottom panels). Three
independent experiments were performed, and one representative experiment is shown.  
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IL-8-induced ERK phosphorylation is higher than GROα-stimulated ERK1/2 
activation  
Migration in response to IL-8 was much higher than the GROα-induced 
chemotaxis of healthy and MDS neutrophils. To investigate whether these 
differences between IL-8 and GROα were reflected by differences in activation of 
signal transduction pathways, we next stimulated neutrophils from healthy donors 
with increasing concentrations of IL-8 and GROα, and compared the activation of 
ERK1/2 and PKB/Akt. As shown in Figure 3, maximal ERK1/2 activation was 
reached at 50 ng/mL GROα, whereas ERK1/2 phosphorylation in response to IL-
8 reached a maximum at 100 ng/mL IL-8. Furthermore, as for migration, the level 
of IL-8-induced ERK1/2 phosphorylation was higher than the GROα-stimulated 
ERK1/2 activation. PKB/Akt activation also increased with increasing amounts of 
IL-8, although this was less apparent for GROα stimulation. Furthermore, the 
differences in height of PKB/Akt activation by IL-8 or GROα were less 
pronounced than observed for ERK1/2 phosphorylation.      
 
Reduced IL-8-stimulated ERK1/2 and PKB/Akt phosphorylation in 
neutrophils from MDS patients 
As we found that neutrophil migration in response to an IL-8 gradient was 
dependent on the activation of ERK1/2, we wondered whether the disturbed 
migration of MDS neutrophils might be a result of ineffective ERK1/2 activation in 
these cells. We therefore examined the phosphorylation of this signal transducer 
in neutrophils from MDS patients (n=5) and healthy volunteers (n=5). Figure 4 
Figure 3. Differences in IL8-
and GROα-induced ERK1/2
and PKB phosphorylation
in healthy neutrophils  
Neutrophils were stimulated
with increasing concentration
of IL-8 or GROα for the
indicated times. Stimulation
of the neutrophils was
stopped by boiling the 
samples in 1X Laemmli buffer. ERK1/2 activation was detected by Western blotting, using antibodies
against phosphorylated ERK1/2 (p-ERK; top panel). PKB activation was detected using against
phosphorylated PKB (p-PKB; middle panel) The blots were reprobed with total ERK1/2 antibody, to
control for equal loading (bottom panel). Three independent experiments were performed, and one
representative experiment is shown.  Impaired migration and ERK activation in MDS 
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shows that in neutrophils from MDS patients and healthy donors, IL-8 stimulation 
resulted in a rapid and transient activation of ERK1/2. In healthy neutrophils, 
increasing concentrations of IL-8 (10 ng/mL vs. 50 ng/mL) induced a significantly 
increased phosphorylation of ERK1/2 (23±4 vs. 36±3 AU at t=30 seconds, P= 
0.04; 2±1 vs. 7±2 AU at t=2 minutes, P=0.04; Figure 4b). In neutrophils from 
MDS patients, a similar concentration-dependent increase in ERK1/2 activation 
was observed (10±1 vs. 20±43 AU at t=30 seconds, P=0.04; 0 vs. 1±1 AU at t=2 
minutes,  P=0.3).  When the amount of phosphorylated ERK1/2 present in 
neutrophil lysates from MDS patients was expressed as a percentage of that 
present in lysates from healthy neutrophils run on the same Western blot, it was 
apparent that IL-8-induced a much weaker response in MDS neutrophils (Figure 
4c). Furthermore, in four out of five patients, phosphorylation of PKB/Akt was 
also decreased when compared to neutrophil lysates of healthy donors, run on 
the same Western blot (Figure 4a, middle panels). These results demonstrate 
that in MDS patients, IL-8-induced ERK1/2 and PKB/Akt phosphorylation is 
impaired, likely resulting in the disturbed migration towards an IL-8 gradient. 
 
Reduced GROα-stimulated ERK1/2 phosphorylation in neutrophils from 
MDS patients 
As GROα-induced migration was also disturbed in neutrophils from MDS 
patients, we next investigated the GROα-stimulated ERK1/2 and PKB/Akt 
phosphorylation in neutrophils from five MDS patients and five healthy donors 
(Figure 5a). As for IL-8 stimulation, ERK phosphorylation in response to 10 
ng/mL GROα was much lower in MDS neutrophils compared with their healthy 
counterparts (6±1 vs. 25±2 AU at t=10 seconds, P=0.003; 12±3 vs. 50±5 AU at 
t=30 seconds, P=0.002l; 1±1 vs. 6±4 AU at t=2 minutes, P=0.3; Figure 5b). In 
contrast, PKB/Akt phosphorylation was not decreased in neutrophils from MDS 
patients (Figure 5a, middle panels). These data imply that although both ERK 
and PI-3K are involved in CXCR2-induced migration, PKB/Akt is not responsible 
for the decreased chemotactic response to GROα observed in MDS neutrophils. 
More likely, impaired signalling through the ERK1/2 pathway results in the 
disturbed GROα-induced migration.  Furthermore, the normal phosphorylation of 
PKB/Akt indicates that the inefficient migration and ERK phosphorylation seen in 
neutrophils from MDS patients is not due to a general CXCR2 defect.   
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Figure 4. Disturbed ERK1/2 activation by IL-8 in neutrophils from MDS patients 
(a) Neutrophils from five healthy volunteers and five MDS patients were stimulated with 10 or 50
ng/mL IL-8 for the indicated times. Western blotting was performed using an antibody against
phosphorylated ERK1/2 (p-ERK; top panels) or phosphorylated PKB (p-PKB; middle panels). Equal
loading was demonstrated by reprobing the blots with an antibody against ERK1/2 (lower panels).
Two independent experiments are shown. (b) For quantification of phosphorylated ERK protein,
densitometry values were divided by the densitometry values of total ERK1/2 protein present in the
same samples. Means of five independent experiments are shown. *, Significant differences between
groups stimulated with 10 or 50 ng/mL IL-8 are indicated (P < 0.05). **, Significant differences
between healthy donors and MDS patients are indicated (P < 0.05). (c) The level of phosphorylation
of ERK1/2 in neutrophil lysates from MDS patients was expressed as a percentage of the
phosphorylation observed in cell lysates from healthy donors, run on the same gel. *, Significant
differences are indicated (P < 0.05). 
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IL-8-stimulated activation of Ras is normal in neutrophils from MDS 
patients 
As activation of ERK1/2 appeared to be the common denominator in IL-8- and 
GROα-induced disturbed migration of MDS neutrophils, we wished to investigate 
whether this defect was located at the level of ERK1/2 itself, or whether it was 
caused by disturbed activation of an upstream signalling molecule. As GROα-
induced responses were marginal compared to those triggered by IL-8 (compare 
migration [figures 1 and 2] and ERK phosphorylation [Figure 3]) we chose to 
focus our study on IL-8.  
 
 
Figure 5. Disturbed ERK1/2 phosphorylation by GROα in neutrophils from MDS patients. 
(a) Neutrophils from five healthy volunteers and five MDS patients were stimulated with 10 ng/mL
GROα for the indicated times. Western blotting was performed using an antibody against
phosphorylated ERK1/2 (p-ERK; top panels) or phosphorylated PKB (p-PKB; middle panels). Equal
loading was demonstrated by reprobing the blots with an antibody against ERK1/2 (lower panels).
Two independent experiments are shown. (b and c) Quantification was performed as described in
Figure 4, b and c. *, Significant differences are indicated (P < 0.05). Chapter 5 
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As ERK1/2 is known to be an important member of the well-described 
Ras-Raf-Mek-ERK1/2 signalling pathway, we next investigated the activation of 
the small GTPase Ras by employing a pull-down assay in which only active 
GTPase is precipitated. We first excluded the possibility of Ras being activated 
by PI-3K by showing normal Ras activation in response to 10 ng/mL IL-8 in the 
presence of the PI-3K inhibitor LY294002 (Figure 6a). We next tested the 
activation of Ras in neutrophils from MDS patients (n=6) and healthy donors 
(n=6). Figure 6b shows that stimulation of cells with IL-8 resulted in a rapid and 
transient activation of Ras that was equal in neutrophils from healthy donors and 
MDS patients (14±3 vs. 15±2 AU at t=10 seconds, P= 0.8; 30±5 vs. 34±6 AU at 
t=30 seconds, P=0.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Ras activation in
neutrophils from healthy donors and
MDS patients.  
(a) Neutrophils were stimulated with 10
ng/mL IL-8 for the indicated times, with
or without pretreatment with 10 µM
LY294002 for 30 minutes. Activated Ras
was precipitated using GST-Raf-RBD  
protein, and visualised by Western blotting with Ras antibodies. Four independent experiments were
performed, of which two are shown. (b) Neutrophils from six healthy controls and six MDS patients
were stimulated with 10 ng/mL IL-8 for the indicated times, and activated Ras was precipitated.
Three representative experiments are shown. Protein levels of activated Ras were quantified by
densitometry of the films. The means of the normalised values were calculated for the MDS patients
and healthy donors. Impaired migration and ERK activation in MDS 
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Inefficient IL-8-induced activation of Rac in neutrophils from MDS patients 
Another GTPase implicated in ERK1/2-dependent and ERK1/2-independent 
migration is Rac. Stimulation of Rac activation by IL-8 was not inhibited by 
pretreatment of neutrophils with the PI-3K inhibitor LY294002 (Figure 7a; n=5). 
Figure 7b shows a high basal activity of Rac present in unstimulated neutrophils. 
Stimulation of neutrophils from healthy donors (n=5) with 10 ng/mL IL8 resulted 
in a rapid and transient activation of Rac, with a maximum at 10 seconds of 
stimulation. (9±1 at t=0 vs. 15±2 at t=10 seconds, P=0.04, 9±1 at t=0 vs. 11±1 at 
t=30 seconds, P=0.08). Although there was no significant difference in amount of 
activation of Rac in MDS patients in direct comparison with healthy donors (12±1 
vs. 15±2 at t=10 seconds, P=0.35), Rac activation in MDS neutrophils did not 
reach statistical significance at 10 seconds of IL-8 stimulation (8±1 at t=0 vs. 
12±1 at t=10 seconds, P=0.14, 8±1 at t=0 vs. 12±1 at t=30 seconds, P=0.08). 
These results show that Rac activation is less efficient in MDS patients, possibly 
resulting in the disturbed ERK activation observed in MDS cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Rac activation in
neutrophils from healthy donors
and MDS patients  
(a) Neutrophils were stimulated with
10 ng/mL IL-8 for the indicated times,
with or without pretreatment with 10
µM LY294002 for 30 minutes.  
  Activated Rac was precipitated using GST-PAK-CRIB and visualised by Western blotting with Rac
antibodies. Five independent experiments were performed, of which two are shown. (b) Neutrophils
from five healthy controls and five MDS patients were stimulated with 10 ng/mL IL-8 for the indicated
times, and activated Rac was precipitated. Three representative experiments are shown. Protein
levels of activated Rac were quantified by densitometry of the films. The means of the normalised
values were calculated for the MDS patients and healthy donors. *, Significant differences between
unstimulated and IL-8 stimulated groups are indicated (P < 0.05). 
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Normal Ral activation in neutrophils from MDS patients 
Another signal transduction molecule that has been implicated in cell migration 
and cytoskeletal reorganisation is the small GTPase Ral 
39;40. We first ruled out 
that activation of Ral is dependent on PI-3K or ERK1/2 activity. Figure 8a shows 
that IL-8-induced Ral activity was not attenuated by either the PI-3K inhibitor 
LY294002 or the ERK1/2 inhibitor U0126. Next, we studied the activation of Ral 
in neutrophils from healthy donors (n=4) and MDS patients (n=4). As shown in 
Figures 8, b and c, Ral activation in response to 10 ng/mL IL-8 in was rapid and 
transient in neutrophils from healthy donors, and similar to that in neutrophils 
from MDS patients (67±9 vs. 60±5 AU for t=30 seconds, P=0.7; 15±4 vs. 17±2 
AU for t=2 minutes, P=0.7).  
Taken together, these results demonstrate that IL-8-triggered Ras and 
Ral activation is normal in MDS neutrophils, thereby eliminating the possibility 
that the decreased migration and ERK phosphorylation observed in neutrophils 
from MDS patients is due to a general IL-8 receptor defect.  
 
 
 
Figure 8. Ral activation in
neutrophils from healthy donors
and MDS patients  
(a) Neutrophils were stimulated with
10 ng/mL IL-8 for the indicated times,  
  with or without pretreatment with 10 µM LY294002 or 10 µM U0126 for 30 minutes. Activated Ral was
precipitated using GST-RLIP-RBD protein and visualised by Western blotting with Ral antibodies.
Four independent experiments were performed, of which two are shown. (b) Neutrophils from six
healthy controls and four MDS patients were stimulated with 10 ng/mL IL-8 for the indicated times,
and activated Ral was precipitated. Two representative experiments are shown. Protein levels of
activated Ral were quantified by densitometry of the films. The means of the normalised values were
calculated for the MDS patients and healthy donors.  Impaired migration and ERK activation in MDS 
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Discussion 
 
Neutrophils from patients suffering from myelodysplasia generally show impaired 
neutrophil functioning. Several processes involved in the attraction of neutrophils 
towards sites of inflammation and the killing of invading bacteria have been 
shown to be affected. For example, chemotaxis of neutrophils from patients with 
MDS towards a fMLP gradient were shown to be impaired 
13;41. We now show 
that neutrophil migration towards IL-8 and GROα chemotactic gradients are also 
disturbed in MDS patients.  
Motility of neutrophils is preceded by polymerisation of cytoplasmic F-
actin and pseudopod extension. A recent study demonstrated that whereas 
activation of PI-3K was essential for fMLP-induced pseudopod extension, IL-8-
stimulated pseudopod extension was much less dependent on PI-3K 
42. 
Furthermore, IL-8-, but not fMLP-induced F-actin polymerisation, pseudopod 
extension and migration have been shown to be enhanced by pre-treatment of 
cells with GM-CSF or insulin 
30;42;43. Moreover, this GM-CSF priming was PI-3K-
dependent, whereas priming by insulin was PI-3K-independent. These data 
clearly indicate the existence of multiple pathways leading to migration in 
response to different stimuli. This would seem logical; neutrophils encountering 
an IL-8 gradient in the human body are recruited to the general vicinity of a 
source of infection, where intracellular signalling hierarchy dictates that cells 
subsequently migrate towards end-target chemotractants such as fMLP, by 
overriding IL-8-induced signalling 
19;20. 
IL-8 stimulates two receptors, CXCR1 and CXCR2, whereas GROα 
specifically activates the CXCR2 receptor. The disturbed migration towards a 
GROα gradient in MDS neutrophils indicates that CXCR2 signalling is affected. It 
is therefore likely that at least part of the reduced migration of MDS neutrophils 
towards IL-8 is due to impaired CXCR2 signalling. However, the maximal 
achievable migration induced by GROα was much lower than that induced by IL-
8, indicating that CXCR1 plays the major part in IL-8-stimulated migration. 
Furthermore, the reduction of IL-8-induced migration in MDS neutrophils was too 
large to be explained solely by disturbed CXCR2 signalling, indicating that 
CXCR1 signalling is also affected.  
In the present study, we show that both IL-8- and GROα-induced 
migration were dependent on the activation of the MAPK ERK1/2. However, 
despite complete abrogation of ERK1/2 phosphorylation by U0126, migration 
was not completely abolished, implicating the involvement of other signal 
transduction pathways. Indeed, we also demonstrated that the lipid kinase PI-3K Chapter 5 
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was involved in IL8- and GROα-induced migration. As ERK1/2 phosphorylation 
was not significantly affected by the PI-3K inhibitor LY294002, it can be 
concluded that activation of CXCR1 and CXCR2 leads to migration through 
multiple, independent pathways. Indeed, a recent study has shown that yet 
another MAPK, p38, might also regulate directional granulocyte migration 
towards IL-8 
44.  
The dependency of neutrophil migration on ERK1/2 and PI-3K activation 
prompted us to investigate the activation of these signal transduction pathways in 
MDS neutrophils. We showed that the activation of ERK1/2 was severely 
impaired in neutrophils from MDS patients. Not merely the height of activation, 
but also the duration of activation of ERK1/2 was disturbed in MDS neutrophils in 
response to IL-8. Although the GROα-stimulated chemotaxis was shown to be 
attenuated by the ERK1/2 and the PI-3K inhibitor, only ERK1/2 activation was 
affected in MDS patients. This indicates that CXCR2-activated PI-3K activation 
possibly results in migration through a PKB/Akt-independent pathway. However, 
studies using cell lines transfected with dominant negative or constitutive active 
PKB/Akt constructs have clearly demonstrated its involvement in migration of 
these cell lines 
45;46.  
Several signal transducers have been shown to be able to activate 
ERK1/2 in vitro. The best described of these is the small GTPase Ras. Our 
studies indicate that Ras activation in response to IL-8 stimulation is normal in 
MDS neutrophils. The GTPase Rac has also been described to activate ERK1/2 
47;48, via PAK 
33. Our studies show that IL-8-triggered activation of Rac is less 
effective in neutrophils from MDS patients, possibly resulting in the disturbed 
ERK1/2 activation and subsequently disturbed migration. In addition, Rac and 
ERK activation have also been described to lead to migration through two 
separate mechanisms 
49. The disturbed IL-8-induced migration of MDS 
neutrophils could therefore also be a result of disturbed activation by Rac and 
ERK1/2 of two independent pathways leading to migration.    
Upon stimulation of the neutrophils with IL-8, its receptors become 
desensitised and are less susceptible to subsequent restimulation with IL-8. 
Desensitisation results in a decreased migration and phosphorylation of IL-8 
receptor targets 
50. A recent study has suggested that in MDS patients, serum 
levels of IL-8 are elevated 
51. It would therefore be conceivable that in these 
patients, in vivo desensitisation of CXCR1 and CXCR2 might result in a 
decreased in vitro stimulation of IL-8 receptor functions. However, the normal IL-
8-stimulated Ras and Ral activation that was observed in MDS neutrophils 
makes it unlikely that desensitisation plays an important role in this study.  Impaired migration and ERK activation in MDS 
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In conclusion, we showed that ERK1/2-dependent migration towards IL-8 
is impaired in neutrophils from MDS patients and that IL-8-stimulated activation 
of Rac and phosphorylation of ERK1/2 and PKB/Akt are disturbed in MDS 
neutrophils, despite a normal activation of Ras and Ral. Furthermore, impaired 
GROα-stimulated migration and ERK1/2 activation indicates that disturbed 
CXCR2 signalling, besides a defective CXCR1 signalling, plays a role in this. Our 
results suggest a defective IL-8-induced Rac-ERK and PI-3K signalling in MDS 
patients, which might result in an increased susceptibility to bacterial infections 
by affecting neutrophil chemotaxis.  
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Summary 
 
MDS is a clonal hematological disorder, characterised by disturbed differentiation 
of the erythroid, megakaryocytic and myeloid lineages. A high incidence of 
bacterial infection related deaths has implicated an important role for disturbed 
neutrophil functions in the pathology of the myelodysplastic syndromes. Studies 
into the mechanisms of the impaired neutrophil-mediated immune defence are 
essential to further improve our knowledge of this disease and its possible 
treatment.  
 
In chapter 2 we have shown that in neutrophils from patients with low-
risk MDS, the production of reactive oxygen species (ROS), an important 
bactericidal mediator, was normal in response to stimulation with the bacterial 
peptide fMLP. In addition, F-actin polymerisation in response to fMLP was normal 
in most patients, as was the fMLP-mediated activation of Rac, implicated in ROS 
production and cytoskeletal reorganisations. These results would suggest that 
fMLP-mediated responses are functional. In contrast, GM-CSF priming of the 
fMLP-stimulated respiratory burst was severely impaired. Stimulation of MDS 
neutrophils with the receptor-independent agonist PMA resulted in a high ROS 
production, indicating that ROS production is possible in these cells but that 
triggering of the respiratory burst is defective in a receptor-mediated way. We 
investigated the signal transduction pathways involved in ROS production, and 
showed that inhibition of ERK1/2 resulted in attenuation of ROS production in 
GM-CSF primed healthy neutrophils. Inhibition of PI3K activity inhibited fMLP-
induced respiratory burst in both unprimed and GM-CSF-primed neutrophils. In 
accordance with these results, phosphorylation of ERK1/2 and the PI3K 
downstream target PKB were enhanced by GM-CSF pretreatment of cells. That 
this effect was synergistic rather then accumulative was shown by the fact that 
hardly any ROS production, PKB phosphorylation or ERK1/2 phosphorylation 
took place upon stimulation of neutrophils with GM-CSF alone. Using a PI3K 
Class 1A recognising antibody, we found that the protein levels of the p110 
subunit were increased in MDS neutrophils. In both GM-CSF-primed and 
unprimed neutrophils from MDS patients, PKB and ERK1/2 phosphorylation were 
decreased in response to fMLP stimulation. However, GM-CSF stimulated a 
normal STAT5 activation in MDS neutrophils, indicating that GM-CSF-receptors 
were present and functional in MDS patients. Taken together, these results 
demonstrated that GM-CSF priming in MDS neutrophils was impaired, possibly Chapter 6 
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as a result of impaired convergence of fMLP and GM-CSF signalling, which 
involved both the ERK1/2 and the PI3K pathways.  
 
We further investigated the involvement of the PI3K signal transduction 
pathway in GM-CSF priming of neutrophils in chapter 3. We showed that fMLP-
induced accumulation of the PI3K product PtdIns(3,4,5)P3 could be enhanced by 
GM-CSF pretreatment of healthy neutrophils. In MDS patients, GM-CSF priming 
of PtdIns(3,4,5)P3 accumulation in response to fMLP stimulation was impaired. 
When investigating the PI3K activator Ras, we found that although fMLP-
triggered Ras activation could also be primed by GM-CSF, Ras activity was 
normal in MDS patients. This suggests that either PtdIns(3,4,5)P3 accumulation 
occurs independently of Ras, or the defect at the Ras-PI3K pathway is located 
downstream of Ras. In accordance with these results, fMLP-stimulated activation 
of another Ras target, Ral, which could not be primed by GM-CSF, was 
independent of PI3K activity, and normal in MDS neutrophils. We next looked at 
the putative PI3K target Rac, and showed that as for PtdIns(3,4,5)P3 
accumulation, GM-CSF priming could enhance Rac activation in healthy 
neutrophils. Furthermore, Rac activity was at least partially dependent on PI3K 
activity in both unprimed and GM-CSF-primed cells, indicating that a PI3K-Rac 
pathway is present in neutrophils. In addition, fMLP-induced activation of Rac 
could not be primed by GM-CSF in MDS neutrophils. These results suggest that 
a PI3K-Rac pathway downstream of Ras activity is impaired in GM-CSF-primed 
neutrophils from MDS patients.  
 
Some studies have suggested that priming might be a result of increased 
expression of the NADPH oxidase component flavocytochrome b558 at the 
plasma membrane. To gain further insight into the mechanistic process involved 
in impaired priming, we investigated the flavocytochrome b558 expression in MDS 
neutrophils compared with healthy donors in chapter 4. We showed that fMLP 
and GM-CSF stimulation resulted in an increased expression of flavocytochrome 
b558 at the plasma membrane of healthy neutrophils. No priming of GM-CSF on 
fMLP-mediated flavocytochrome b558 expression was observed. In MDS 
neutrophils fMLP-, but not GM-CSF-induced plasma membrane expression of 
flavocytochrome b558 was impaired. This was not a result of decreased 
degranulation of either secretory vesicles or specific granules, as plasma 
membrane expression of CD35 and CD66b, markers for these granules, 
increased normally on MDS neutrophils upon stimulation. GM-CSF did not 
increase CD66b expression on healthy neutrophils, indicating that exocytosis of Summary, General Discussion and Future Perspectives 
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secretory vesicles rather then specific granules is involved in GM-CSF mediated 
flavocytochrome b558 upregulation at the plasma membrane. When investigating 
the protein levels of flavocytochrome b558, we found that total protein expression 
of the gp91
phox and p22
phox subunits of flavocytochrome b558 were decreased in 
neutrophils from MDS patients. As fMLP induced a normal release of secretory 
vesicle and specific granule in MDS cases, it is tempting to speculate that 
decreased expression of flavocytochrome b558 in other granules, for instance 
tertiary granules, which also degranulate upon fMLP stimulation, is involved in 
the decreased fMLP-triggered flavocytochrome b558 plasma expression on MDS 
neutrophils.  
 
Although ROS production is essential for neutrophil anti-bactericidal 
activity, other cellular functions, such as migration and phagocytosis, are also of 
importance. Furthermore, other stimuli besides fMLP and GM-CSF are capable 
of activating neutrophil functions, and might function through either similar or 
different pathways. We addressed these questions in chapter 5, where we 
investigated neutrophil migratory behaviour in response to gradients of 
Interleukin-8 and GROα, two GPCR-agonists. We demonstrated that MDS 
neutrophils migrate significantly less towards an IL-8 or GROα gradient. We 
provide evidence that the PI3K and ERK1/2 signalling pathways are involved in 
IL-8/GROα-induced migration by applying their specific inhibitors. Next, we 
demonstrated that ERK1/2 phosphorylation was reduced in response to both IL-8 
and GROα stimulation in MDS neutrophils, whereas PKB phosphorylation was 
only affected when cells were stimulated with IL-8. Furthermore, as the CXCR1 
and CXCR2 agonist IL-8 induced much higher responses than the specific 
CXCR2 agonist GROα, it seemed that CXCR1 was the major receptor 
responsible for IL-8-induced effects. As both ERK1/2 and PI3K-PKB pathways 
can be activated by Ras, we subsequently investigated IL-8-induced Ras 
activation in MDS neutrophils, and found that it was normal. In contrast, 
activation of Rac, also implicated in ERK1/2 activation, was found to be inefficient 
in MDS neutrophils. These results indicate that IL-8/GROα-induced chemotaxis 
is disturbed in MDS patients, which might be the result of impaired PI3K, Rac 
and ERK1/2 activation.  
In summary, these data indicate that multiple cellular responses are 
affected in MDS patients, in response to different stimuli. Overall, the same 
signal transduction pathways are implicated in the defects observed. Chapter 6 
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General discussion 
 
The importance of proper neutrophil functioning is underscored by the fact that 
patients with neutrophil deficits are prone to lethal bacterial infections 
1-3.  In 
chapter 2 and chapter 5 we demonstrated that neutrophil respiratory burst and 
neutrophil migration, respectively, were impaired in MDS patients. With regards 
to the signal transduction pathways involved, it was apparent that the ERK1/2 
and the PI3K pathways play an important role in these processes, although there 
might appear to be some discrepancies.  
First of all, when looking at the signal transduction pathways utilised by 
fMLP in stimulating ROS production in unprimed cells, we demonstrated in 
chapter 2 that PI3K was required for a full respiratory burst, and that PKB 
phosphorylation in response to fMLP stimulation was decreased in MDS 
neutrophils. Nevertheless, fMLP-stimulated ROS production was normal in these 
patients (figure 1). These results might suggest that although PI3K activity is 
required for ROS production, PKB activation might not be essential. Although this 
would seem incompatible with observations by Chen et al, who claim PKB is 
responsible for p47
phox phosphorylation and respiratory burst activity 
4, it is in 
accordance with results from a later study by Yamamori et al 
5, who suggest that 
PI3K-mediated phosphorylation of p47
phox is independent of PKB activity. Another 
possibility is that low levels of PKB are enough to induce proper ROS production 
by fMLP stimulation, i.e., threshold levels of PKB activity might be required for 
respiratory burst activity. These findings are confirmed by the fact that in chapter 
3, PtdIns(3,4,5)P3 accumulation in response to fMLP stimulation was also normal 
in neutrophils from MDS patients. Furthermore, fMLP-induced activation of Rac 
was PI3K-dependent, and also normal in MDS neutrophils (chapters 2 and 3).  
  Secondly, activation of ERK1/2 was not required for fMLP-induced ROS 
production. Nevertheless, ERK1/2 activation upon fMLP stimulation was 
decreased in MDS neutrophils. These results suggest that other as yet 
unidentified ERK1/2-dependent cellular functions might be impaired upon fMLP 
stimulation of MDS neutrophils. As fMLP is a well-known chemoattractant for 
neutrophils, and fMLP-induced migration might be ERK1/2 dependent 
6, it would 
be conceivable that the decreased ERK1/2 phosphorylation results in a 
decreased migration of MDS neutrophils towards an fMLP gradient. In fact, a 
similar defect was found in chapter 5, where IL-8-and GROα-induced ERK1/2 
phosphorylation were impaired in MDS neutrophils, as was the ERK1/2-
dependent chemotaxis towards IL-8 and GROα. In this study a similar apparent 
discrepancy was found; although PI3K was involved in GROα-induced migration, Summary, General Discussion and Future Perspectives 
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which was impaired in MDS neutrophils, PKB phosphorylation was normal in 
response to GROα stimulation. In contrast, PKB phosphorylation was impaired in 
IL-8-stimulated MDS neutrophils. However, these data might easily be explained 
by suggesting that whereas both CXCR1 and CXCR2 signalling result in PI3K-
PKB activation, only CXCR1-induced PI3K activity is impaired in MDS 
neutrophils. However, both CXCR1-and CXCR2-mediated ERK1/2 activities are 
impaired in MDS. It is unclear what molecular mechanism might underlie these 
differences. It is tempting to speculate that besides an ERK1/2 activation defect 
present in both CXCR1 and CXCR2, binding of PI3K might be affected in the 
CXCR1 receptor alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Signal transduction pathways investigated in this thesis. 
The signal transduction pathways that were activated by fMLP, GM-CSF + fMLP, IL-8 and GROα 
stimulation, and the connections between the signalling molecules that were found in this thesis are 
indicated with a closed line arrow. Connections that were suggested in literature but not directly 
proven in the studies in this thesis are indicated with dashed arrows. Signal transduction molecules 
that were described to be affected in MDS neutrophils are indicated in grey. (B) An upward pointing 
arrow indicates the activation of signalling molecules in response to fMLP that were primed by GM-
CSF pre-treatment. See text for details.  Chapter 6 
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Of all signal transduction pathways tested, only the Ral GTPase could 
not be primed by GM-CSF pretreatment prior to fMLP stimulation (figure 1C). 
Ras activation, PtdIns(3,4,5)P3 accumulation, Rac activation (chapter 3), ERK1/2 
and PKB activation (chapter2) and ROS production were all increased by GM-
CSF. It is tempting to speculate that a general mechanism results in enhanced 
activation of these signalling pathways. In theory, increased activation of Ras 
might result in heightened activity of all signalling molecules, as Ras has been 
described to activate the raf-MEK-ERK1/2, the PI3K-Rac and Ral pathways 
7-10. 
The fact that Ral activity was not primed by GM-CSF suggests a Ras 
independent manner of Ral activation. Precedents for such Ras-independent 
activation of Ral can be found in literature 
11;12. Theoretically, it is possible that a 
defect downstream of Ras is responsible for the disturbed priming of PI3K, Rac, 
PKB, and ERK in neutrophils from MDS patients. Nevertheless, these pathways 
can all be activated independently from Ras as well, so there might be another 
common defect. Rac, PKB and ERK1/2 have been described to be activated 
through PI3K. However, our own evidence suggests that ERK1/2 is activated 
independently of PI3K, as the PI3K inhibitor LY294002 did not attenuate ERK1/2 
phosphorylation in chapter 2. Rac has been shown to activate ERK1/2 
independently of Ras 
13. Therefore, although we show that Rac activity is at least 
partially dependent on PI3K activity in response to fMLP, residual PI3K-
indendent Rac activity might activate ERK1/2 in our system.   
  
Possible mechanisms of priming; NADPH oxidase assembly 
Although some of the signal transduction pathways involved in priming of the 
neutrophil respiratory burst are slowly emerging, the exact mechanism of priming 
still remains unclear. Some studies have suggested that increased expression of 
flavocytochrome b558 at the plasma membrane as a result of stimulation of cells 
with priming agents explains the action of these agents 
14;15. However, although 
treatment of neutrophils with GM-CSF did increase the amount of 
flavocytochrome b558 present at the plasma membrane, this expression was not 
affected in MDS patients and can therefore not fully explain the priming defect of 
GM-CSF in MDS (chapter 4). We show that fMLP stimulation also increases 
flavocytochrome expression, and that this process is impaired in MDS 
neutrophils. These results suggest that threshold levels of flavocytochrome b558 
induced by fMLP might restrict the production of ROS in GM-CSF-primed cells. 
These hypothesis is supported by the observation that ROS production in GM-
CSF-primed cells and flavocytochrome b558 translocation in unprimed cells in 
response to fMLP are partially ERK1/2-dependent (chapter 2 and unpublished Summary, General Discussion and Future Perspectives 
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results), whereas fMLP-induced ROS production in unprimed cells was ERK1/2-
independent. However, inhibition of PI3K, although attenuating ROS production, 
did not reduce flavocytochrome translocation to the plasma membrane of healthy 
neutrophils. This suggests that other mechanisms beside flavocytochrome b558 
translocation are involved in priming of the neutrophil respiratory burst. Other 
components of the NADPH oxidase complex, not investigated in our studies, 
might also be involved; PI3K-dependent phosphorylation of p47
phox was shown to 
be involved in priming of ROS production 
16;17. In patients with arthritis, it has 
been shown that ROS production by neutrophils is increased as a result of 
increased p47
phox phosphorylation because of in vivo priming of neutrophils by 
increased serum levels of the priming agents IL-8, TNFα, but not GM-CSF 
18. 
Activation of p47
phox and other NADPH oxidase components remains to be 
investigated in MDS neutrophils.   
 
Possible mechanisms of priming; lipid raft formation 
A major point of focus in our priming studies is the convergence of different 
signal transduction pathways upon stimulation with GPCRs and priming agents. 
It is likely that this convergence is impaired in MDS, although the mechanism of 
convergence is not fully elucidated. Cross talk between GPCRs and tyrosine 
kinase receptors has been established in some cell-types (reviewed in 
19;20). For 
instance, the epidermal growth factor receptor (EGFR) can become 
phosphorylated upon GPCR signalling, without EGF binding. This 
phosphorylation and subsequent signalling can be a result of GPCR-stimulated 
Src kinase activity, or by complex formation between the G protein subunits and 
the cytokine receptors 
21. It is conceivable that pretreatment of cells with priming 
agents such as GM-CSF results in enhanced signal transduction by fMLP-
receptors by bringing the responsible signalling molecules into close proximity to 
each other, thereby 'readying' the cell for subsequent stimulation. The signalling 
platforms necessary for efficient signalling are called signalosomes, and contain 
both receptors and signal transduction molecules. Signalosomes are located in 
specific cholesterol- and glycosphingolipid-rich membrane subdomains, the so-
called lipid rafts, with a density different from the bulk of the plasma membrane 
(reviewed in 
22). More and more evidence suggests that lipid rafts play an 
important role in cell signalling and functions. For instance, polarisation of T-cells 
or human neutrophils, necessary for chemotaxis of cells 
23 requires lipid rafts 
24;25. Both IL-8-and fMLP-induced migration were decreased upon disruption of 
lipid rafts with the cholesterol-depleting agent methyl-β-cyclodextrin (CD) 
26. 
Furthermore, chemoattractant-stimulated neutrophil granule release is dependent Chapter 6 
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on lipid rafts in some studies 
27,  although not in others 
25, which might depend on 
the stimulus used and type of granule studied 
26. In addition, ROS production in 
response to chemoattractants in neutrophilic cells is also dependent on the 
presence of cholesterol-rich lipid rafts 
27. NADPH oxidase components localise to 
lipid rafts, and lipid rafts determine the efficiency of oxidase activation 
28;29. Our 
preliminary studies also suggest that fMLP-stimulated ROS production in 
unprimed or GM-CSF-primed cells is dependent on integrity of lipid rafts, as 
preincubation of healthy neutrophils with CD inhibits the respiratory burst (figure 
2, unpublished data). CD was not toxic to the cells, as removal of CD resulted in 
partial restoration of ROS production capacity. In contrast to these results, others 
have suggested that pretreatment of neutrophils with CD actually primes the 
fMLP-mediated ROS production 
30;31. These conflicting results are hard to 
reconcile, and further studies will have to be performed to elucidate the exact role 
of lipid rafts in neutrophil ROS production.  
 
      
 
  
 
 
 
 
 
 
 
 
 
Figure 2. The effect of cholesterol depletion on ROS production.  
Neutrophils from healthy donors that were unprimed (A) or primed for 15 min with 5 ng/ml GM-CSF 
(B) were stimulated with 10 µM fMLP for the indicated time and intracellular ROS production was 
measured as described in chapter 2. To assess the effect of cholesterol depletion on ROS 
production, cells were pre-incubated with 10 µM methyl-β-cyclodextrin (CD) for 30 min (open circles) 
prior to priming with GM-CSF and stimulation with fMLP. In addition, to determine the toxicity of the 
CD treatment, cells were washed after CD treatment, allowed to recover for 45 min at 37 °C. They 
were then stimulated with fMLP, with or without ptior pre-treatment with GM-CSF, and ROS 
production was measured (closed triangles). Mean results for 6 independent experiments are shown. 
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Lipid rafts have also been implied in receptor-induced signalling. For 
instance, PI3K localisation and activation are dependent on lipid raft integrity in a 
number of cell-types 
32-34. Furthermore, PKB phosphorylation can be partially 
inhibited by cholesterol depletion 
32;35. Active Rac is present at lipid rafts 
36 and 
prolonged activation of Rac is dependent on membrane lipid organisation 
25. In 
addition, activation of ERK1/2 has also been reported to be dependent on the 
presence of lipid rafts 
26;35, although one study did not find reduced ERK1/2 
activity upon CD treatment of cells 
32.  
Intriguingly, a recent study suggests that ERK1/2 phosphorylation, but not STAT5 
activation, is lipid raft-dependent in growth hormone signalling in mouse 
adipocytes 
37. This is of particular interest when examining the data described in 
this thesis; in MDS neutrophils STAT5 activation upon GM-CSF stimulation was 
normal, whereas both PKB and ERK1/2 activities were impaired in fMLP-
stimulated primed or unprimed cells. These results suggest a potential role for 
lipid rafts in the disturbed signalling in MDS cases. We investigated the 
involvement of lipid rafts in GM-CSF and fMLP signalling in healthy neutrophils. 
Our preliminary data (figure 3) suggest that phosphorylation of ERK1/2 and PKB 
in response to fMLP stimulation and the GM-CSF priming thereof are partially 
attenuated by pretreatment of cells with CD. This implies that fMLP signalling is 
dependent on the presence of cholesterol-rich microdomains in the plasma 
membrane. In contrast, GM-CSF-induced phosphorylation of STAT5 was not 
affected by disruption of lipid rafts. Recently, it has been shown that the fMLP-
receptor moves into lipid rafts upon ligand binding, and that this receptor 
clustering might be necessary for maximal signalling 
38. This would explain the 
inhibiting effects of CD on fMLP-stimulated signal transduction observed in figure 
3. It is conceivable that the GM-CSF-receptor does not enter lipid rafts itself, 
explaining the lack of effect of CD on GM-CSF-induced STAT5 activation, but 
rather induces an increased clustering of fMLP-receptor containing lipid rafts, 
resulting in enhanced fMLP signalling. Although many GPCRs have been 
described to be present in lipid rafts, which is required for their activity, 
microdomain localisation has only been suggested for few growth factor 
receptors, amongst which are the EGF-receptor and platelet derived growth 
factor (PDGF)-receptor 
39;40. Alternatively, GM-CSF-receptors might act by 
integrating into the lipid rafts with the fMLP-receptors.  
 
 
 
 Chapter 6 
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has recently been suggested that PDGF stimulation of PDGF-receptors in raft 
fractions causes tyrosine phosphorylation of EGF-receptors present in the same 
membrane fractions, suggesting that cross talk between receptors might be 
facilitated by movement into the same microdomains 
41. Furthermore, a similar 
question has arisen for insulin signalling; whereas insulin-dependent second 
messenger generation is microdomain dependent, the insulin receptor might or 
might not be present in lipid rafts 
22. No data are available as yet on the 
localisation of the GM-CSF-receptor in the plasma membrane.  
Figure 3. The effect of cholesterol depletion on the activation of signal transduction
pathways. 
(A+B) Unprimed or GM-CSF primed healthy neutrophils were stimulated with 10 µM fMLP for the
indicated time. Where indicated, cells were pretreated with 10 µM methyl-β-cyclodextrin (CD) for 30
min. To assess the effect of restoration of lipid rafts, cells were treated with CD, washed, allowed to
recover for 45 min at 37 °C and subsequently stimulated with GM-CSF and fMLP. Western blot
analysis was performed, active ERK1/2 was detected with phopho-ERK1/2 antibodies (A, upper
panel) and active PKB was detected with phospho-PKB antibodies (B, upper panel) as described in
chapter 2. To control for equal loading, blots were reprobed with ERK1/2 antibodies. (C) Healthy
neutrophils were stimulated with 5 ng/ml GM-CSF for 15 min, with or without pretreatment with 10
µM CD.   Summary, General Discussion and Future Perspectives 
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Several markers for lipid rafts have been identified, amongst which are 
Caveolin-1, -2, -3, Flotilin-1, -2 and the gangliosides GM1 and GM3. Recent 
evidence suggests there are different populations of lipid rafts, which differ in 
their protein and lipid content 
42-44. This is confirmed by the observation that the 
fMLP-receptor clusters specifically to GM-1-rich, but not flotilin-rich microdomains 
38. Furthermore, some neutrophil membrane rafts contain flotilin, but not Caveolin 
28. Recent studies suggest the existence of lipid rafts that are cholesterol-
independent, and might therefore resistant to treatment with CD 
45;46. Possibly, 
the GM-CSF-receptor is located in one of these rafts.  
Upon stimulation or culture of different cell types, lipid rafts within the 
plasma membrane are redistributed, according to the polarised nature of the cells 
24;47. Redistribution of lipid raft markers from the cytoplasm to the plasma 
membrane and lipid raft clustering have also been observed 
48;49. These 
processes can be visualised by either confocal microscopy or fluorescence 
acquired cell sorting (FACS) analysis by staining cells for lipid raft markers such 
as GM1, which is bound specifically by the cholera toxin B 
50-52. As lipid rafts 
were involved in both ROS production and signalling in fMLP-stimulated 
unprimed and GM-CSF-primed neutrophils in our studies, we wondered what the 
effect of neutrophil stimulation on lipid raft assembly would be. We therefore 
investigated cholera toxin B binding by FACS analysis, and showed that upon 
fMLP stimulation, the expression of GM1 at the plasma membrane increased in 
healthy neutrophils (figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. GM1 plasma
membrane expression on
healthy neutrophils. 
Unprimed or GM-CSF primed
neutrophils from healthy
volunteers were stimulated with
10  µM fMLP for the indicated
time. Stimulations were stopped
by addition of cold PBS and
centrifugation. Neutrophils were
incubated for 60 min with 5
µg/ml phycoerythin-coupled
cholera toxin subunit B to detect
GM1 expression. Upon washing
twice with cold PBS cells were
subjected to FACS analysis. Chapter 6 
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Although not providing conclusive evidence, these results suggest that lipid raft 
formation might increase upon fMLP-receptor activation. Furthermore, when cells 
were pretreated with GM-CSF, the amount of GM1 at the cell surface increased, 
and could be further enhanced by subsequent stimulation with fMLP. This implies 
that GM-CSF-receptor activation possibly results in lipid raft formation, thereby 
enabling fMLP to transduce its signals more efficiently. It would be of interest to 
investigate GM1 expression in MDS neutrophils to determine to what extent 
impaired GM-CSF priming of ROS production is reflected by a disturbed lipid raft 
formation in response to GM-CSF.  
 
Possible mechanism of impaired PtdIns(3,4,5)P3 accumulation 
Impaired lipid raft formation might be a mechanism involved in impaired GM-CSF 
priming of PtdIns(3,4,5)P3 accumulation and subsequent respiratory burst in 
neutrophils from MDS patients. However, PI3K activity is not the only factor 
regulating the presence of PtdIns(3,4,5)P3 and related lipids. Phosphatase with 
tensin homology (PTEN) and SH2-containing inositol phosphatase (SHIP) are 
lipid phosphatases that convert PtdIns(3,4,5)P3 into PtdIns(4,5)P2 and 
PtdIns(3,4)P2, respectively. Theoretically, increased phosphatase activity might 
result in decreased PtdIns(3,4,5)P3 accumulation within cells. Activation of SHIP 
isoforms and PTEN is correlated with their protein expression levels 
53. 
Furthermore, increased stimulation of PKB activation was observed in murine 
SHIP-/- cells 
54;55. We therefore investigated the expression of SHIP1, SHIP2 and 
PTEN in neutrophils from MDS patients. There was no significant difference in 
RNA expression of either of the phosphatases between MDS patients (n=5) and 
healthy volunteers (n=5), as assessed by Real Time PCR (unpublished data, not 
shown). In contrast, protein expression of SHIP1 and SHIP2, but not PTEN was 
significantly increased in a number of MDS cases (data not shown), which might 
contribute to the decreased PtdIns(3,4,5)P3 accumulation observed in GM-CSF 
primed cells. However, in MDS neutrophils fMLP-stimulated ROS production and 
PtdIns(3,4,5)P3 accumulation were normal. Therefore, increased SHIP levels 
alone can not explain the disturbed priming in MDS; there has to be a receptor 
mediated event in SHIP1/2 phosphatase activity. SHIP1 becomes 
phosphorylated upon stimulation, which might possibly regulate its activity 
54;55. 
SHIP2 is also tyrosine phosphorylated 
56, although this phosphorylation might not 
affect its phosphatase activity 
57. However, we did not find any differences in GM-
CSF-induced phosphorylation of SHIP1 between 3 MDS patients and 3 healthy 
donors (unpublished results). SHIP and PTEN have been found to localise to 
lipid rafts upon stimulation of cells, thereby reducing the activation signal 
58-61. It Summary, General Discussion and Future Perspectives 
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is conceivable that translocation of increased levels of SHIP towards priming-
induced rafts might result in the decreased PtdIns(3,4,5)P3 accumulation and 
ROS production observed in neutrophils from MDS patients.  
 
Apoptosis in MDS neutrophils 
An increasing amount of evidence suggests a role for lipid rafts in apoptosis. The 
death-inducing ligand Fas and its apoptotic targets such as caspase 8 have been 
shown to cluster in lipid rafts in several cell systems 
62-64. In neutrophils, 
spontaneous apoptosis has been shown to de initiated by clustering of death 
receptors in lipid rafts 
65. Furthermore, phospholipid flip-flop, a hallmark of 
apoptosis measured by Annexin V staining, is localised to lipid rafts in fMLP-
stimulated human neutrophils 
66.   
  In low-risk MDS patients, an increased percentage of apoptotic bone 
marrow CD34+ cells is found. This increased apoptosis might lead to neutropenia 
in MDS. It is of interest to determine whether this increased apoptotic potential is 
also present in mature MDS neutrophils, as this might underlie the impaired 
neutrophil functions observed in MDS patients. In fact, a recent study 
determining the morphology and TUNEL staining of peripheral blood smears 
suggested that apoptosis was abundant in peripheral blood neutrophils from 
MDS patients, contributing to the cytopenia 
67. However, we have determined the 
level of spontaneous neutrophil apoptosis over time by analysing annexin-V 
binding as well as measuring mitochondrial integrity by binding of Rhodamine-
123, and found no significant differences between MDS patients and healthy 
controls (unpublished data). The effect of the apoptosis-delaying agent GM-CSF 
was examined, and also found to be normal in neutrophils from MDS patients. In 
view of the role of Fas/FasL in the apoptotic process of early precursor cells, the 
expression of the Fas-receptor on the membrane of MDS and healthy neutrophils 
was also studied, and found to be identical in both groups. Consistent with these 
data, we did not find differences in apoptosis induced by FasL in neutrophils from 
MDS patients and healthy volunteers (unpublished data). It would therefore seem 
that the decreased number of circulating neutrophils cannot be explained by an 
increase in programmed cell death in the differentiated cells. Rather, it appears 
that neutrophils residing in the peripheral blood have escaped the apoptosis-
mechanism during development. Nevertheless, the residual mature granulocytes 
consist of pathological clones, as intracellular signalling and subsequent cellular 
functions are disturbed in these cells. Recently, it has been suggested that the 
increased cell-death in MDS bone marrow might be attributed to necrosis rather 
than apoptosis 
68. However, comparison of PI+/AnnexinV- neutrophil populations Chapter 6 
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did not reveal any differences between MDS patients and healthy donors in our 
study (unpublished data).  
 
In conclusion, the data presented in this thesis have identified some of the signal 
transduction pathways that might be involved in the impaired neutrophil functions 
observed in MDS. Identification of general mechanisms and pathways affected in 
multiple cell functions in response to different stimuli might lead to a better 
understanding into the deregulated myelopoiesis in MDS cases. Furthermore, 
although a lot of questions remain to be answered, our data provide new insights 
into the mechanism of the intriguing process of neutrophil priming. As the 
importance of ROS production is so clearly established, elucidating these 
mechanisms is of the utmost importance.  Summary, General Discussion and Future Perspectives 
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Future perspectives.  
 
The studies in this thesis have tried to provide more insight into the mechanisms 
responsible for the impaired neutrophil functions in MDS. These functions, i.e. 
ROS production and migration, play an important role in the increased 
susceptibility of MDS patients to bacterial infections. However, it is also 
conceivable that defective neutrophil functioning might result in physical 
problems other than immunological responses in MDS patients. For instance, 
mobilisation of hematopoietic stem cells, required for autologous transplantation 
therapies, is not very efficient in MDS patients 
69. Mobilisation takes place upon 
administration of agents such as G-CSF, SCF, SDF-1 and IL-8 
70;71. Stem cells 
are retained in the bone marrow by interactions of adhesion molecules such as 
VLA-4 to their bone marrow stroma counterpart, VCAM-1. It is becoming 
increasingly clear that neutrophils might play a role in stem cell mobilisation. G-
CSF administration results in activation of neutrophils, leading to their release of 
elastase and cathepsin G. These proteases have been shown to mediate 
cleavage of VCAM1, which inhibits retention of stem cells in the bone marrow, 
and cleavage of SDF-1, its receptor CXCR4 and the SCF receptor c-Kit, which 
prevents homing of circulating stem cells back to the bone marrow 
72-76. G-CSF 
administration 
77 and possibly SDF-1 stimulation 
78 lead to an increased serum 
level of IL-8, which results in activation of neutrophils and their attraction to the 
bone marrow. It is therefore conceivable that impaired neutrophil responses to IL-
8 result in a low mobilisation potential in MDS patients. Neutrophil granule 
release in response to G-CSF and IL-8 will need to be investigated in MDS 
neutrophils in order to answer this question. 
  
Impaired signalling in MDS progenitor cells. 
In addition to neutrophil dysfunction, it is apparent that intrinsic defects are 
present in the MDS precursor cells. It has been shown that colony formation from 
progenitors of the erythrocyte, myeloid and megakaryocyte lineages are 
decreased, implying impaired proliferation and differentiation of MDS progenitors. 
It would be of interest to examine whether the signal transduction pathways that 
were responsible for the disturbed neutrophil functions in MDS are also involved 
in the disturbed myelopoiesis in these patients. Furthermore, other cell lineages 
are also affected, most noticeably the erythroid lineage, and need to be 
investigated.  
In MDS neutrophils, the common denominator for the impaired functions 
appeared to be the decreased ERK and PI3K activity in response to different Chapter 6 
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stimuli. ERK1/2 and PI3K are also active in hematopoietic progenitor cells in 
response to cytokine stimulation, and are involved in proliferation and 
differentiation of erythroid and myeloid lineages 
79-83. Enhancement of myeloid 
progenitor survival was dependent on PKB and ERK1/2 activity 
84. Furthermore, 
a reduced CFU-E formation was observed in PI3K subunit p85-/- mice, in 
combination with impaired enucleation of erythrocytes, a hallmark of terminal 
differentiation 
85. In addition, inhibition of PKB blocks progenitor proliferation, and 
abolishes myeloid differentiation in favour of eosinophil differentiation in an in 
vitro system (M.Buitenhuis, personal communication). Interestingly, in some MDS 
patients a neutropenia is observed, although eosinophil numbers are relatively 
high, implicating a possible PKB defect in MDS progenitor cells. It is possible to 
induce terminal erythroid or myeloid differentiation of stem cells in ex vivo 
systems 
86;87. It would be interesting to culture and induce differentiation of MDS 
CD34+ cells and investigate the activation and expression patterns of the 
ERK1/2 and PI3K pathway, including PKB. Proof for the involvement of these 
signalling proteins in the disturbed MDS hematopoiesis might come from over-
expression studies of PI3K subunits, PKB and ERK1/2 in MDS progenitor cells, 
and examining their effects on proliferation, colony formation potential and 
differentiation.  
The ERK1/2 and PI3K pathways are not the only pathways that might 
play a role in the disturbed hematopoiesis in MDS patients. For instance, the lipid 
phosphatase SHIP is expressed upon maturation of stem cells, and plays a 
negative regulatory role in hematopoiesis 
88. In SHIP-1-/- mice, an increase in 
erythroid and myeloid progenitor cells is observed, corresponding with increased 
colony formation potential 
89. As we demonstrated an increased SHIP1 and 2 
expression in MDS neutrophils, it is conceivable that over-expression of this 
phosphatase in progenitor cells during erythropoiesis and myelopoiesis in MDS 
patients might explain the differentiation defects observed. In addition, the p38 
MAPK and JNK pathways have also been implicated in erythroid differentiation 
90;91. Recently, a novel peptide array technology was described, making it 
possible to study the activation of a plethora of kinases in one cell lysate 
92. 
Applying lysates of resting and stimulated CD34+ cells from MDS patients in 
comparison to healthy cells on these kinase arrays might result in the 
identification of alternative signal transduction pathways that might be affected in 
MDS hematopoietic progenitors.  
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Lipid rafts in hematopoietic progenitor cells 
The chemokine SDF-1 is involved in hematopoiesis by regulating hematopoietic 
stem cell migration to micro-niches in the bone marrow, which is a PI3K-
dependent process 
93-95. Both Class 1A and Class 1B PI3Ks can be activated by 
SDF-1 
96. Upon stimulation with SDF-1, hematopoietic progenitor cells become 
polarised, with a leading edge at the front pole and a uropod at the rear pole. 
Lipid raft markers have been shown to become distributed in a polarised fashion 
in these cells 
47, and the SDF-1 receptor CXCR4 co-localises with these rafts at 
the leading edge of the cell 
97. In MDS patients, CD34+ cells have been shown to 
be unresponsive to SDF-1-induced chemotaxis, despite normal CXCR4 
expression and increased SDF-1 plasma levels 
98. It is tempting to speculate that 
impaired PtdIns(3,4,5)P3 accumulation in MDS progenitor cells might play a role 
in these observations. The signal transduction pathways involved in the impaired 
migration of MDS progenitor cells remains to be investigated, as does the 
formation of lipid rafts in these cells. 
Another intriguing observation is that priming of cellular functions and 
signal transduction pathways not only occurs in mature neutrophils, but also in 
precursor cells. For instance, erythropoiesis might be synergistically supported 
by SCF and EPO or prostaglandin-E2 and EPO by enhancing ERK1/2 and PI3K 
activation 
99, or by increasing STAT5 transactivation 
100;101. Furthermore, 
transforming growth factor-β augments GM-CSF-induced CD34+ proliferation by 
synergistically enhancing STAT5, but not ERK1/2 activation 
102. In addition, GM-
CSF-stimulated cell growth of a model cell-line, MO7-e, was increased by SCF 
by prolonged and increased activation of both ERK1/2 and PI3K 
103. In the same 
cells, SDF-1 was shown to act synergistically with GM-CSF, TPO and SCF on 
activation of PKB and ERK1/2 
84. Furthermore, SCF enhanced the SDF-1-
induced migration of both MO7-e and CD34+ cells 
104. A recent study suggests 
that components of leukapheresis products prime the SDF-1 mediated migration 
and actin polymerisation in hematopoietic stem cells by increasing the 
association of CXCR4 with lipid rafts 
105. As priming is specifically impaired in 
MDS neutrophils, which might be a result of impaired lipid raft formation, it would 
be appealing to investigate the priming effect of these cytokines on signal 
transduction pathways, lipid raft formation, cell functions and proliferation in MDS 
progenitor cells.  
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Taken together, it can be concluded that although ample research has focussed 
on the apoptosis and proliferation potential of MDS stem cells, only few studies 
have looked at the multi-lineage differentiation defects or the signal transduction 
pathways involved in these aberrations. We have now established some of the 
signalling pathways that are affected in mature neutrophils in MDS patients; the 
next step will be to investigate these pathways in MDS precursor cells.  
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Het bloed bestaat, naast plasma, uit verschillende celtypes. De rode bloedcellen 
zorgen voor zuurstof transport naar de verschillende weefsels. De witte 
bloedcellen zijn betrokken bij de afweer van het lichaam tegen bacteriële en 
virale infecties, en kunnen worden onderverdeeld in B-cellen, T-cellen, 
monocyten en neutrofiele granulocyten. Nog een ander bloedceltype is de 
megakaryocyt, die de bloedplaatjes produceert die een belangrijke rol spelen in 
de stolling van het bloed bij wondjes. De volwassen cellen in het bloed ontstaan 
uit voorlopercellen die zich in het beenmerg bevinden. Deze voorlopercellen 
vermenigvuldigen zich, en kunnen bij iedere celdeling verder uitrijpen in de 
richting van één van de volwassen celtypes. Bij mensen met Myelodysplasie 
(MDS) is er een tekort aan volwassen rode bloedcellen, granulocyten of 
bloedplaatjes in het bloed. Waarschijnlijk komt dit doordat de voorlopercellen van 
MDS patiënten niet goed kunnen uitrijpen, en eerder dood gaan dan de voorloper 
cellen van gezonde mensen. Bovendien functioneren de cellen die in het bloed 
van MDS patiënten aanwezig zijn niet naar behoren. Een belangrijke aanwijzing 
hiervoor is het feit dat deze patiënten een verhoogd risico lopen te overlijden aan 
de complicaties van bacteriële infecties. Dit duidt met name op een verstoord 
functioneren van granulocyten. 
  Om een bacteriële infectie te bestrijden moet een granulocyt een lange 
weg afleggen. Op de plek waar bacteriën het lichaam zijn binnengedrongen 
worden plaatselijk groeifactoren afgegeven. Granulocyten die in het bloed 
circuleren herkennen een concentratiegradiënt van deze stoffen als ze langs de 
plaats van infectie komen, en zullen vanuit het bloed de weefsels binnentreden. 
De cellen bewegen zich in de richting van de bacteriën die vervolgens worden 
opgeruimd doordat de granulocyt ze 'opeet' via de zogenaamde fagocytose. 
Bovendien maakt de granulocyt zuurstof radicalen die dodelijk zijn voor 
bacteriën. De zuurstofradicaal productie wordt gestimuleerd door stoffen die 
afkomstig zijn van de infectieuze bacteriën. Een van deze stoffen is het 
bacteriële eiwit fMLP. De hoeveelheid zuurstofradicalen die door de granulocyt 
gemaakt wordt in respons op een fMLP stimulatie is echter gering. Om toch 
voldoende radicalen te kunnen produceren heeft de natuur een trucje bedacht; 
de granulocyt wordt in een verhoogde staat van paraatheid gebracht door de 
groeifactoren die door cellen in de omgeving van de infectie worden 
aangemaakt.  Nederlandse samenvatting 
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Dit proces wordt 'priming' genoemd. Een granulocyt die in deze staat van priming 
verkeerd kan vervolgens veel adequater reageren op stimuli die afkomstig zijn 
van bacteriën. Het gevolg hiervan is dat een granulocyt die priming heeft 
ondergaan en die vervolgens wordt gestimuleerd met fMLP beduidend meer 
zuurstof radicalen maakt dan een granulocyt die niet in staat van priming 
verkeert. 
  Voordat een granulocyt echter reageert op een stimulus heeft er een 
cascade van reacties binnen in de cel plaatsgevonden. Groeifactoren of 
bacteriële producten binden aan de oppervlakte van de granulocyt middels 
receptoren die slechts één of enkele specifieke stimuli herkennen. De receptor 
wordt door deze binding geactiveerd en is vervolgens in staat eiwitten en 
enzymen binnen in de cel te activeren. Deze enzymen activeren op hun beurt 
weer andere moleculen, met als gevolg een signaal transductie cascade. Op 
deze manier wordt het signaal van buiten de cel via verschillende signaal 
transductie moleculen doorgegeven naar binnen, wat uiteindelijk resulteert in een 
reactie van de cel op de in de omgeving aanwezige stimuli. 
In dit proefschrift laten wij zien dat priming van de fMLP-gestimuleerde 
zuurstofradicaal productie met de groeifactor GM-CSF ernstig verstoord is in 
granulocyten van MDS patiënten (hoofdstuk 2). Om de oorzaak van deze 
verlaagde priming te achterhalen werd vervolgens bestudeerd welke signaal 
transductie moleculen betrokken zijn bij de zuurstofradicaal productie. Twee 
moleculen in het bijzonder bleken erg belangrijk zijn voor de GM-CSF-
gemedieerde priming van de radicalen productie; het eiwit ERK1/2 en het eiwit 
PI3K. Wij toonden aan dat, net als voor zuurstofradicaal productie, de fMLP-
gemedieerde ERK1/2 activatie en PI3K activatie verhoogd zijn als de cel is 
voorbehandeld met GM-CSF. Dit is in overeenkomst met het idee dat een cel die 
in staat van priming verkeert beter kan reageren op bacteriële producten.  
  Aangezien ERK1/2 en PI3K belangrijk waren voor de productie van 
zuurstof radicalen, en de priming hiervan verstoord was in MDS patiënten, werd 
vervolgens de activatie van deze signaal transductie routes bestudeerd in 
granulocyten van de patiënten (hoofdstuk 2 en 3). Wij vonden dat de priming van 
zowel ERK1/2 als PI3K activatie verlaagd waren in fMLP-gestimuleerde 
granulocyten van MDS patiënten. De activatie van signaal transductie moleculen 
die door PI3K worden geactiveerd, zoals PKB en Rac, konden worden verhoogd 
door GM-CSF behandeling van gezonde granulocyten. Bij MDS patiënten was de 
priming van deze activatie echter verminderd. Deze resultaten tonen duidelijk 
aan dat de activatie van de PI3K-route verstoord is in granulocyten van MDS 
patiënten die priming met GM-CSF hebben ondergaan. Nederlandse samenvatting 
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Een belangrijke activator van PI3K is het molecuul Ras. Wij toonden echter aan 
dat hoewel ook Ras activatie verhoogd kon worden door GM-CSF, deze activatie 
normaal verliep in granulocyten van MDS patiënten. Al met al laten deze 
resultaten zien dat er een defect bestaat in de activatie van de PI3K-Rac route in 
granulocyten van MDS patiënten en dat dit defect waarschijnlijk gelokaliseerd is 
bij PI3K zelf. Deze hypothese werd verder onderbouwd door het feit dat we 
afwijkende hoeveelheden van het PI3K eiwit vonden in MDS granulocyten.  
  Zuurstof radicaal productie vindt plaats in zogenaamde 'NADPH oxidase 
complexen'. Een van de componenten van dit complex is het 
membraangebonden flavocytochroom b558. Behalve in de celmembraan bevindt 
flavocytochroom b558 zich ook in opslagblaasjes in het binnenste van de cel. We 
wilden bestuderen of een verstoorde vorming van het NADPH oxidase complex 
wellicht een additionele rol zou kunnen spelen bij de verstoorde zuurstofradicaal 
productie in granulocyten van MDS patiënten. De resultaten in hoofdstuk 4 
wijzen uit dat stimulatie van granulocyten met fMLP resulteert in een verhoogde 
hoeveelheid flavocytochroom b558 moleculen op de membraan van de cel, 
waarschijnlijk als gevolg van fusie van de flavocytochroom b558-bevattende 
blaasjes met de celmembraan. De fMLP-gestimuleerde expressie van 
flavocytochroom b558 was echter significant lager op MDS granulocyten. Dit was 
niet het gevolg van een verstoorde fusie van de opslagblaasjes met de MDS 
celmembraan. Wel werd aangetoond dat de totale hoeveelheid flavocytochroom 
b558 in MDS granulocyten verlaagd was. In combinatie met een verstoorde fMLP-
gemedieerde membraan expressie van flavocytochroom b558 zou dit kunnen 
zorgen voor een limiet in de hoeveelheid zuurstofradicalen die kunnen worden 
gevormd in granulocyten van MDS patiënten.  
  Om een bacteriële infectie te bestrijden moet een granulocyt naast de 
productie van zuurstof radicalen ook in staat zijn om in de nabijheid van de 
bacteriën te komen. Een gebrek in deze eigenschap zou een belangrijke rol 
kunnen spelen in de verstoorde bestrijding van bacteriële infecties die gevonden 
wordt bij MDS patiënten. In hoofdstuk 5 van dit proefschrift laten wij zien dat 
granulocyten van MDS patiënten een verminderd vermogen hebben om zich te 
begeven in de richting van een concentratiegradiënt van de fysiologische 
groeifactor IL-8. Ook dit defect wordt mogelijk veroorzaakt door een verstoorde 
activatie van ERK1/2 en PI3K, aangezien deze eiwitten verminderd werden 
aangeschakeld in IL-8-gestimuleerde granulocyten van MDS patiënten. Tevens 
werd gevonden dat de activatie van Rac, een mogelijke activator van ERK1/2 in 
dit systeem, minder efficiënt verliep in MDS granulocyten.  Nederlandse samenvatting 
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  Het onderzoek beschreven in dit proefschrift maakt duidelijk dat 
meerdere cellulaire functies van granulocyten verstoord verlopen bij MDS 
patiënten. Hoewel verschillende stimuli werden onderzocht, bleken er belangrijke 
overeenkomsten te liggen in de signaal transductie moleculen die ten grondslag 
lagen aan de verstoorde celfuncties in MDS patiënten.  
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